"Rank","NCT Number","Title","Acronym","Status","Study Results","Interventions","Phases","Results First Posted","URL"
1,"NCT02266147","Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma",,"Completed","No Results Available","Drug: SD-101|Radiation: Radiation therapy","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02266147"
2,"NCT02055924","Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas","BIBLOS","Terminated","No Results Available","Drug: Ibrutinib and immunochemotherapies","Phase 1","null","https://ClinicalTrials.gov/show/NCT02055924"
3,"NCT02395601","A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas",,"Active, not recruiting","No Results Available","Drug: CPI-1205","Phase 1","null","https://ClinicalTrials.gov/show/NCT02395601"
4,"NCT00162656","Treatment of Mature B-cell Lymphoma/Leukaemia",,"Completed","No Results Available","Drug: half cyclophosphamide|Drug: without COPADM3|Drug: mini CYVE, without 3 maintenance courses|Drug: LMB B|Drug: LMB C","Phase 3","null","https://ClinicalTrials.gov/show/NCT00162656"
5,"NCT03424122","INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",,"Recruiting","No Results Available","Drug: INCB050465|Drug: Rituximab|Drug: Bendamustine|Drug: Ibrutinib","Phase 1","null","https://ClinicalTrials.gov/show/NCT03424122"
6,"NCT02247609","Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas","4SCAR19273","Unknown status","No Results Available","Genetic: Anti-CD19 CAR T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02247609"
7,"NCT01478269","Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen","ProDLBCL","Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01478269"
8,"NCT03664336","Refractory Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03664336"
9,"NCT03258047","Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma",,"Recruiting","No Results Available","Combination Product: CAR-T","Phase 2","null","https://ClinicalTrials.gov/show/NCT03258047"
10,"NCT02433795","Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)",,"Active, not recruiting","No Results Available","Drug: bendamustine plus rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02433795"
11,"NCT03146533","CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.",,"Recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19 CART","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03146533"
12,"NCT02547948","CD19-targeting CAR T Cells for B Cell Lymphoma",,"Completed","No Results Available","Biological: CD19-targeting CAR T Cells infusion","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02547948"
13,"NCT03189524","A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma",,"Recruiting","No Results Available","Drug: BGB-3111","Phase 1","null","https://ClinicalTrials.gov/show/NCT03189524"
14,"NCT03101709","The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19","Phase 1","null","https://ClinicalTrials.gov/show/NCT03101709"
15,"NCT03670888","A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients",,"Not yet recruiting","No Results Available","Biological: JHL1101|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03670888"
16,"NCT02842138","Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Biological: autologous anti-CD19 CAR T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02842138"
17,"NCT03218072","A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas",,"Completed","No Results Available","Drug: HLX01","Phase 1","null","https://ClinicalTrials.gov/show/NCT03218072"
18,"NCT02741388","A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP","SELINDA","Recruiting","No Results Available","Drug: selinexor|Drug: Rituximab|Drug: Dexamethasone|Drug: Oxaliplatin|Drug: Cisplatin|Drug: Cytarabine|Drug: Gemcitabine","Phase 1","null","https://ClinicalTrials.gov/show/NCT02741388"
19,"NCT02060435","Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Other: EBER","","null","https://ClinicalTrials.gov/show/NCT02060435"
20,"NCT02060656","Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","LEGEND","Unknown status","No Results Available","Drug: Gemcitabine|Drug: Methylprednisolone|Drug: Rituximab|Drug: Cisplatin|Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02060656"
21,"NCT01068392","Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)",,"Completed","No Results Available","Drug: Oxaliplatin, Prednisolone","Phase 2","null","https://ClinicalTrials.gov/show/NCT01068392"
22,"NCT02531308","Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)","DLBCL","Terminated","Has Results","Drug: Metformin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: pegfilgrastim","Phase 2","January 27, 2017","https://ClinicalTrials.gov/show/NCT02531308"
23,"NCT02945215","A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients",,"Recruiting","No Results Available","Drug: IBI301|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02945215"
24,"NCT00944567","A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00944567"
25,"NCT03692767","Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma",,"Not yet recruiting","No Results Available","Biological: Anti-CD22 CAR NK Cells","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT03692767"
26,"NCT03690310","Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma",,"Not yet recruiting","No Results Available","Biological: Anti-CD19 CAR NK Cells","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT03690310"
27,"NCT00097929","An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)",,"Completed","No Results Available","Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months","Phase 2","null","https://ClinicalTrials.gov/show/NCT00097929"
28,"NCT01226849","Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma","SGH652","Completed","No Results Available","Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin","Phase 1","null","https://ClinicalTrials.gov/show/NCT01226849"
29,"NCT02767674","Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: Rituximab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02767674"
30,"NCT00801216","High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement","SCNSL1","Unknown status","No Results Available","Drug: High-dose sequential chemotherapy and autologous transplant","Phase 2","null","https://ClinicalTrials.gov/show/NCT00801216"
31,"NCT00761384","High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma","HITT","Completed","No Results Available","Drug: 90Y-ibritumomab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00761384"
32,"NCT00965289","High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma",,"Completed","No Results Available","Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00965289"
33,"NCT01369784","Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma","PRO-R-IPI","Completed","Has Results","","","April 18, 2016","https://ClinicalTrials.gov/show/NCT01369784"
34,"NCT01793844","A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients",,"Unknown status","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01793844"
35,"NCT03630159","Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients","PORTIA","Recruiting","No Results Available","Biological: Tisagenlecleucel|Drug: Pembrolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03630159"
36,"NCT02733380","Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: Chidamide|Drug: Vinorelbine|Drug: Liposomal Doxorubicin or mitoxantrone|Drug: Dexamethasone|Drug: Thalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02733380"
37,"NCT03188198","Risk Adapted Therapy in Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim","Phase 2","null","https://ClinicalTrials.gov/show/NCT03188198"
38,"NCT03704298","Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma","ZUMA-11","Not yet recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Axicabtagene Ciloleucel|Biological: Utomilumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03704298"
39,"NCT03391726","CART-19 Cells for R/R B-cell Lymphoma","CCFRRBL","Recruiting","No Results Available","Other: CART-19 cells","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT03391726"
40,"NCT02777736","CNS Prophylaxis in Diffuse Large B-cell Lymphoma","CLSG-CNS-001","Recruiting","No Results Available","Drug: Methotrexate","Phase 3","null","https://ClinicalTrials.gov/show/NCT02777736"
41,"NCT00906841","Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Drug: 90Y-DOTA-hLL2","Phase 2","null","https://ClinicalTrials.gov/show/NCT00906841"
42,"NCT01626352","Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy",,"Completed","Has Results","Drug: Bendamustine|Drug: Ofatumumab","Phase 2","October 18, 2017","https://ClinicalTrials.gov/show/NCT01626352"
43,"NCT00846157","Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients","NKCell","Unknown status","No Results Available","Biological: NKM injection","Phase 3","null","https://ClinicalTrials.gov/show/NCT00846157"
44,"NCT00754117","Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00754117"
45,"NCT01402440","Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Drug: AEB071","Phase 1","null","https://ClinicalTrials.gov/show/NCT01402440"
46,"NCT01854606","Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma","COEB071X2103","Completed","No Results Available","Drug: AEB071|Drug: Everolimus","Phase 1","null","https://ClinicalTrials.gov/show/NCT01854606"
47,"NCT02715843","Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma",,"Available","No Results Available","Drug: MT-3724","","null","https://ClinicalTrials.gov/show/NCT02715843"
48,"NCT01202448","Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma","PROCESS","Completed","No Results Available","Procedure: CSF analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01202448"
49,"NCT03513601","Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Drug: (R)-CHOP regimen|Drug: (R)-CVP regimen","Phase 4","null","https://ClinicalTrials.gov/show/NCT03513601"
50,"NCT02227251","A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: Selinexor","Phase 2","null","https://ClinicalTrials.gov/show/NCT02227251"
51,"NCT03719560","Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma","BrUOG-377","Not yet recruiting","No Results Available","Drug: Methotrexate|Drug: Cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT03719560"
52,"NCT00169468","Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma",,"Completed","No Results Available","Drug: Rituximab -CHOP plus Velcade","Phase 2","null","https://ClinicalTrials.gov/show/NCT00169468"
53,"NCT03576443","Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma","ILIAD","Recruiting","No Results Available","Drug: Idelalisib","Phase 2","null","https://ClinicalTrials.gov/show/NCT03576443"
54,"NCT03208556","Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Biological: iPD1 CD19 eCAR T cells|Drug: Fludarabine and cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT03208556"
55,"NCT01046825","Mature B-Cell Lymphoma And Leukemia Study III",,"Recruiting","No Results Available","Drug: COPAD|Drug: COP, COPD M3, CYM|Drug: COP, COPADM8, CYVE","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT01046825"
56,"NCT03579082","A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: Decitabine","Phase 4","null","https://ClinicalTrials.gov/show/NCT03579082"
57,"NCT00895661","High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas",,"Completed","Has Results","Drug: rituximab","Phase 2","May 9, 2017","https://ClinicalTrials.gov/show/NCT00895661"
58,"NCT03650933","A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients",,"Not yet recruiting","No Results Available","Biological: G-CHOP|Biological: R-CHOP","Phase 3","null","https://ClinicalTrials.gov/show/NCT03650933"
59,"NCT03681535","Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma","DLBCL","Not yet recruiting","No Results Available","Radiation: Radiation Therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03681535"
60,"NCT02708732","Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02708732"
61,"NCT02951728","Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma","DR-CHOP","Recruiting","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Decitabine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02951728"
62,"NCT01799083","Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas","CIK","Unknown status","No Results Available","Drug: Decitabine|Biological: cytokine-induced killer cell","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01799083"
63,"NCT01499303","Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer",,"Completed","Has Results","Drug: Fostamatinib","Phase 2","August 22, 2014","https://ClinicalTrials.gov/show/NCT01499303"
64,"NCT03415399","Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma",,"Recruiting","No Results Available","Biological: ET190L1 ARTEMIS™ T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03415399"
65,"NCT03104478","Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)","RT3","Recruiting","No Results Available","Procedure: Biological samples collection","","null","https://ClinicalTrials.gov/show/NCT03104478"
66,"NCT01622439","Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma","VALFRID","Completed","No Results Available","Drug: Valproate|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01622439"
67,"NCT02763319","A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","B-MIND","Recruiting","No Results Available","Drug: Rituximab (RTX)|Drug: MOR208|Drug: Bendamustine (BEN)","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT02763319"
68,"NCT01805557","Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","FIL_VERAL12","Unknown status","No Results Available","Drug: R-DHAP|Drug: BR-DHAP","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT01805557"
69,"NCT03399513","Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma","R-CHOEP-brut","Recruiting","No Results Available","Drug: Ibrutinib Oral Capsule [Imbruvica]|Drug: R-CHOEP chemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT03399513"
70,"NCT01278602","R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma",,"Unknown status","No Results Available","Drug: R-ESHAP","Phase 2","null","https://ClinicalTrials.gov/show/NCT01278602"
71,"NCT00138086","Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma",,"Completed","No Results Available","Drug: Zevalin plus BEAM","Phase 2","null","https://ClinicalTrials.gov/show/NCT00138086"
72,"NCT03688152","A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Drug: INCB053914|Drug: INCB050465","Phase 1","null","https://ClinicalTrials.gov/show/NCT03688152"
73,"NCT03123393","TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: TAK-659","Phase 2","null","https://ClinicalTrials.gov/show/NCT03123393"
74,"NCT03064867","Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Venetoclax|Drug: RICE","Phase 1","null","https://ClinicalTrials.gov/show/NCT03064867"
75,"NCT03200015","Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Metformin","Phase 2","null","https://ClinicalTrials.gov/show/NCT03200015"
76,"NCT03485118","RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma","Hi-CHOP","Completed","No Results Available","Drug: HS006+CHOP|Drug: Rituximab+CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT03485118"
77,"NCT03036904","Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","V+DA-EPOCH-R","Recruiting","No Results Available","Drug: Venetoclax|Drug: Rituximab|Drug: Etoposide|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Doxorubicin Hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT03036904"
78,"NCT03383406","A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma","IVAM","Enrolling by invitation","No Results Available","Drug: Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT03383406"
79,"NCT01289210","VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas",,"Terminated","Has Results","Drug: VTX-2337 plus radiotherapy","Phase 1|Phase 2","October 6, 2014","https://ClinicalTrials.gov/show/NCT01289210"
80,"NCT03121456","18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma","LYMPHODTECT","Recruiting","No Results Available","Other: 18F-FDG PET SCAN|Other: MRI DIFFUSION","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03121456"
81,"NCT03670901","A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)",,"Not yet recruiting","No Results Available","Biological: JHL1101|Biological: MabThera","Phase 3","null","https://ClinicalTrials.gov/show/NCT03670901"
82,"NCT03022123","The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Drug: PL-doxorubicin and epirubicin","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03022123"
83,"NCT03145064","Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: BGB-3111","Phase 2","null","https://ClinicalTrials.gov/show/NCT03145064"
84,"NCT02595242","Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma",,"Withdrawn","No Results Available","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Phase 1","null","https://ClinicalTrials.gov/show/NCT02595242"
85,"NCT01466868","Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma","AKTIL","Terminated","No Results Available","Drug: MK2206","Phase 2","null","https://ClinicalTrials.gov/show/NCT01466868"
86,"NCT01238692","A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)",,"Active, not recruiting","No Results Available","Drug: LBH589|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01238692"
87,"NCT00001271","A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma",,"Completed","No Results Available","Drug: IgG-RFB4-SMPT-dgA","Phase 1","null","https://ClinicalTrials.gov/show/NCT00001271"
88,"NCT01949818","Treatment of Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Drug: Yangzhengxiaoji capsule combined with CHOP regimen|Drug: CHOP regimen","Phase 4","null","https://ClinicalTrials.gov/show/NCT01949818"
89,"NCT03677154","A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy",,"Recruiting","No Results Available","Drug: Mosunetuzumab|Drug: Tocilizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03677154"
90,"NCT00645359","Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma","dMRI","Terminated","Has Results","Procedure: diffusion MRI","","October 8, 2014","https://ClinicalTrials.gov/show/NCT00645359"
91,"NCT01676558","A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Unknown status","No Results Available","Drug: 131I-rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01676558"
92,"NCT02752204","An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma","TORCH","Active, not recruiting","No Results Available","Drug: AZD 2014|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02752204"
93,"NCT03399747","Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma",,"Enrolling by invitation","No Results Available","Drug: Abb-R-CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT03399747"
94,"NCT01282476","Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Terminated","Has Results","Drug: Panobinostat with Rituximab","Phase 2","March 31, 2017","https://ClinicalTrials.gov/show/NCT01282476"
95,"NCT01766583","A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma","CLEAR","Completed","No Results Available","Drug: CC-292 + lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01766583"
96,"NCT03274492","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","POLARIX","Recruiting","No Results Available","Drug: Polatuzumab Vedotin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Vincristine Placebo|Drug: Prednisone|Drug: Polatuzumab vedotin Placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT03274492"
97,"NCT01556035","Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma","REV-LEG","Completed","No Results Available","Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT01556035"
98,"NCT02449265","Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02449265"
99,"NCT02449278","The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02449278"
100,"NCT02692248","Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: Rituximab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Dexamethasone","Phase 2","null","https://ClinicalTrials.gov/show/NCT02692248"
101,"NCT02412267","Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)","DLBL","Completed","No Results Available","Drug: O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)","Phase 2","null","https://ClinicalTrials.gov/show/NCT02412267"
102,"NCT02951156","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","Javelin DLBCL","Recruiting","No Results Available","Biological: Avelumab|Biological: Utomilumab|Biological: Rituximab|Other: Azacitidine|Drug: Bendamustine|Drug: Gemcitabine|Drug: Oxaliplatin","Phase 3","null","https://ClinicalTrials.gov/show/NCT02951156"
103,"NCT01197560","Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: Lenalidomide|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Rituximab|Drug: Etoposide","Phase 2|Phase 3","August 20, 2014","https://ClinicalTrials.gov/show/NCT01197560"
104,"NCT01054781","Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","No Results Available","Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01054781"
105,"NCT00530179","FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma","PET Chop","Unknown status","No Results Available","Procedure: Autologous Blood Stem Transplantation|Drug: R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00530179"
106,"NCT00776802","GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","GCS-100LE","Withdrawn","No Results Available","Drug: GCS-100|Drug: Etoposide; Dexamethasone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00776802"
107,"NCT02329080","New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement",,"Recruiting","No Results Available","Drug: Methotrexate|Drug: Rituximab|Drug: Cytarabine|Drug: Thiotepa|Drug: liposomial cytarabine|Drug: Etoposide|Drug: Ifosfamide|Drug: Carmustine|Radiation: whole brain radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT02329080"
108,"NCT01865058","The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.",,"Unknown status","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01865058"
109,"NCT02340936","Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: LR-ESHAP (lenalidomide 5 mg)|Drug: LR-ESHAP (lenalidomide 10 mg)|Drug: LR-ESHAP (lenalidomide 15 mg)|Drug: LR-ESHAP (lenalidomide 20 mg)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02340936"
110,"NCT03589469","Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Loncastuximab tesirine","Phase 2","null","https://ClinicalTrials.gov/show/NCT03589469"
111,"NCT01164267","Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)",,"Completed","No Results Available","Drug: Everolimus","Phase 2","null","https://ClinicalTrials.gov/show/NCT01164267"
112,"NCT02142049","Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Drug: Ibrutinib|Drug: Part 1: Dose Level 1","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02142049"
113,"NCT00486759","A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","Drug: Bevacizumab|Drug: Rituximab|Drug: CHOP|Drug: Placebo","Phase 3","December 31, 2012","https://ClinicalTrials.gov/show/NCT00486759"
114,"NCT01606605","Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01606605"
115,"NCT01481129","Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Drug: Akt Inhibitor MK2206|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Phase 2","April 7, 2017","https://ClinicalTrials.gov/show/NCT01481129"
116,"NCT02780830","AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","INHIBITOR","Withdrawn","No Results Available","Drug: AZD2014|Drug: Ibrutinib","Phase 1","null","https://ClinicalTrials.gov/show/NCT02780830"
117,"NCT02926833","A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","ZUMA-6","Recruiting","No Results Available","Biological: axicabtagene ciloleucel|Drug: atezolizumab (anti-PD-L1)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02926833"
118,"NCT01741792","Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: Blinatumomab","Phase 2","July 27, 2015","https://ClinicalTrials.gov/show/NCT01741792"
119,"NCT01599559","Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma",,"Recruiting","No Results Available","Other: observation|Radiation: 3D-Conformal Radiotherapy (3D-CRT)","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01599559"
120,"NCT02471911","KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma","KPT-330+RICE","Recruiting","No Results Available","Drug: KPT-330|Drug: Rituximab|Drug: Etoposide|Drug: Carboplatin|Drug: Ifosfamide|Drug: Dexamethasone","Phase 1","null","https://ClinicalTrials.gov/show/NCT02471911"
121,"NCT01186978","Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma","DLBCL","Active, not recruiting","No Results Available","Radiation: Radiation Therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01186978"
122,"NCT02753062","Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma","PTLD","Recruiting","No Results Available","Drug: bendamustine, rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02753062"
123,"NCT01481272","Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients","PLRG8","Completed","No Results Available","Drug: Ofatumumab|Drug: Etoposide|Drug: Ifosfamid|Drug: Mesna|Drug: Cytarabine|Drug: Methotrexate|Drug: Leukovorin|Drug: Granulocyte-Colony Stimulating Factor","Phase 2","null","https://ClinicalTrials.gov/show/NCT01481272"
124,"NCT01470456","Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Drug: SAR3419|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01470456"
125,"NCT01004991","Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: doxorubicin|Drug: prednisone|Drug: azacytidine","Phase 1|Phase 2","April 10, 2017","https://ClinicalTrials.gov/show/NCT01004991"
126,"NCT02874404","TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: PI3K-delta Inhibitor TGR-1202","Phase 2","null","https://ClinicalTrials.gov/show/NCT02874404"
127,"NCT03376958","Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: Apatinib","Phase 4","null","https://ClinicalTrials.gov/show/NCT03376958"
128,"NCT01472887","SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","STARLYTE","Completed","No Results Available","Drug: SAR3419","Phase 2","null","https://ClinicalTrials.gov/show/NCT01472887"
129,"NCT00169169","Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Drug: ACVBP|Drug: ACE|Drug: rituximab|Procedure: Autologous stem cell transplant","Phase 3","null","https://ClinicalTrials.gov/show/NCT00169169"
130,"NCT00790036","Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","PILLAR2","Completed","Has Results","Drug: Everolimus|Drug: Everolimus Placebo","Phase 3","July 12, 2017","https://ClinicalTrials.gov/show/NCT00790036"
131,"NCT03023878","Safety and Efficacy of Blinatumomab in Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Blinatumomab|Drug: Investigator's Choice Chemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT03023878"
132,"NCT01423539","A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)",,"Withdrawn","No Results Available","Drug: bendamustine|Drug: navitoclax|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01423539"
133,"NCT00836173","Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Withdrawn","No Results Available","Drug: RICE|Drug: GaRD Treatment","Phase 2","null","https://ClinicalTrials.gov/show/NCT00836173"
134,"NCT02957019","A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: L19-IL2 - Ph I|Drug: L19-IL2 at RD - Ph II|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02957019"
135,"NCT01678404","131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma",,"Unknown status","No Results Available","Drug: 131I-rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01678404"
136,"NCT03255096","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: RO6870810|Drug: Venetoclax|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03255096"
137,"NCT02112526","ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma",,"Unknown status","No Results Available","Drug: ACP-196","Phase 1","null","https://ClinicalTrials.gov/show/NCT02112526"
138,"NCT00869999","Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Completed","Has Results","Drug: Everolimus|Drug: rituximab","Phase 2","October 27, 2014","https://ClinicalTrials.gov/show/NCT00869999"
139,"NCT00978432","Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Terminated","Has Results","Drug: RAD001|Drug: LBH589|Drug: Doublet (RAD001 and LBH589)","Phase 2","June 7, 2016","https://ClinicalTrials.gov/show/NCT00978432"
140,"NCT01562990","Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse",,"Completed","No Results Available","Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01562990"
141,"NCT01502982","Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)","CRY-04","Completed","No Results Available","Drug: R-CHOEP14x6+HD-AraC+HD-Mtx","Phase 2","null","https://ClinicalTrials.gov/show/NCT01502982"
142,"NCT00831597","Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","904","Completed","No Results Available","Drug: bendamustine|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00831597"
143,"NCT01066429","DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Drug: Dexamethasone and dose-dense immunochemoterapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT01066429"
144,"NCT02530125","Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission",,"Terminated","Has Results","Other: Laboratory Biomarker Analysis|Biological: Pidilizumab","Phase 2","March 19, 2018","https://ClinicalTrials.gov/show/NCT02530125"
145,"NCT00474188","A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Terminated","Has Results","Drug: CC-5013 (lenalidomide)|Drug: dexamethasone","Phase 2","August 13, 2009","https://ClinicalTrials.gov/show/NCT00474188"
146,"NCT01287741","A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)",,"Completed","Has Results","Drug: Rituximab|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 3","August 17, 2017","https://ClinicalTrials.gov/show/NCT01287741"
147,"NCT02898259","Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Ixazomib|Drug: Lenalidomide|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02898259"
148,"NCT00169143","Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Drug: Rituximab + ACVBP regimen plus Pegfilgrastim|Procedure: Autologous stem cell transplant","Phase 2","null","https://ClinicalTrials.gov/show/NCT00169143"
149,"NCT00788606","R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma",,"Terminated","No Results Available","Drug: bevacizumab, Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00788606"
150,"NCT02077166","Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Ibrutinib|Drug: Lenalidomide|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02077166"
151,"NCT00918463","A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Terminated","Has Results","Drug: dasatinib","Phase 2","August 31, 2018","https://ClinicalTrials.gov/show/NCT00918463"
152,"NCT03391466","A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma","ZUMA-7","Recruiting","No Results Available","Drug: Axicabtagene Ciloleucel|Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.","Phase 3","null","https://ClinicalTrials.gov/show/NCT03391466"
153,"NCT02271945","Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas",,"Completed","Has Results","Drug: MEDI-551 12 mg/kg|Drug: MEDI0680 2.5 mg/kg|Drug: MEDI0680 10 mg/kg","Phase 1|Phase 2","March 12, 2018","https://ClinicalTrials.gov/show/NCT02271945"
154,"NCT00440583","The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP",,"Completed","No Results Available","Drug: chemotherapy followed by Zevalin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00440583"
155,"NCT02670616","Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: vincristine|Drug: Prednisolone","Phase 2","null","https://ClinicalTrials.gov/show/NCT02670616"
156,"NCT01040871","Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Drug: VELCADE|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Phase 2","November 27, 2013","https://ClinicalTrials.gov/show/NCT01040871"
157,"NCT02420210","Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","Drug: Bendamustine Hydrochloride|Biological: Obinutuzumab|Drug: Dexamethasone|Other: Quality-of-Life Assessment|Other: Laboratory Biomarker Analysis","Phase 2","March 14, 2018","https://ClinicalTrials.gov/show/NCT02420210"
158,"NCT03681938","Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?",,"Active, not recruiting","No Results Available","Procedure: Autograft","","null","https://ClinicalTrials.gov/show/NCT03681938"
159,"NCT00118209","Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone|Drug: etoposide|Drug: filgrastim|Drug: pegfilgrastim","Phase 3","null","https://ClinicalTrials.gov/show/NCT00118209"
160,"NCT00209014","Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease",,"Terminated","No Results Available","Drug: Thalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00209014"
161,"NCT02904577","Indolent Non Follicular Lymphomas Prognostic Project",,"Recruiting","No Results Available","Other: Any treatment, watch and wait policy included","","null","https://ClinicalTrials.gov/show/NCT02904577"
162,"NCT03569696","Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy","NivoM","Not yet recruiting","No Results Available","Biological: nivolumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03569696"
163,"NCT02992834","Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma",,"Not yet recruiting","No Results Available","Biological: IL-2 pre-treated CD19 cells|Biological: IL-7/IL-15 pre-treated CD19 cells","Phase 4","null","https://ClinicalTrials.gov/show/NCT02992834"
164,"NCT02679196","The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma",,"Recruiting","No Results Available","Drug: KA2237","Phase 1","null","https://ClinicalTrials.gov/show/NCT02679196"
165,"NCT02594163","Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","Drug: Brentuximab Vedotin|Drug: Rituximab|Drug: Bendamustine","Phase 2","October 16, 2018","https://ClinicalTrials.gov/show/NCT02594163"
166,"NCT02596971","A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Active, not recruiting","No Results Available","Drug: Atezolizumab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02596971"
167,"NCT00575406","Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma","NHL-14","Completed","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: liposomal Doxorubicin|Drug: Vincristin|Drug: Prednisolone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00575406"
168,"NCT01195714","Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years",,"Completed","No Results Available","Drug: Ofatumumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01195714"
169,"NCT02474550","Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02474550"
170,"NCT01852435","R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B",,"Active, not recruiting","No Results Available","Drug: R-CEOP-70|Drug: R-CEOP-90|Drug: R-CHOP-50","Phase 3","null","https://ClinicalTrials.gov/show/NCT01852435"
171,"NCT03003039","A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Biological: GB241|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03003039"
172,"NCT03283202","Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors",,"Recruiting","No Results Available","Drug: Avadomide (CC-122)|Drug: Rituximab|Drug: Cyclophosphamide 750mg/m2 by IV infusion|Drug: Vincristine|Drug: Prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03283202"
173,"NCT00394693","Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma",,"Completed","No Results Available","Genetic: Adenovirus Interferon gamma","Phase 2","null","https://ClinicalTrials.gov/show/NCT00394693"
174,"NCT03307746","A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma","RiVa","Recruiting","No Results Available","Drug: Varlilumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03307746"
175,"NCT03458546","Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Drug: Roflumilast","Phase 1","null","https://ClinicalTrials.gov/show/NCT03458546"
176,"NCT00931918","Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients",,"Completed","Has Results","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 2","January 11, 2017","https://ClinicalTrials.gov/show/NCT00931918"
177,"NCT02486952","MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma",,"Completed","Has Results","Drug: Cyclophosphamide|Drug: Hydroxydaunorubicin|Drug: Oncovin|Drug: Prednisone|Drug: Rituximab","","February 22, 2016","https://ClinicalTrials.gov/show/NCT02486952"
178,"NCT00316511","Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma",,"Completed","No Results Available","Drug: Aroplatin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00316511"
179,"NCT01786018","Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","TBF","Unknown status","No Results Available","Drug: Thiotepa|Drug: Busulfan|Drug: Fludarabin|Procedure: transplant (HCT)|Radiation: Cytoreduction|Drug: Immunosuppression|Drug: Cyclosporine|Drug: Methotrexate|Drug: ATG|Procedure: Collection and infusions of Donor PBSC","Phase 2","null","https://ClinicalTrials.gov/show/NCT01786018"
180,"NCT02891590","Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas",,"Recruiting","No Results Available","Drug: DTRMWXHS-12","Phase 1","null","https://ClinicalTrials.gov/show/NCT02891590"
181,"NCT00147121","Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)",,"Completed","No Results Available","Drug: Rituximab + Standard CHOP|Drug: Rituximab + Bi-weekly CHOP","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT00147121"
182,"NCT02600897","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02600897"
183,"NCT00434629","Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant",,"Completed","No Results Available","Drug: Bexxar","Phase 1","null","https://ClinicalTrials.gov/show/NCT00434629"
184,"NCT02542111","A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL",,"Recruiting","No Results Available","Drug: Bortezomib|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin","Phase 2","null","https://ClinicalTrials.gov/show/NCT02542111"
185,"NCT00499018","Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma","DLCL04","Unknown status","No Results Available","Drug: Rituximab|Drug: Ciclofosfamide|Drug: Doxorubicina|Drug: Vincristina|Drug: Prednisone|Drug: Pegfilgrastim|Drug: Mitoxantrone|Drug: ARA-C|Drug: Lenograstim|Drug: BCNU|Drug: VP-16|Procedure: ASCT","Phase 3","null","https://ClinicalTrials.gov/show/NCT00499018"
186,"NCT01724021","A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a",,"Completed","Has Results","Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Drug: Bendamustine|Drug: Rituximab","Phase 3","August 29, 2016","https://ClinicalTrials.gov/show/NCT01724021"
187,"NCT01788189","Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas","LeMLAR","Recruiting","No Results Available","Drug: Lenalidomide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01788189"
188,"NCT01044004","Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue",,"Withdrawn","No Results Available","Drug: Armodafinil|Drug: placebo","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01044004"
189,"NCT01453205","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: MEDI-551 2 mg/kg|Drug: Rituximab|Drug: ICE|Drug: DHAP|Procedure: Autologous Stem Cell Transplant (ASCT)|Drug: MEDI-551 4 mg/kg","Phase 2","March 12, 2018","https://ClinicalTrials.gov/show/NCT01453205"
190,"NCT02354846","An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02354846"
191,"NCT00038571","Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy",,"Completed","No Results Available","Drug: PS341 (Bortezomib)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00038571"
192,"NCT02660710","Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Drug: R-CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT02660710"
193,"NCT00849654","Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma","PCYC-04753","Completed","No Results Available","Drug: PCI-32765","Phase 1","null","https://ClinicalTrials.gov/show/NCT00849654"
194,"NCT03206671","Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","B-NHL 2013","Recruiting","No Results Available","Drug: Rituximab window|Drug: Additional doses of Rituximab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin hydrochloride|Drug: Vindesine Sulfate|Drug: Etoposide|Drug: Ifosfamide|Drug: Methotrexate|Drug: Prednisolone|Drug: Vincristine","Phase 3","null","https://ClinicalTrials.gov/show/NCT03206671"
195,"NCT03060850","A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL",,"Recruiting","No Results Available","Drug: AC0010MA","Phase 1","null","https://ClinicalTrials.gov/show/NCT03060850"
196,"NCT02900716","Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas",,"Recruiting","No Results Available","Drug: DTRMWXHS-12|Drug: DTRM-505|Drug: DTRM-555","Phase 1","null","https://ClinicalTrials.gov/show/NCT02900716"
197,"NCT02576990","Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)",,"Active, not recruiting","No Results Available","Biological: Pembrolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02576990"
198,"NCT03281551","Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma",,"Recruiting","No Results Available","Drug: PZ01 CAR-T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03281551"
199,"NCT01414855","A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)",,"Completed","Has Results","Drug: obinutuzumab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone|Drug: vincristine","Phase 2","March 19, 2015","https://ClinicalTrials.gov/show/NCT01414855"
200,"NCT01087424","Mini-CHOP and Rituximab in Patients Aged Over 80 Years",,"Completed","No Results Available","Drug: R mini CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT01087424"
201,"NCT02229981","Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma","ABC-102","Withdrawn","No Results Available","Drug: ABC294640","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02229981"
202,"NCT02570542","Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Procedure: leukapheresis|Drug: Plerixafor|Drug: carmustine, etoposide, cytarabine, melphalan|Procedure: Autologous Stem Cell Transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT02570542"
203,"NCT00867087","Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: inotuzumab ozogamicin (CMC-544)|Drug: rituximab","Phase 2","August 22, 2017","https://ClinicalTrials.gov/show/NCT00867087"
204,"NCT01965119","Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma","JAK2","Completed","No Results Available","Drug: Ruxolitinib","Phase 2","null","https://ClinicalTrials.gov/show/NCT01965119"
205,"NCT00338494","Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma",,"Completed","No Results Available","Drug: Clofarabine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00338494"
206,"NCT00216164","Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Drug: Rituximab|Drug: Gemcitabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00216164"
207,"NCT01325701","Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Completed","Has Results","Drug: ibrutinib","Phase 2","February 16, 2017","https://ClinicalTrials.gov/show/NCT01325701"
208,"NCT03129828","Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","ImbruVeRCHOP","Recruiting","No Results Available","Drug: Ibrutinib and Bortezomib + R-CHOP","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03129828"
209,"NCT02976857","A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects","C-CAR011","Recruiting","No Results Available","Biological: C-CAR-011","Phase 1","null","https://ClinicalTrials.gov/show/NCT02976857"
210,"NCT01535989","Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma","IOSI-LND-001","Completed","No Results Available","Drug: Inotuzumab Ozogamicin|Drug: Temsirolimus","Phase 1","null","https://ClinicalTrials.gov/show/NCT01535989"
211,"NCT02219737","Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Drug: Carboplatin|Drug: Etoposide|Drug: Ibrutinib|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02219737"
212,"NCT00558220","R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas","R-MCEB","Completed","No Results Available","Procedure: immunotherapy|Procedure: Induction treatment part 1|Procedure: Induction treatment part 2 with PBPC collection|Procedure: Induction treatment part 3|Procedure: Consolidation treatment part 1: HD-chemotherapy with ASCT|Radiation: Consolidation treatment part 2: Radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00558220"
213,"NCT02268045","Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: RTXM83","Phase 3","null","https://ClinicalTrials.gov/show/NCT02268045"
214,"NCT00054665","PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: PS-341|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Filgrastim","Phase 2","September 11, 2012","https://ClinicalTrials.gov/show/NCT00054665"
215,"NCT01854372","Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.",,"Withdrawn","No Results Available","Drug: R-HCVAD and R-MC","Phase 2","null","https://ClinicalTrials.gov/show/NCT01854372"
216,"NCT01510184","Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy",,"Terminated","No Results Available","Drug: Zevalin (ibritumomab tiuxetan)","Phase 3","null","https://ClinicalTrials.gov/show/NCT01510184"
217,"NCT01991184","A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.",,"Active, not recruiting","No Results Available","Drug: GDC-0853","Phase 1","null","https://ClinicalTrials.gov/show/NCT01991184"
218,"NCT03287817","CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","ALEXANDER","Recruiting","No Results Available","Biological: AUTO3","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03287817"
219,"NCT01715961","Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma","SARCOPENIE","Completed","No Results Available","Procedure: anthropometric measurement","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01715961"
220,"NCT01976585","In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy",,"Recruiting","No Results Available","Drug: rhuFlt3L/CDX-301|Drug: Poly-ICLC","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01976585"
221,"NCT03151044","R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL",,"Recruiting","No Results Available","Drug: High-dose Epirubicin Combined with CVP ± Rituximab|Drug: Standard-dose Epirubicin Combined with CVP ± Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT03151044"
222,"NCT00799513","Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00799513"
223,"NCT03346642","Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs",,"Recruiting","No Results Available","Drug: Decitabine|Drug: GVD chemotherapy|Drug: SHR-1210","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03346642"
224,"NCT01846390","Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Romidepsin","Phase 1","null","https://ClinicalTrials.gov/show/NCT01846390"
225,"NCT00386321","Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Drug: Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00386321"
226,"NCT01582776","Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Lenalidomide and GA101","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01582776"
227,"NCT00553943","Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis",,"Completed","No Results Available","Drug: Rituximab|Drug: Cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00553943"
228,"NCT01523834","Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT","FIL_PanAL10","Completed","No Results Available","Drug: Panobinostat","Phase 2","null","https://ClinicalTrials.gov/show/NCT01523834"
229,"NCT00400478","A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13",,"Completed","No Results Available","Drug: Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00400478"
230,"NCT00717925","Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)",,"Completed","No Results Available","Drug: Inotuzumab Ozogamicin (CMC-544)","Phase 1","null","https://ClinicalTrials.gov/show/NCT00717925"
231,"NCT02054559","R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL","ASPIRE","Withdrawn","No Results Available","Drug: R-CHOP|Radiation: Radiotherapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT02054559"
232,"NCT03029338","CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma",,"Recruiting","No Results Available","Biological: CD19 CAR T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03029338"
233,"NCT03259529","Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL","BeGeRN","Recruiting","No Results Available","Drug: Bendamustine hydrochloride|Drug: Gemcitabine 500 mg|Drug: Gemcitabine 700 mg|Drug: Gemcitabine 1000 mg|Drug: Nivolumab|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03259529"
234,"NCT01679119","Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","INCA","Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisolone|Drug: Rituximab|Drug: Inotuzumab Ozogamicin|Drug: Gemcitabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01679119"
235,"NCT01925612","Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)",,"Terminated","Has Results","Drug: brentuximab vedotin|Drug: rituximab|Drug: vincristine|Drug: cyclophosphamide|Drug: prednisone|Drug: doxorubicin","Phase 2","June 21, 2018","https://ClinicalTrials.gov/show/NCT01925612"
236,"NCT03656835","Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Procedure: Molecular Nanotechnology","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03656835"
237,"NCT03072771","Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: Blinatumomab|Procedure: Autologous stem cell transplant|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Procedure: Peripheral blood draws","Phase 1","null","https://ClinicalTrials.gov/show/NCT03072771"
238,"NCT01670370","Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.",,"Active, not recruiting","No Results Available","Drug: R-GemOx","Phase 2","null","https://ClinicalTrials.gov/show/NCT01670370"
239,"NCT01653067","STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma","STORM","Unknown status","No Results Available","Drug: Rituximab, Temsirolimus, DHAP, intravenous","Phase 2","null","https://ClinicalTrials.gov/show/NCT01653067"
240,"NCT02734771","A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","BV mini CHP","Recruiting","No Results Available","Drug: Brentuximab vedotin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT02734771"
241,"NCT03305445","Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL",,"Recruiting","No Results Available","Drug: Ipilimumab|Drug: Nivolumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03305445"
242,"NCT01516567","Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation",,"Active, not recruiting","No Results Available","Drug: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01516567"
243,"NCT01279902","Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL",,"Unknown status","No Results Available","Drug: Rituximab plus CHOP Immunochemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT01279902"
244,"NCT01859819","Treatment for Advanced B-Cell Lymphoma","REBOOT","Recruiting","No Results Available","Drug: Rituximab|Drug: IT Cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01859819"
245,"NCT00498914","Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects",,"Terminated","No Results Available","Drug: YM155","Phase 2","null","https://ClinicalTrials.gov/show/NCT00498914"
246,"NCT02252146","Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation",,"Completed","Has Results","Drug: IMO-8400","Phase 1|Phase 2","November 14, 2017","https://ClinicalTrials.gov/show/NCT02252146"
247,"NCT03715296","Lenalidomide Based Immunotherapy in the Treatment of DLBCL",,"Not yet recruiting","No Results Available","Drug: Lenalidomide 25mg","","null","https://ClinicalTrials.gov/show/NCT03715296"
248,"NCT01724294","An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01724294"
249,"NCT03610061","A Trial of Radiotherapy and Durvalumab in DLBCL","RaDD","Not yet recruiting","No Results Available","Drug: Durvalumab|Radiation: Radiotherapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT03610061"
250,"NCT03136497","A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Drug: ABT-199|Drug: Ibrutinib|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03136497"
251,"NCT03311958","Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance",,"Recruiting","No Results Available","Drug: Nivolumab, IV, 240 mg","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT03311958"
252,"NCT03456726","Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation",,"Recruiting","No Results Available","Drug: Tazemetostat","Phase 2","null","https://ClinicalTrials.gov/show/NCT03456726"
253,"NCT02423291","A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL","FIL_SGN01","Completed","Has Results","Drug: Brentuximab Vedotin","Phase 2","June 26, 2017","https://ClinicalTrials.gov/show/NCT02423291"
254,"NCT03349346","Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents",,"Recruiting","No Results Available","Drug: Idelalisib|Drug: Rituximab|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide","Phase 1","null","https://ClinicalTrials.gov/show/NCT03349346"
255,"NCT03201471","Chidamide With R-CHOP Regimen for DLBCL Patients","DLBCL","Recruiting","No Results Available","Drug: Chidamide + R-CHOP regimen","Phase 2","null","https://ClinicalTrials.gov/show/NCT03201471"
256,"NCT03639181","Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)",,"Recruiting","No Results Available","Biological: GB226","Phase 2","null","https://ClinicalTrials.gov/show/NCT03639181"
257,"NCT01340443","An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01340443"
258,"NCT03009344","A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Drug: tazemetostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT03009344"
259,"NCT00204659","Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma",,"Completed","No Results Available","Drug: Rituximab + CHOP chemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00204659"
260,"NCT02890602","Erythropoietin for Management of Anemia Caused by Chemotherapy",,"Active, not recruiting","No Results Available","Drug: Darbepoetin alfa|Drug: R-CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT02890602"
261,"NCT03263026","Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™",,"Recruiting","No Results Available","Drug: Enzastaurin Hydrochloride|Other: R-CHOP + placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT03263026"
262,"NCT03364439","R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients","FIL_DLCL10","Active, not recruiting","No Results Available","Drug: Treatment plan","Phase 2","null","https://ClinicalTrials.gov/show/NCT03364439"
263,"NCT02758925","CyBeR Association in Relapsed/Refractory DLBCL","CyBeR-Lymph","Not yet recruiting","No Results Available","Drug: Rituximab|Drug: Bendamustine|Drug: Cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT02758925"
264,"NCT01693614","Safety and Efficacy of BKM120 in Relapsed and Refractory NHL",,"Completed","Has Results","Drug: Buparlisib","Phase 2","September 28, 2018","https://ClinicalTrials.gov/show/NCT01693614"
265,"NCT02617485","MabionCD20® Compared to MabThera® in Lymphoma Patients",,"Unknown status","No Results Available","Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: prednisone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02617485"
266,"NCT00968331","Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Terminated","No Results Available","Drug: Lenalidomide plus Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00968331"
267,"NCT03105596","Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)",,"Not yet recruiting","No Results Available","Drug: Chidamide plus DICE Regimen","Phase 2","null","https://ClinicalTrials.gov/show/NCT03105596"
268,"NCT02753647","Chidamide Plus R-CHOP in Elderly DLBCL",,"Recruiting","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Chidamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02753647"
269,"NCT02857998","A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms",,"Recruiting","No Results Available","Drug: HMPL-523","Phase 1","null","https://ClinicalTrials.gov/show/NCT02857998"
270,"NCT03671018","A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Mosunetuzumab|Drug: Polatuzumab vedotin|Drug: Rituximab|Drug: Bendamustine|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Tocilizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03671018"
271,"NCT00466258","LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","LINFOTARGAM","Completed","No Results Available","Drug: R-CHOP|Drug: Highly active antiretroviral therapy|Drug: Central nervous system (CNS) prophylaxis|Drug: Prophylaxis of opportunistic infections and support treatment","Phase 4","null","https://ClinicalTrials.gov/show/NCT00466258"
272,"NCT02752815","Reduced Chemotherapy in Low Risk DLBCL",,"Recruiting","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Vincristine|Drug: Prednisone","Phase 4","null","https://ClinicalTrials.gov/show/NCT02752815"
273,"NCT01659099","GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma","GAINED","Terminated","No Results Available","Drug: GA101|Drug: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Bleomycin|Drug: Vindesin|Drug: Vincristine","Phase 3","null","https://ClinicalTrials.gov/show/NCT01659099"
274,"NCT02549651","MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)",,"Recruiting","No Results Available","Drug: MEDI4736|Drug: tremelimumab|Drug: AZD9150","Phase 1","null","https://ClinicalTrials.gov/show/NCT02549651"
275,"NCT01914718","Dose-adjusted EPOCH-R in MYC Positive DLBCL",,"Terminated","No Results Available","Drug: DA-EPOCH-R","Phase 2","null","https://ClinicalTrials.gov/show/NCT01914718"
276,"NCT01729806","Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma",,"Completed","No Results Available","Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01729806"
277,"NCT03677141","A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Mosunetuzumab|Drug: Polatuzumab Vedotin|Drug: Rituxumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Tocilizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03677141"
278,"NCT02323230","A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL",,"Unknown status","No Results Available","Biological: DPX-Survivac|Drug: Cyclophosphamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02323230"
279,"NCT02399085","A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL","L-MIND","Active, not recruiting","No Results Available","Drug: MOR00208|Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02399085"
280,"NCT00850512","Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy","CHOP21+R-Z","Completed","No Results Available","Drug: CHOP21-R|Drug: Zevalin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00850512"
281,"NCT01965977","Bortezomib Maintenance in High Risk DLBCL","Borma","Recruiting","No Results Available","Drug: Bortezomib","Phase 2","null","https://ClinicalTrials.gov/show/NCT01965977"
282,"NCT02653989","Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Withdrawn","No Results Available","Biological: MDV9300","Phase 2","null","https://ClinicalTrials.gov/show/NCT02653989"
283,"NCT03719989","Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","EPIC","Not yet recruiting","No Results Available","Drug: azacitidine plus R-GDP","Phase 2","null","https://ClinicalTrials.gov/show/NCT03719989"
284,"NCT01804127","Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL",,"Unknown status","No Results Available","Drug: R-CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT01804127"
285,"NCT03484819","Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma",,"Not yet recruiting","No Results Available","Drug: Copanlisib|Other: Laboratory Biomarker Analysis|Biological: Nivolumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03484819"
286,"NCT02456207","A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Drug: SCT400|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02456207"
287,"NCT02815397","DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma","DLBCL","Terminated","Has Results","Drug: Metformin","Phase 2","November 17, 2017","https://ClinicalTrials.gov/show/NCT02815397"
288,"NCT03367143","Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL",,"Recruiting","No Results Available","Drug: Lenalidomide|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03367143"
289,"NCT02670317","Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.","FIL-GALILEO","Terminated","No Results Available","Drug: Obinutuzumab|Drug: Ibrutinib|Drug: CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT02670317"
290,"NCT02445248","Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients","JULIET","Active, not recruiting","No Results Available","Biological: CTL019","Phase 2","null","https://ClinicalTrials.gov/show/NCT02445248"
291,"NCT00085696","VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma",,"Completed","No Results Available","Drug: VELCADE and rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00085696"
292,"NCT02658968","Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)",,"Recruiting","No Results Available","Drug: Betalutin","Phase 1","null","https://ClinicalTrials.gov/show/NCT02658968"
293,"NCT02955628","RICE-ibrutinib in Relapsed DLBCL",,"Recruiting","No Results Available","Drug: Ibrutinib-RICE","Phase 2","null","https://ClinicalTrials.gov/show/NCT02955628"
294,"NCT01933516","GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: GP2013","Phase 1","null","https://ClinicalTrials.gov/show/NCT01933516"
295,"NCT03571568","A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Biological: BI1206","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03571568"
296,"NCT02206308","Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.",,"Completed","No Results Available","Biological: Chimeric anti-CD20 monoclonal antibody","Phase 1","null","https://ClinicalTrials.gov/show/NCT02206308"
297,"NCT01704963","A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms",,"Completed","No Results Available","Drug: PCI-32765","Phase 1","null","https://ClinicalTrials.gov/show/NCT01704963"
298,"NCT02128061","Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+",,"Active, not recruiting","No Results Available","Drug: Lenalidomide|Drug: Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT02128061"
299,"NCT01856192","Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT01856192"
300,"NCT00998946","Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: Pralatrexate Injection|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid","Phase 2","null","https://ClinicalTrials.gov/show/NCT00998946"
301,"NCT01534949","Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial","Triad-DLBCL","Terminated","No Results Available","Biological: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01534949"
302,"NCT00902525","Zevalin Twice in Aggressive Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: 90Y-Ibritumomab Tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00902525"
303,"NCT00521638","Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: TRU-015","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00521638"
304,"NCT02388581","First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL",,"Recruiting","No Results Available","Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole","Phase 2","null","https://ClinicalTrials.gov/show/NCT02388581"
305,"NCT03520920","BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",,"Recruiting","No Results Available","Drug: BGB-3111","Phase 2","null","https://ClinicalTrials.gov/show/NCT03520920"
306,"NCT00577629","Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma",,"Completed","Has Results","Drug: cyclophosphamide|Drug: etoposide|Drug: rituximab|Drug: cytarabine|Drug: doxorubicin|Drug: tositumomab","Phase 2","April 15, 2013","https://ClinicalTrials.gov/show/NCT00577629"
307,"NCT02134262","Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",,"Unknown status","No Results Available","Drug: Cyclophosphamide or Bendamustine|Genetic: Dose Level -1|Genetic: Dose Level 1|Genetic: Dose Level 2|Genetic: Dose Level 3","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02134262"
308,"NCT02700022","A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",,"Terminated","No Results Available","Drug: Alisertib","Phase 1","null","https://ClinicalTrials.gov/show/NCT02700022"
309,"NCT03298412","Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT",,"Recruiting","No Results Available","Drug: Blinatumomab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03298412"
310,"NCT00299494","Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Drug: inotuzumab ozogamicin|Drug: Rituximab","Phase 1|Phase 2","March 8, 2018","https://ClinicalTrials.gov/show/NCT00299494"
311,"NCT00924326","CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR PBL","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00924326"
312,"NCT03401853","Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03401853"
313,"NCT00211276","A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: ONTAK (denileukin diftitox)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00211276"
314,"NCT00073749","Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Inotuzumab ozogamicin [CMC-544]","Phase 1","October 26, 2018","https://ClinicalTrials.gov/show/NCT00073749"
315,"NCT00271050","External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Other: external beam radiotherapy plus 90-Y ibritumomab tiuxetan","Phase 1","null","https://ClinicalTrials.gov/show/NCT00271050"
316,"NCT01569750","A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",,"Completed","No Results Available","Drug: Part 1, Cohort 1|Drug: Part 1, Cohort 2|Drug: Part 1, Cohort 3|Drug: Part 2, Cohort 1|Drug: Part 2, Cohort 2","Phase 1","null","https://ClinicalTrials.gov/show/NCT01569750"
317,"NCT00515138","A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant",,"Terminated","No Results Available","Drug: Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT00515138"
318,"NCT03558750","Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma",,"Recruiting","No Results Available","Biological: Nivolumab|Biological: Rituximab|Drug: Lenalidomide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03558750"
319,"NCT03488251","PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_002)",,"Recruiting","No Results Available","Drug: MT-3724","Phase 2","null","https://ClinicalTrials.gov/show/NCT03488251"
320,"NCT02361346","PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia","MT-3724NHL001","Recruiting","No Results Available","Drug: MT-3724","Phase 1","null","https://ClinicalTrials.gov/show/NCT02361346"
321,"NCT03340766","Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)",,"Recruiting","No Results Available","Drug: Blinatumomab|Drug: Pembrolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03340766"
322,"NCT01148108","Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma",,"Completed","No Results Available","Drug: Canfosfamide HCl for injection","Phase 2","null","https://ClinicalTrials.gov/show/NCT01148108"
323,"NCT00556127","Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma","DLBCL","Completed","No Results Available","Drug: Rituximab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Granulocyte-colony-stimulating factor|Drug: Mitoxantrone|Drug: Cytarabine ARA-C|Drug: Dexamethasone|Drug: Carmustine BCNU|Drug: Etoposide|Drug: Melphalan|Radiation: Radiotherapy|Procedure: PBSC reinfusion","Phase 2","null","https://ClinicalTrials.gov/show/NCT00556127"
324,"NCT03571828","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",,"Not yet recruiting","No Results Available","Drug: AMG 562","Phase 1","null","https://ClinicalTrials.gov/show/NCT03571828"
325,"NCT02282358","Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",,"Active, not recruiting","No Results Available","Drug: Mocetinostat","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02282358"
326,"NCT01478542","OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","OPTIMAL>60","Recruiting","No Results Available","Drug: Conventional Vincristine|Drug: Liposomal Vincristine|Drug: Ricover-scheme rituximab|Drug: optimised rituximab-schedule","Phase 3","null","https://ClinicalTrials.gov/show/NCT01478542"
327,"NCT00768339","A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas",,"Terminated","No Results Available","Drug: AEG35156 antisense IV infusion","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00768339"
328,"NCT01990144","Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL",,"Unknown status","No Results Available","Drug: Bendamustine+Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01990144"
329,"NCT02674750","Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations",,"Recruiting","No Results Available","Drug: CUDC-907","Phase 2","null","https://ClinicalTrials.gov/show/NCT02674750"
330,"NCT02564744","Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL",,"Recruiting","No Results Available","Drug: Debio 1562|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02564744"
331,"NCT02495454","GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma","FIL_GAEL","Suspended","No Results Available","Drug: Ga101","Phase 2","null","https://ClinicalTrials.gov/show/NCT02495454"
332,"NCT01092182","Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: EPOCH-R|Drug: EPOCH-RR","Phase 2","null","https://ClinicalTrials.gov/show/NCT01092182"
333,"NCT03645395","PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)",,"Not yet recruiting","No Results Available","Drug: MT-3724","Phase 2","null","https://ClinicalTrials.gov/show/NCT03645395"
334,"NCT01241734","Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL","RICER","Unknown status","No Results Available","Drug: Revlimid","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01241734"
335,"NCT03467373","A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Drug: RO7082859|Drug: Obinutuzumab (G)|Drug: Rituximab (R)|Drug: Tocilizumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 1","null","https://ClinicalTrials.gov/show/NCT03467373"
336,"NCT01691898","A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","ROMULUS","Active, not recruiting","Has Results","Drug: Obinutuzumab|Drug: Pinatuzumab Vedotin|Drug: Polatuzumab Vedotin|Drug: Rituximab","Phase 1|Phase 2","April 19, 2018","https://ClinicalTrials.gov/show/NCT01691898"
337,"NCT02836925","Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection",,"Recruiting","No Results Available","Drug: Ledipasvir+Sofosbuvir|Drug: Sofosbuvir+Velpatasvir","Phase 2","null","https://ClinicalTrials.gov/show/NCT02836925"
338,"NCT03244176","Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study","AvR-CHOP","Recruiting","No Results Available","Drug: Avelumab","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT03244176"
339,"NCT00724971","Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab",,"Completed","No Results Available","Drug: Inotuzumab Ozogamicin (CMC-544)|Drug: Rituximab (Rituxan)","Phase 1","null","https://ClinicalTrials.gov/show/NCT00724971"
340,"NCT01234467","Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma",,"Completed","Has Results","Drug: Bendamustine|Drug: Rituximab","Phase 2","April 26, 2017","https://ClinicalTrials.gov/show/NCT01234467"
341,"NCT01471210","Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: Urelumab (BMS-663513)","Phase 1","null","https://ClinicalTrials.gov/show/NCT01471210"
342,"NCT01415765","MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma",,"Withdrawn","No Results Available","Drug: MLN4924|Drug: Etoposide|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Rituximab|Drug: Filgrastim","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01415765"
343,"NCT02584920","A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma",,"Completed","No Results Available","Drug: HLX01|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02584920"
344,"NCT03664297","Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor",,"Recruiting","No Results Available","Drug: SHR1459","Phase 1","null","https://ClinicalTrials.gov/show/NCT03664297"
345,"NCT02205333","A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies","MEDI6469","Terminated","Has Results","Biological: MEDI6469 Monotherapy|Biological: MEDI6469 Plus Tremelimumab|Biological: MEDI6469 Plus Durvalumab|Biological: MEDI6469 plus Rituximab","Phase 1|Phase 2","May 8, 2017","https://ClinicalTrials.gov/show/NCT02205333"
346,"NCT01944943","Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia","VISMOLY","Terminated","No Results Available","Drug: Vismodegib","Phase 2","null","https://ClinicalTrials.gov/show/NCT01944943"
347,"NCT01361191","Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","R-MEGACHOP","Completed","No Results Available","Drug: R-MEGACHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT01361191"
348,"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Drug: Venetoclax|Drug: Ibrutinib|Drug: Prednisone|Drug: Obinutuzumab|Drug: Revlimid (lenalidomide)","Phase 1","null","https://ClinicalTrials.gov/show/NCT03223610"
349,"NCT03422523","Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy","ARGO","Recruiting","No Results Available","Drug: Atezolizumab|Drug: Rituximab|Drug: Gemcitabine 1000 mg|Drug: Oxaliplatin 100 MG","Phase 2","null","https://ClinicalTrials.gov/show/NCT03422523"
350,"NCT02049541","Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: PI3K inhibitor BKM120|Biological: rituximab|Other: Pharmacodynamics|Other: Correlative studies","Phase 1","null","https://ClinicalTrials.gov/show/NCT02049541"
351,"NCT02207062","Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02207062"
352,"NCT02592876","Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma",,"Terminated","No Results Available","Drug: denintuzumab mafodotin|Drug: rituximab|Drug: ifosfamide|Drug: carboplatin|Drug: etoposide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02592876"
353,"NCT03483688","A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects",,"Not yet recruiting","No Results Available","Biological: CD19-directed CAR-T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03483688"
354,"NCT00946023","Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab",,"Terminated","Has Results","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: Rituximab|Biological: Allogeneic Bone Marrow Transplant (BMT)","Phase 2","July 24, 2018","https://ClinicalTrials.gov/show/NCT00946023"
355,"NCT02732236","Marginal Zone Lymphoma Cohort in Korea",,"Recruiting","No Results Available","Other: Rituximab","","null","https://ClinicalTrials.gov/show/NCT02732236"
356,"NCT01009970","Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Doxorubicin","Phase 2","null","https://ClinicalTrials.gov/show/NCT01009970"
357,"NCT03372837","Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT03372837"
358,"NCT02044276","A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia","AVOID","Completed","No Results Available","Drug: lipegfilgrastim|Drug: pegfilgrastim","Phase 3","null","https://ClinicalTrials.gov/show/NCT02044276"
359,"NCT00842595","Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas",,"Completed","No Results Available","Drug: rituximab|Drug: vinorelbine|Drug: ifosfamide|Drug: Mitoxantrone|Drug: Prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00842595"
360,"NCT00841945","Treatment of Aggressive Localized Lymphoma",,"Terminated","No Results Available","Drug: rituximab|Drug: doxorubicin|Drug: vincristine|Drug: prednisone|Procedure: radiotherapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00841945"
361,"NCT02843061","Combination of Rituximab and NK Immunotherapy for B Lymphoma",,"Recruiting","No Results Available","Drug: Rituximab|Biological: NK immunotherapy","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02843061"
362,"NCT01809600","Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults","RBL","Completed","No Results Available","Other: No intervention (observational study)","","null","https://ClinicalTrials.gov/show/NCT01809600"
363,"NCT03684694","Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",,"Not yet recruiting","No Results Available","Drug: Loncastuximab Tesirine and Ibrutinib","Phase 1","null","https://ClinicalTrials.gov/show/NCT03684694"
364,"NCT00586391","CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL","CRETI-NH","Active, not recruiting","No Results Available","Genetic: CD19CAR-28-zeta T cells|Drug: Ipilimumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00586391"
365,"NCT01959698","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Drug: Carboplatin|Drug: Carfilzomib|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01959698"
366,"NCT02633111","DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Other: collected at pre-treatment tumor biopsy|Other: Peripheral blood tests|Device: PET/CT","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02633111"
367,"NCT00599170","Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00599170"
368,"NCT01397825","MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine",,"Completed","Has Results","Drug: Alisertib (MLN8237)|Drug: Rituximab|Drug: Vincristine","Phase 1|Phase 2","March 27, 2018","https://ClinicalTrials.gov/show/NCT01397825"
369,"NCT02955823","A Phase II Study of the FIL on Elderly Frail Patients With DLBCL",,"Recruiting","No Results Available","Drug: Rituximab-Dexamethasone-Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02955823"
370,"NCT03255018","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas",,"Recruiting","No Results Available","Drug: Pembrolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03255018"
371,"NCT02737085","the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)",,"Active, not recruiting","No Results Available","Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02737085"
372,"NCT01613300","Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients",,"Active, not recruiting","No Results Available","Drug: Ofatumumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01613300"
373,"NCT01718691","Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma",,"Completed","Has Results","Drug: SyB L-0501|Drug: rituximab","Phase 2","April 27, 2016","https://ClinicalTrials.gov/show/NCT01718691"
374,"NCT03207178","Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Biological: Mixed CD19/CD20 CAR-T Transfer","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03207178"
375,"NCT00487513","Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials",,"Completed","No Results Available","Procedure: Procurement of Follicular B Cell Lymphoma Cells","","null","https://ClinicalTrials.gov/show/NCT00487513"
376,"NCT03321643","Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma",,"Suspended","No Results Available","Drug: Atezolizumab|Drug: Gemcitabine|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03321643"
377,"NCT00324467","Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","LYTPET","Active, not recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Ondansetron|Drug: Dexamethasone|Drug: Diphenhydramine|Drug: Acetaminophen|Drug: Ifosfamide|Drug: Mesna (IV)|Drug: Mesna (oral)|Drug: Carboplatin|Drug: Etoposide|Drug: Rituximab|Other: PET Scan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00324467"
378,"NCT03314922","A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)",,"Recruiting","No Results Available","Drug: INCB050465","Phase 1","null","https://ClinicalTrials.gov/show/NCT03314922"
379,"NCT02867553","Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions","RADIO-LYMPH","Active, not recruiting","No Results Available","Drug: rituximab|Radiation: Multi-fields radiotherapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT02867553"
380,"NCT00455897","CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: GM-CSF|Drug: CHOP|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00455897"
381,"NCT02012088","Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb",,"Active, not recruiting","No Results Available","Drug: RCOMP|Drug: RCHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT02012088"
382,"NCT01235793","The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma","DRBEAT","Recruiting","No Results Available","Drug: Temozolomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT01235793"
383,"NCT02443077","Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Procedure: Autologous Bone Marrow Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Etoposide|Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Other: Pharmacogenomic Study|Other: Placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT02443077"
384,"NCT03465527","Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL",,"Active, not recruiting","No Results Available","Drug: PrednisoLONE 50 MG","Phase 2","null","https://ClinicalTrials.gov/show/NCT03465527"
385,"NCT02628405","R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02628405"
386,"NCT01516580","Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients",,"Active, not recruiting","No Results Available","Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C","Phase 3","null","https://ClinicalTrials.gov/show/NCT01516580"
387,"NCT03213977","R-DA-EDOCH Versus R-CEOP90, w/o Upfront Auto-HSCT in Young Patients With Intermediate/High-risk DLBCL",,"Recruiting","No Results Available","Drug: R-DA-EPOCH|Drug: R-DA-EPOCH + auto-HSCT|Drug: R-CEOP90|Drug: R-CEOP90 + auto-HSCT","Phase 3","null","https://ClinicalTrials.gov/show/NCT03213977"
388,"NCT01148446","R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL","ANZINTER3","Completed","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Epirubicin|Drug: Vinblastine|Drug: Rituximab|Drug: G-CSF","Phase 3","null","https://ClinicalTrials.gov/show/NCT01148446"
389,"NCT03028103","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",,"Active, not recruiting","No Results Available","Drug: Tazemetostat|Drug: Fluconazole|Drug: Omeprazole|Drug: Repaglinide","Phase 1","null","https://ClinicalTrials.gov/show/NCT03028103"
390,"NCT03318835","Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients",,"Recruiting","No Results Available","Drug: Thalidomide combined with R-CHOP|Drug: R-CHOP","Phase 3","null","https://ClinicalTrials.gov/show/NCT03318835"
391,"NCT02900651","Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",,"Recruiting","No Results Available","Drug: MAK683","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02900651"
392,"NCT01939730","Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma",,"Completed","No Results Available","Drug: Rituximab|Drug: GM-CSF","Phase 2","null","https://ClinicalTrials.gov/show/NCT01939730"
393,"NCT01266668","The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01266668"
394,"NCT00561379","Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab",,"Completed","No Results Available","Drug: CHOP+RITUXIMAB|Drug: CEEP-RITUXIMAB","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00561379"
395,"NCT02792491","Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over",,"Unknown status","No Results Available","Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT02792491"
396,"NCT02772822","A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients",,"Not yet recruiting","No Results Available","Drug: SCT400 plus CHOP|Drug: Rituximab plus CHOP","Phase 3","null","https://ClinicalTrials.gov/show/NCT02772822"
397,"NCT02853370","Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma",,"Active, not recruiting","No Results Available","Drug: Bendamustine and Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02853370"
398,"NCT02431988","Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation","COBALT","Recruiting","No Results Available","Procedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-Cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02431988"
399,"NCT03576807","The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma",,"Recruiting","No Results Available","Drug: CD20 CAR-T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03576807"
400,"NCT02272686","Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma",,"Terminated","No Results Available","Drug: Ibrutinib","Phase 2","null","https://ClinicalTrials.gov/show/NCT02272686"
401,"NCT01458366","Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas",,"Active, not recruiting","No Results Available","Drug: Bendamustine|Drug: Ofatumumab|Drug: Carboplatin|Drug: Etoposide|Procedure: CT Scan|Procedure: PET Scan|Genetic: Stem Cell Transplant (STC)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01458366"
402,"NCT03625037","GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",,"Recruiting","No Results Available","Biological: GEN3013 (DuoBody®-CD3xCD20)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03625037"
403,"NCT01897571","Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL",,"Recruiting","No Results Available","Drug: Tazemetostat","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01897571"
404,"NCT00333008","A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.",,"Unknown status","No Results Available","Drug: Doxil|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab|Drug: Pegfilgrastim","Phase 2","null","https://ClinicalTrials.gov/show/NCT00333008"
405,"NCT01181999","Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01181999"
406,"NCT00168740","Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)",,"Completed","No Results Available","Drug: rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00168740"
407,"NCT03373019","Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: Chidamide combined with R-GDP","Phase 2","null","https://ClinicalTrials.gov/show/NCT03373019"
408,"NCT03378947","EBV-associated Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Other: clinical and pathological data EBV-related GZL and DLBCL","","null","https://ClinicalTrials.gov/show/NCT03378947"
409,"NCT02151903","Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL",,"Completed","No Results Available","Drug: DI-Leu16-IL2","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02151903"
410,"NCT03696784","Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",,"Not yet recruiting","No Results Available","Biological: iC9-CAR19 T cells|Drug: Bendamustine|Drug: Fludarabine|Drug: AP1903","Phase 1","null","https://ClinicalTrials.gov/show/NCT03696784"
411,"NCT00379574","Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL",,"Completed","Has Results","Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: Lenograstim","Phase 1|Phase 2","March 14, 2013","https://ClinicalTrials.gov/show/NCT00379574"
412,"NCT02541565","Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","Phase 1","null","https://ClinicalTrials.gov/show/NCT02541565"
413,"NCT03505762","Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Biological: Rituximab|Drug: Vincristine Sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT03505762"
414,"NCT01874288","Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL","DI-Leu16-IL2","Completed","No Results Available","Drug: 0.5 mg/m2 DI-Leu16-IL2|Drug: 1.0 mg/m2 DI-Leu16-IL2|Drug: 2.0 mg/m2 DI-Leu16-IL2|Drug: 4.0 mg/m2 DI-Leu16-IL2|Drug: 6.0 mg/m2 DI-Leu16-IL2|Drug: 8.0 mg/m2 DI-Leu16-IL2|Drug: 10.0 mg/m2 DI-Leu16-IL2|Drug: 50mg/m2 Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01874288"
415,"NCT03161054","Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas",,"Recruiting","No Results Available","Drug: Prednisone|Drug: Vinorelbine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03161054"
416,"NCT03440567","Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",,"Recruiting","No Results Available","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Avelumab|Drug: Carboplatin|Drug: Etoposide Phosphate|Drug: Ibrutinib|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Biological: Rituximab|Biological: Utomilumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03440567"
417,"NCT03211702","Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03211702"
418,"NCT00538096","A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma",,"Withdrawn","No Results Available","Drug: MEDI-538","Phase 1","null","https://ClinicalTrials.gov/show/NCT00538096"
419,"NCT02910063","Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL",,"Recruiting","No Results Available","Drug: Blinatumomab|Drug: Investigator's Choice Chemotherapy","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT02910063"
420,"NCT02555267","Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02555267"
421,"NCT03118180","CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma",,"Recruiting","No Results Available","Biological: CD19 targeted chimeric antigen receptor T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03118180"
422,"NCT00927797","Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)","PERLL","Unknown status","No Results Available","Drug: Cyclophosphamide, Pentostatin, Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00927797"
423,"NCT00561756","Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma",,"Completed","No Results Available","Biological: plasmid DNA vaccine therapy|Other: flow cytometry|Other: immunoenzyme technique","Phase 1","null","https://ClinicalTrials.gov/show/NCT00561756"
424,"NCT03038672","Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study|Drug: Varlilumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03038672"
425,"NCT02933320","BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia",,"Recruiting","No Results Available","Biological: BI-1206 single agent dose escalation phase|Biological: BI-1206 single agent expansion phase|Biological: Combination of BI-1206 with Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02933320"
426,"NCT03332121","B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma",,"Recruiting","No Results Available","Biological: B001","Phase 1","null","https://ClinicalTrials.gov/show/NCT03332121"
427,"NCT02494700","Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma",,"Recruiting","No Results Available","Radiation: Radiation Therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT02494700"
428,"NCT03150329","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Vorinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT03150329"
429,"NCT00220285","Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: Zevalin (SH L 749 , BAY86-5128)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00220285"
430,"NCT01157988","90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Drug: ibritumomab tiuxetan (Zevalin)","Phase 2","null","https://ClinicalTrials.gov/show/NCT01157988"
431,"NCT01263418","Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas",,"Withdrawn","No Results Available","Drug: Ofatumumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01263418"
432,"NCT03189836","Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma",,"Recruiting","No Results Available","Biological: ACTR707|Biological: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03189836"
433,"NCT02776813","Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma",,"Recruiting","No Results Available","Biological: ACTR087|Biological: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02776813"
434,"NCT03579927","CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",,"Not yet recruiting","No Results Available","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Biological: Filgrastim|Drug: Melphalan|Biological: Rituximab|Biological: Umbilical Cord Blood-derived Natural Killer Cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03579927"
435,"NCT02213913","Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",,"Recruiting","No Results Available","Drug: lenalidomide|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: rituximab|Other: quality-of-life assessment|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02213913"
436,"NCT02436707","Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: Rituximab|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Mesna|Drug: Cyclophosphamide|Drug: Etoposide|Drug: G-CSF","Phase 2","null","https://ClinicalTrials.gov/show/NCT02436707"
437,"NCT00201422","Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma",,"Completed","No Results Available","Other: Omeprazole, Amoxicillin, Clarithromycin","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00201422"
438,"NCT02531841","High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma","MATRix","Recruiting","No Results Available","Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)","Phase 3","null","https://ClinicalTrials.gov/show/NCT02531841"
439,"NCT02760485","A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: itacitinib|Drug: ibrutinib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02760485"
440,"NCT02842931","R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis",,"Recruiting","No Results Available","Drug: R-DA-EPOCH-21|Drug: R-DA-EPOCH-21 + auto-SCT|Drug: R-mNHL-BFM-90|Drug: R-mNHL-BFM-90 + auto-SCT","Phase 3","null","https://ClinicalTrials.gov/show/NCT02842931"
441,"NCT03352765","Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients",,"Recruiting","No Results Available","Drug: rituximab|Drug: bendamustine|Drug: melphalan|Procedure: Autologous Stem Cell Transplantation (ASCT)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03352765"
442,"NCT02529852","A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02529852"
443,"NCT00689169","Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma","ZBEAM2","Completed","No Results Available","Drug: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Procedure: ASCT|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00689169"
444,"NCT02998476","A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)",,"Active, not recruiting","No Results Available","Drug: INCB050465","Phase 2","null","https://ClinicalTrials.gov/show/NCT02998476"
445,"NCT02285062","Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","ROBUST","Active, not recruiting","No Results Available","Drug: lenalidomide|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: prednisone|Drug: vincristine","Phase 3","null","https://ClinicalTrials.gov/show/NCT02285062"
446,"NCT03356054","Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse","HOVON 136 NHL","Not yet recruiting","No Results Available","Combination Product: R-DHAP|Drug: Brentuximab Vedotin","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03356054"
447,"NCT02702141","A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: SGN-CD19B","Phase 1","null","https://ClinicalTrials.gov/show/NCT02702141"
448,"NCT01213095","Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)",,"Completed","No Results Available","Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01213095"
449,"NCT01536561","Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)","Phase 1","March 30, 2012","https://ClinicalTrials.gov/show/NCT01536561"
450,"NCT03478514","Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",,"Recruiting","No Results Available","Drug: Palbociclib|Drug: Ibrutinib","Phase 2","null","https://ClinicalTrials.gov/show/NCT03478514"
451,"NCT01109069","Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia",,"Enrolling by invitation","No Results Available","Drug: PCI-32765","Phase 2","null","https://ClinicalTrials.gov/show/NCT01109069"
452,"NCT03003520","A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Durvalumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03003520"
453,"NCT00286832","Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV",,"Completed","No Results Available","Procedure: PET scan","","null","https://ClinicalTrials.gov/show/NCT00286832"
454,"NCT01511562","Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: thiotepa|Procedure: stem cell transplant|Drug: G-CSF","Phase 2","null","https://ClinicalTrials.gov/show/NCT01511562"
455,"NCT01277172","TREatment of degeNerative and Neoplastic Diseases With Rituximab","TREND","Unknown status","No Results Available","Biological: Rituximab","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT01277172"
456,"NCT00689845","Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma",,"Unknown status","No Results Available","Biological: bleomycin sulfate|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: methotrexate|Drug: prednisolone|Drug: prednisone|Drug: vincristine sulfate|Drug: vindesine","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00689845"
457,"NCT03010982","Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors",,"Recruiting","No Results Available","Drug: Tazemetostat and [14C] Tazemetostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT03010982"
458,"NCT02825836","BTK Inhibitor in B Cell Malignancies",,"Active, not recruiting","No Results Available","Drug: M7583","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02825836"
459,"NCT01459887","Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma",,"Completed","No Results Available","Drug: CHOP combined with CMAB304|Drug: CHOP, CMAB304","Phase 3","null","https://ClinicalTrials.gov/show/NCT01459887"
460,"NCT01448096","Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Rituximab|Procedure: Prophylactic intrathecal chemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT01448096"
461,"NCT02636322","Smart Start: Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Rituximab|Drug: Ibrutinib|Drug: Lenalidomide|Drug: Etoposide|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin","Phase 2","null","https://ClinicalTrials.gov/show/NCT02636322"
462,"NCT00634179","A Phase I/II Trial of VR-CHOP in Lymphoma Patients",,"Completed","Has Results","Drug: Bortezomib|Biological: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Phase 1|Phase 2","March 15, 2016","https://ClinicalTrials.gov/show/NCT00634179"
463,"NCT01560117","Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma",,"Completed","No Results Available","Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01560117"
464,"NCT03720457","Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Lymphoma",,"Recruiting","No Results Available","Drug: Human CD19 targeted T Cells Injection","Phase 1","null","https://ClinicalTrials.gov/show/NCT03720457"
465,"NCT00983944","Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma",,"Withdrawn","No Results Available","Biological: bleomycin sulfate|Biological: rituximab|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00983944"
466,"NCT00446095","Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma",,"Completed","Has Results","Drug: fostamatinib","Phase 1|Phase 2","December 18, 2014","https://ClinicalTrials.gov/show/NCT00446095"
467,"NCT02589145","Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype",,"Active, not recruiting","No Results Available","Drug: Lenalidomide|Drug: Vorinostat|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Rituximab|Drug: Dexamethasone|Drug: Caphosol|Drug: Glutamine|Drug: Pyridoxine|Drug: Enoxaparin|Procedure: Stem Cell Transplant|Drug: Palifermin","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02589145"
468,"NCT02532192","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Withdrawn","No Results Available","Drug: Belinostat|Drug: Rituximab|Drug: Cisplatin|Drug: Cytarabine|Drug: Dexamethasone|Drug: Ciprofloxacin|Drug: Fluconazole","Phase 1","null","https://ClinicalTrials.gov/show/NCT02532192"
469,"NCT02366663","BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL","SPINOZA","Terminated","Has Results","Radiation: 90-Yttrium Ibritumomab tiuxetan|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Procedure: Autologous Hematopoietic Stem Cell Transplant|Biological: Rituximab","Phase 3","February 13, 2018","https://ClinicalTrials.gov/show/NCT02366663"
470,"NCT02141451","ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL",,"Recruiting","No Results Available","Drug: Rituximab|Drug: INCB7839","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02141451"
471,"NCT02803840","Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma",,"Unknown status","No Results Available","Radiation: Low-dose radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT02803840"
472,"NCT03299738","A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL",,"Not yet recruiting","No Results Available","Biological: C-CAR011","Phase 1","null","https://ClinicalTrials.gov/show/NCT03299738"
473,"NCT02405078","Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model",,"Recruiting","No Results Available","Drug: 18F-fluorodeoxyglucose|Procedure: FDG PET/CT Imaging|Procedure: Blood Draws","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02405078"
474,"NCT02928861","18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Device: 18F-FDG PET/CT","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02928861"
475,"NCT00411086","Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma",,"Completed","Has Results","Biological: Rituximab|Biological: Sargramostim (GM-CSF)","Phase 2","December 5, 2017","https://ClinicalTrials.gov/show/NCT00411086"
476,"NCT03540303","Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma",,"Recruiting","No Results Available","Drug: CAR19 T cells carrying cytoplasmic activated PD-1","Phase 1","null","https://ClinicalTrials.gov/show/NCT03540303"
477,"NCT00169195","Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma",,"Completed","No Results Available","Drug: Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00169195"
478,"NCT01354392","AZD1152 in Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Drug: AZD1152","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01354392"
479,"NCT00794638","A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: SyB L-0501|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00794638"
480,"NCT01434472","High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma",,"Recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Radiation: Indium In-111 Ibritumomab Tiuxetan|Drug: Mycophenolate Mofetil|Other: Pharmacological Study|Biological: Rituximab|Radiation: Total-Body Irradiation|Radiation: Yttrium Y-90 Ibritumomab Tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT01434472"
481,"NCT03349450","DPX-Survivac and Checkpoint Inhibitor in DLBCL","SPiReL","Recruiting","No Results Available","Biological: DPX-Survivac|Biological: Pembrolizumab|Drug: Cyclophosphamide 50mg","Phase 2","null","https://ClinicalTrials.gov/show/NCT03349450"
482,"NCT01357733","Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients",,"Recruiting","No Results Available","Other: Early interim FDG PET/CT after 1 cycle of R-CHOP","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01357733"
483,"NCT03571308","A Phase Ib/II Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","ACCEPT","Recruiting","No Results Available","Drug: acalabrutinib","Phase 2","null","https://ClinicalTrials.gov/show/NCT03571308"
484,"NCT00987493","Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: bendamustine hydrochloride|Drug: lenalidomide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00987493"
485,"NCT03283137","Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL",,"Recruiting","No Results Available","Drug: TGR-1202|Drug: Pembrolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03283137"
486,"NCT02086604","Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Brentuximab vedotin|Drug: Lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT02086604"
487,"NCT01855750","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Ibrutinib|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone (or equivalent)","Phase 3","null","https://ClinicalTrials.gov/show/NCT01855750"
488,"NCT02931201","Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma",,"Recruiting","No Results Available","Device: 18F-FDG PET/CT","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02931201"
489,"NCT00290667","Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma",,"Completed","No Results Available","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: pharmacological study|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00290667"
490,"NCT02362997","Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL",,"Recruiting","No Results Available","Drug: Pembrolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02362997"
491,"NCT02889523","Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemiotherapy","Epi-RCHOP","Suspended","No Results Available","Drug: Tazemetostat|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisolone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02889523"
492,"NCT00355199","Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.",,"Completed","Has Results","Drug: Rituximab-HDS|Drug: Rituximab-CHOP","Phase 3","August 10, 2017","https://ClinicalTrials.gov/show/NCT00355199"
493,"NCT02871869","Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: vindesine|Drug: cyclophosphamide|Drug: Epirubicin|Drug: prednisone tablets|Drug: Cinobufacini Tablets|Drug: Rituximab","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT02871869"
494,"NCT02391116","Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: Copanlisib (BAY80-6946)","Phase 2","January 8, 2018","https://ClinicalTrials.gov/show/NCT02391116"
495,"NCT03151876","Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma",,"Recruiting","No Results Available","Drug: Chidamide|Drug: Cladribine|Drug: gemcitabine|Drug: Busulfan|Procedure: Autologous hematopoietic stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT03151876"
496,"NCT00834951","Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Radiation: Low dose total body irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00834951"
497,"NCT03682796","Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: TRPH-222","Phase 1","null","https://ClinicalTrials.gov/show/NCT03682796"
498,"NCT00670358","Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma",,"Recruiting","No Results Available","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lenalidomide|Drug: prednisone|Drug: vincristine sulfate|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00670358"
499,"NCT01848132","Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.",,"Completed","No Results Available","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01848132"
500,"NCT01324596","A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib","REMoDL-B","Completed","No Results Available","Drug: Intravenous|Drug: Bortezomib","Phase 3","null","https://ClinicalTrials.gov/show/NCT01324596"
501,"NCT02544724","NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy",,"Unknown status","No Results Available","Biological: NM-IL-12","Phase 2","null","https://ClinicalTrials.gov/show/NCT02544724"
502,"NCT02428751","R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma",,"Recruiting","No Results Available","Drug: Pegylated liposomal doxorubicin|Drug: Doxorubicin|Drug: Rituximab|Drug: Cyclophophamide|Drug: Vincristine|Drug: Prednisone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02428751"
503,"NCT03245905","Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL",,"Not yet recruiting","No Results Available","Drug: Chidamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03245905"
504,"NCT02728882","Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma","EECBL","Recruiting","No Results Available","Biological: CD19-targeted CAR-T cells","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02728882"
505,"NCT03217253","Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction",,"Suspended","No Results Available","Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Tazemetostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT03217253"
506,"NCT02384954","QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",,"Recruiting","No Results Available","Biological: Rituximab|Biological: ALT-803","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02384954"
507,"NCT03229616","BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT",,"Recruiting","No Results Available","Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)|Drug: Etoposide (VP-16)","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT03229616"
508,"NCT00058422","Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Biological: darbepoetin alfa|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00058422"
509,"NCT02867566","A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients",,"Recruiting","No Results Available","Drug: IBI301 plus CHOP|Drug: Rituximab plus CHOP","Phase 3","null","https://ClinicalTrials.gov/show/NCT02867566"
510,"NCT01156259","30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy",,"Unknown status","No Results Available","Radiation: 3D-CRT based Involved Field Radiotherapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT01156259"
511,"NCT02991638","Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers",,"Recruiting","No Results Available","Drug: Ibrutinib","Phase 3","null","https://ClinicalTrials.gov/show/NCT02991638"
512,"NCT01279772","This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas","IELSG33","Terminated","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01279772"
513,"NCT02031419","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma",,"Active, not recruiting","No Results Available","Drug: CC-122|Drug: CC-223|Drug: Rituximab|Drug: CC-292","Phase 1","null","https://ClinicalTrials.gov/show/NCT02031419"
514,"NCT01359592","S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: R-CHOP regimen|Other: laboratory biomarker analysis|Radiation: fludeoxyglucose F 18|Radiation: selective external radiation therapy|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT01359592"
515,"NCT03379493","Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Biological: ET190L1 ARTEMIS™ T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03379493"
516,"NCT01563861","S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Genetic: RNA analysis|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT01563861"
517,"NCT01144403","A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.",,"Terminated","Has Results","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mitoxantrone|Drug: Rituximab","Phase 2","August 29, 2016","https://ClinicalTrials.gov/show/NCT01144403"
518,"NCT03003546","Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Not yet recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT03003546"
519,"NCT02343536","A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",,"Active, not recruiting","No Results Available","Drug: Oral Azacitidine|Drug: Rituximab|Drug: cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Phase 1","null","https://ClinicalTrials.gov/show/NCT02343536"
520,"NCT03450343","Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma",,"Not yet recruiting","No Results Available","Drug: Oral azacitidine|Drug: R-ICE","Phase 1","null","https://ClinicalTrials.gov/show/NCT03450343"
521,"NCT03280394","Liquid Biopsy in Mature B-cell Tumors",,"Recruiting","No Results Available","Diagnostic Test: Liquid Biopsy","","null","https://ClinicalTrials.gov/show/NCT03280394"
522,"NCT03479918","R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)",,"Recruiting","No Results Available","Drug: R-DA-EPOCH-21|Drug: R-BL-M-04|Drug: R-DA-EPOCH-21 + auto-SCT|Drug: R-BL-M-04 + auto-SCT","Phase 3","null","https://ClinicalTrials.gov/show/NCT03479918"
523,"NCT01334502","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: everolimus|Drug: prednisone|Drug: vincristine sulfate","Phase 1","null","https://ClinicalTrials.gov/show/NCT01334502"
524,"NCT01278615","Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",,"Terminated","Has Results","Other: Laboratory Biomarker Analysis|Drug: Selumetinib","Phase 2","February 3, 2016","https://ClinicalTrials.gov/show/NCT01278615"
525,"NCT00880581","A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas",,"Completed","Has Results","Drug: PF-3512676|Radiation: Local radiotherapy","Phase 2","March 14, 2017","https://ClinicalTrials.gov/show/NCT00880581"
526,"NCT01321541","Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","PIX-R","Completed","No Results Available","Drug: Pixantrone + Rituximab|Drug: Gemcitabine + Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT01321541"
527,"NCT01649856","A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Drug: CHOP|Drug: rituximab [MabThera/Rituxan]","Phase 3","February 12, 2016","https://ClinicalTrials.gov/show/NCT01649856"
528,"NCT00981097","Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma",,"Completed","No Results Available","Genetic: polymerase chain reaction|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT00981097"
529,"NCT02257567","A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Bendamustine|Drug: Obinutuzumab|Drug: Polatuzumab vedotin (Liquid)|Drug: Rituximab|Drug: Polatuzumab vedotin (Lyophilized)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02257567"
530,"NCT02776891","A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Radiation: Gallium citrate","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02776891"
531,"NCT02855359","Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma",,"Terminated","No Results Available","Drug: denintuzumab mafodotin|Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT02855359"
532,"NCT02964858","Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","DOBL","Recruiting","No Results Available","Radiation: Standard Arm|Radiation: Experimental Arm","Phase 3","null","https://ClinicalTrials.gov/show/NCT02964858"
533,"NCT01131208","Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab",,"Completed","No Results Available","Genetic: gene expression analysis|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT01131208"
534,"NCT00851552","Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",,"Terminated","Has Results","Biological: rituximab|Drug: bortezomib|Drug: pegylated liposomal doxorubicin hydrochloride|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Genetic: proteomic profiling|Other: flow cytometry|Other: laboratory biomarker analysis","Phase 2","July 21, 2014","https://ClinicalTrials.gov/show/NCT00851552"
535,"NCT01926665","Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Drug: Carfilzomib|Drug: Dexamethasone","Phase 1","null","https://ClinicalTrials.gov/show/NCT01926665"
536,"NCT01351935","Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",,"Completed","No Results Available","Drug: AVL-292","Phase 1","null","https://ClinicalTrials.gov/show/NCT01351935"
537,"NCT02920697","Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: S 55746","Phase 1","null","https://ClinicalTrials.gov/show/NCT02920697"
538,"NCT02038933","Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)",,"Active, not recruiting","Has Results","Drug: Nivolumab","Phase 2","May 30, 2017","https://ClinicalTrials.gov/show/NCT02038933"
539,"NCT00156013","Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)",,"Completed","Has Results","Drug: CLOFARABINE","Phase 1|Phase 2","July 9, 2012","https://ClinicalTrials.gov/show/NCT00156013"
540,"NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","ORCHARRD","Completed","Has Results","Drug: OFATUMUMAB + DHAP|Drug: RITUXIMAB + DHAP","Phase 3","October 16, 2014","https://ClinicalTrials.gov/show/NCT01014208"
541,"NCT00136591","A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma",,"Terminated","No Results Available","Drug: Bortezomib","Phase 2","null","https://ClinicalTrials.gov/show/NCT00136591"
542,"NCT00644124","Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma",,"Completed","No Results Available","Drug: aflibercept","Phase 1","null","https://ClinicalTrials.gov/show/NCT00644124"
543,"NCT02128945","Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies","FLUDATEP","Completed","No Results Available","Other: [18F] - Fludarabine PET/CT","Phase 1","null","https://ClinicalTrials.gov/show/NCT02128945"
544,"NCT00445341","Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Drug: Flavopiridol","Phase 1|Phase 2","October 5, 2012","https://ClinicalTrials.gov/show/NCT00445341"
545,"NCT01555541","Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: Ofatumumab|Drug: Etoposide|Drug: Cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01555541"
546,"NCT00135499","R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Drug: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vindesine|Drug: Bleomycin|Drug: Prednisone|Drug: Vincristine","Phase 3","null","https://ClinicalTrials.gov/show/NCT00135499"
547,"NCT00140660","ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Drug: rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00140660"
548,"NCT00971763","Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: gemcitabine hydrochloride|Drug: prednisolone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00971763"
549,"NCT00950755","Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology",,"Completed","Has Results","Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)","Phase 2","August 29, 2012","https://ClinicalTrials.gov/show/NCT00950755"
550,"NCT00829205","Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",,"Withdrawn","No Results Available","Biological: filgrastim|Biological: rituximab|Dietary Supplement: Se-methyl-seleno-L-cysteine|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00829205"
551,"NCT00144807","ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide|Procedure: autologous stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00144807"
552,"NCT01410630","FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma",,"Suspended","No Results Available","Diagnostic Test: FLT-PET/CT|Diagnostic Test: FDG-PET/CT|Drug: FLT","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01410630"
553,"NCT00066508","Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy",,"Completed","No Results Available","Drug: bortezomib","Phase 2","null","https://ClinicalTrials.gov/show/NCT00066508"
554,"NCT00137995","R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Drug: Rituximab|Drug: Etoposide|Drug: Carboplatine|Drug: Ifosfamide + Mesna|Drug: Cisplatine|Drug: Cytosine Arabinoside|Drug: Dexamethasone|Procedure: Autologous Stem Cell Transplantation|Drug: BCNU|Drug: Cytarabine|Drug: Melphalan","Phase 3","null","https://ClinicalTrials.gov/show/NCT00137995"
555,"NCT00301821","Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Biological: epratuzumab|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 2","March 24, 2015","https://ClinicalTrials.gov/show/NCT00301821"
556,"NCT00898157","Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494",,"Completed","No Results Available","Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT00898157"
557,"NCT00140595","ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1",,"Completed","No Results Available","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide","Phase 3","null","https://ClinicalTrials.gov/show/NCT00140595"
558,"NCT00169130","ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Drug: doxorubicin|Drug: cyclophosphamide|Procedure: Autologous stem cell transplantation","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT00169130"
559,"NCT02631044","Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",,"Recruiting","No Results Available","Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule|Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule","Phase 1","null","https://ClinicalTrials.gov/show/NCT02631044"
560,"NCT01224821","Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies","RIT-II-001","Completed","Has Results","Biological: Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab","Phase 2","April 17, 2012","https://ClinicalTrials.gov/show/NCT01224821"
561,"NCT02840110","Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product",,"Enrolling by invitation","No Results Available","Other: ACTR T Cell Product","","null","https://ClinicalTrials.gov/show/NCT02840110"
562,"NCT00308087","Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma","PREMIER","Terminated","Has Results","Drug: Sargramostim (Leukine)|Drug: Rituximab","Phase 2","August 30, 2010","https://ClinicalTrials.gov/show/NCT00308087"
563,"NCT00268853","A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","RAPID","Completed","No Results Available","Drug: CPOP-R|Drug: CHOP-R","Phase 2","null","https://ClinicalTrials.gov/show/NCT00268853"
564,"NCT00144755","R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Drug: Darbepoetin alfa","Phase 3","null","https://ClinicalTrials.gov/show/NCT00144755"
565,"NCT00193505","Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma",,"Completed","No Results Available","Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: Rituximab|Drug: 90Y Zevalin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00193505"
566,"NCT00544219","PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Procedure: positron emission tomography","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00544219"
567,"NCT03410004","Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",,"Not yet recruiting","No Results Available","Drug: Chidamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03410004"
568,"NCT00435916","Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Drug: SGN-40","Phase 2","null","https://ClinicalTrials.gov/show/NCT00435916"
569,"NCT00307177","Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma",,"Completed","No Results Available","Biological: Trivalent inactivated influenza vaccine|Biological: Trivalent Baculovirus-expressed Influenza HA vaccine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00307177"
570,"NCT02030834","Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas",,"Active, not recruiting","No Results Available","Biological: CART-19","Phase 2","null","https://ClinicalTrials.gov/show/NCT02030834"
571,"NCT03685344","Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",,"Not yet recruiting","No Results Available","Drug: Loncastuximab Tesirine and Durvalumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03685344"
572,"NCT00324831","GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Suspended","No Results Available","Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: rituximab|Drug: sargramostim|Drug: vincristine|Procedure: Intervention/procedure|Procedure: antibody therapy|Procedure: biological therapy|Procedure: chemotherapy|Procedure: colony-stimulating factor therapy|Procedure: cytokine therapy|Procedure: monoclonal antibody therapy|Procedure: non-specific immune-modulator therapy|Procedure: therapeutic procedure|Procedure: tumor cell derivative vaccine|Procedure: vaccine therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00324831"
573,"NCT01239394","Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma",,"Completed","Has Results","Drug: ofatumumab","Phase 2","March 17, 2017","https://ClinicalTrials.gov/show/NCT01239394"
574,"NCT03153462","Axicabtagene Ciloleucel Expanded Access Study","ZUMA-9","Available","No Results Available","Biological: Axicabtagene Ciloleucel","","null","https://ClinicalTrials.gov/show/NCT03153462"
575,"NCT00457782","A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: KW-2478","Phase 1","null","https://ClinicalTrials.gov/show/NCT00457782"
576,"NCT00070083","Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00070083"
577,"NCT02073097","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Drug: carfilzomib|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02073097"
578,"NCT00588094","Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL",,"Completed","Has Results","Drug: Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant","Phase 2","December 4, 2015","https://ClinicalTrials.gov/show/NCT00588094"
579,"NCT01980628","Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma",,"Completed","Has Results","Drug: ibrutinib","Phase 2","February 10, 2017","https://ClinicalTrials.gov/show/NCT01980628"
580,"NCT02281279","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",,"Withdrawn","No Results Available","Biological: rituximab|Drug: lenalidomide|Drug: romidepsin|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02281279"
581,"NCT03135262","A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: Idasanutlin|Drug: Obinutuzumab|Drug: Venetoclax|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03135262"
582,"NCT01994850","A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas",,"Active, not recruiting","No Results Available","Drug: brentuximab vedotin","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01994850"
583,"NCT00764517","Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Cladribine|Other: Laboratory Biomarker Analysis|Biological: Rituximab|Drug: Vorinostat","Phase 2","November 13, 2017","https://ClinicalTrials.gov/show/NCT00764517"
584,"NCT00796731","SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: SAR3419","Phase 1","null","https://ClinicalTrials.gov/show/NCT00796731"
585,"NCT01812005","Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Terminated","Has Results","Drug: alisertib|Biological: rituximab|Other: laboratory biomarker analysis","Phase 2","June 5, 2018","https://ClinicalTrials.gov/show/NCT01812005"
586,"NCT01193842","Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",,"Active, not recruiting","Has Results","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat","Phase 1|Phase 2","June 12, 2018","https://ClinicalTrials.gov/show/NCT01193842"
587,"NCT00622388","Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant",,"Completed","Has Results","Drug: Ofatumumab","Phase 2","September 8, 2011","https://ClinicalTrials.gov/show/NCT00622388"
588,"NCT00945724","Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","IELSG30","Recruiting","No Results Available","Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00945724"
589,"NCT00783367","Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",,"Active, not recruiting","No Results Available","Drug: lenalidomide-low dose dexamethasone plus rituximab|Drug: Lenalidomide + Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00783367"
590,"NCT02220842","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Tazemetostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT02220842"
591,"NCT00901615","Lenalidomide and R-CHOP in B-cell Lymphoma","R2CHOP-1","Completed","No Results Available","Drug: Lenalidomide and R-CHOP","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00901615"
592,"NCT01004718","Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)",,"Unknown status","No Results Available","Radiation: Fludeoxyglucose F18|Procedure: Computed Tomography|Procedure: Positron emission tomography","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01004718"
593,"NCT03132584","Cyclophosphamide and Alemtuzumab In Lymphoma",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Alemtuzumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03132584"
594,"NCT01889069","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)",,"Active, not recruiting","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone|Drug: Bendamustine","Phase 3","null","https://ClinicalTrials.gov/show/NCT01889069"
595,"NCT01063439","BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)",,"Unknown status","No Results Available","Drug: Busulfan, Etoposide, Cytarabine, Melphalan","Phase 2","null","https://ClinicalTrials.gov/show/NCT01063439"
596,"NCT00290472","CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","Has Results","Drug: temsirolimus","Phase 2","February 11, 2014","https://ClinicalTrials.gov/show/NCT00290472"
597,"NCT01539174","Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma",,"Withdrawn","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 2","null","https://ClinicalTrials.gov/show/NCT01539174"
598,"NCT02729896","A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Active, not recruiting","No Results Available","Drug: Atezolizumab [TECENTRIQ]|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02729896"
599,"NCT02965157","Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma",,"Unknown status","No Results Available","Biological: CART20","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02965157"
600,"NCT00288067","Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Terminated","Has Results","Drug: fenretinide|Drug: rituximab","Phase 1|Phase 2","October 6, 2014","https://ClinicalTrials.gov/show/NCT00288067"
601,"NCT02706405","JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Drug: Cyclophosphamide|Biological: Durvalumab|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT02706405"
602,"NCT00312845","Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Bortezomib + Rituximab|Drug: Rituximab","Phase 3","July 26, 2011","https://ClinicalTrials.gov/show/NCT00312845"
603,"NCT01178645","Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma",,"Unknown status","No Results Available","Drug: Busulfan, etoposide, cytarabine, and melphalan","Phase 2","null","https://ClinicalTrials.gov/show/NCT01178645"
604,"NCT03586024","Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)",,"Recruiting","No Results Available","Drug: Pembrolizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03586024"
605,"NCT00972478","Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Active, not recruiting","Has Results","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat","Phase 1|Phase 2","October 31, 2016","https://ClinicalTrials.gov/show/NCT00972478"
606,"NCT00736450","Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",,"Terminated","Has Results","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Procedure: biopsy|Genetic: microarray analysis|Other: immunohistochemistry staining method|Genetic: gene expression analysis|Genetic: cytogenetic analysis","Not Applicable","August 31, 2018","https://ClinicalTrials.gov/show/NCT00736450"
607,"NCT00042666","A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.",,"Completed","No Results Available","Drug: LY317615","Phase 2","null","https://ClinicalTrials.gov/show/NCT00042666"
608,"NCT00392496","Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma",,"Completed","Has Results","Drug: sunitinib malate","Phase 2","December 12, 2013","https://ClinicalTrials.gov/show/NCT00392496"
609,"NCT00712582","Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma",,"Completed","No Results Available","Drug: Etoposide, carboplatin, ifosfamide|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00712582"
610,"NCT00667615","Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim","Phase 1|Phase 2","November 7, 2017","https://ClinicalTrials.gov/show/NCT00667615"
611,"NCT02132624","CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.",,"Completed","No Results Available","Biological: Autologous 3rd generation CD19-targeting CAR T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02132624"
612,"NCT03098355","Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies",,"Recruiting","No Results Available","Biological: 4SCAR19/22 T cells|Drug: Interleukin-2","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03098355"
613,"NCT03068416","CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy",,"Recruiting","No Results Available","Biological: CAR T cells","Phase 2","null","https://ClinicalTrials.gov/show/NCT03068416"
614,"NCT02963038","CAR T Cells for Refractory B Cell Malignancy",,"Recruiting","No Results Available","Biological: Autologous CD19-targeting CAR T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02963038"
615,"NCT02911142","Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma",,"Recruiting","No Results Available","Drug: Lenalidomide|Drug: Rituximab|Drug: Prednisone|Drug: Etopside|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02911142"
616,"NCT00621452","Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Biological: aldesleukin|Genetic: polymerase chain reaction|Genetic: gene rearrangement analysis|Procedure: lymph node biopsy|Biological: genetically engineered lymphocyte therapy|Procedure: bone marrow aspiration|Other: flow cytometry|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay","Phase 1","null","https://ClinicalTrials.gov/show/NCT00621452"
617,"NCT00532259","CT-011 MAb in DLBCL Patients Following ASCT",,"Completed","Has Results","Drug: CT-011","Phase 2","September 12, 2014","https://ClinicalTrials.gov/show/NCT00532259"
618,"NCT03366350","Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies",,"Recruiting","No Results Available","Genetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03366350"
619,"NCT03366324","Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies",,"Recruiting","No Results Available","Genetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT03366324"
620,"NCT01284192","Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)",,"Completed","No Results Available","Drug: ASP3026","Phase 1","null","https://ClinicalTrials.gov/show/NCT01284192"
621,"NCT02965092","CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies",,"Recruiting","No Results Available","Genetic: Second generation CAR-T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02965092"
622,"NCT02300402","Detection and Characterization of Residual Masses in Lymphomas","ADAMANTIUS","Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02300402"
623,"NCT02611323","A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Drug: Obinutuzumab|Drug: Rituximab|Drug: Polatuzumab Vedotin|Drug: Venetoclax","Phase 1","null","https://ClinicalTrials.gov/show/NCT02611323"
624,"NCT02413489","An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",,"Terminated","Has Results","Drug: Daratumumab","Phase 2","June 25, 2018","https://ClinicalTrials.gov/show/NCT02413489"
625,"NCT00703664","Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Drug: Bortezomib|Other: Laboratory Biomarker Analysis|Drug: Vorinostat","Phase 2","August 7, 2018","https://ClinicalTrials.gov/show/NCT00703664"
626,"NCT02787239","Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL",,"Completed","No Results Available","Drug: HLX01|Drug: Rituximab|Drug: CHOP","Phase 3","null","https://ClinicalTrials.gov/show/NCT02787239"
627,"NCT02624986","A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants",,"Active, not recruiting","No Results Available","Drug: Idasanutlin|Drug: Obinutuzumab|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02624986"
628,"NCT00466531","Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",,"Active, not recruiting","No Results Available","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00466531"
629,"NCT02086175","A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Imprime PGG|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02086175"
630,"NCT00880867","Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma",,"Terminated","No Results Available","Drug: Poly-ICLC","Phase 1","null","https://ClinicalTrials.gov/show/NCT00880867"
631,"NCT00294632","Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Drug: Lenalidomide|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00294632"
632,"NCT03410901","TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Biological: Anti-OX40 Antibody BMS 986178|Other: Laboratory Biomarker Analysis|Radiation: Radiation Therapy|Drug: TLR9 Agonist SD-101","Phase 1","null","https://ClinicalTrials.gov/show/NCT03410901"
633,"NCT00210366","Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma",,"Terminated","No Results Available","Drug: Idarubicin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00210366"
634,"NCT00210314","Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma",,"Completed","No Results Available","Drug: high dose methotrexate|Drug: high dose cytarabine|Radiation: radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00210314"
635,"NCT00907348","Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma","REAL07","Unknown status","No Results Available","Drug: LR-CHOP21","Phase 2","null","https://ClinicalTrials.gov/show/NCT00907348"
636,"NCT00329030","Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401)",,"Completed","Has Results","Drug: Autologous transplantation using rituxan/BEAM|Drug: Autologous transplantation using Bexxar/BEAM","Phase 3","June 10, 2016","https://ClinicalTrials.gov/show/NCT00329030"
637,"NCT01118845","Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Drug: SyB L-0501|Drug: Rituximab","Phase 2","July 4, 2013","https://ClinicalTrials.gov/show/NCT01118845"
638,"NCT01300793","Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide","V-RICE","Terminated","No Results Available","Drug: Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01300793"
639,"NCT00256490","Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT",,"Unknown status","No Results Available","Procedure: PET/CT 20 days after the first cycle of chemotherapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00256490"
640,"NCT02082977","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",,"Terminated","No Results Available","Drug: GSK2816126","Phase 1","null","https://ClinicalTrials.gov/show/NCT02082977"
641,"NCT02623920","Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","S-BR","Withdrawn","No Results Available","Drug: Brentuximab|Drug: Bendamustine|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02623920"
642,"NCT02405676","BNHL-2015 for Children or Adolescents in China","BNHL-2015","Recruiting","No Results Available","Drug: Prednisone,Vincristine, Cyclophosphamide|Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Drug: Rituximab","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT02405676"
643,"NCT03147885","Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Selinexor","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03147885"
644,"NCT00968760","CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies",,"Active, not recruiting","No Results Available","Procedure: Leukapheresis|Procedure: Stem Cell Transplant|Procedure: CD19-specific T Cell Infusion|Drug: IL-2|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan","Phase 1","null","https://ClinicalTrials.gov/show/NCT00968760"
645,"NCT02992522","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Lenalidomide|Biological: Obinutuzumab|Drug: Venetoclax","Phase 1","null","https://ClinicalTrials.gov/show/NCT02992522"
646,"NCT00881920","Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","CHARKALL","Recruiting","No Results Available","Biological: Kappa CD28 T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT00881920"
647,"NCT01078922","Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas",,"Terminated","Has Results","Drug: Ofatumumab","Phase 2","May 2, 2014","https://ClinicalTrials.gov/show/NCT01078922"
648,"NCT03570892","Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","BELINDA","Not yet recruiting","No Results Available","Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and HSCT","Phase 3","null","https://ClinicalTrials.gov/show/NCT03570892"
649,"NCT00225212","Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Rituximab 375 mg/m2","Phase 2","September 5, 2014","https://ClinicalTrials.gov/show/NCT00225212"
650,"NCT00482053","Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT",,"Terminated","Has Results","Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)|Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Procedure: Total lymphoid irradiation (TLI)|Drug: Rituximab|Drug: Carmustine|Drug: Etoposide|Drug: Filgrastim|Drug: Anti-thymocyte globulin (ATG)|Drug: Cyclosporine|Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Hydrocortisone|Drug: Methylprednisolone","Phase 2","May 14, 2018","https://ClinicalTrials.gov/show/NCT00482053"
651,"NCT03642626","MT2017-45 :CAR-T Cell Therapy for Heme Malignancies",,"Not yet recruiting","No Results Available","Drug: KYMRIAH|Drug: YESCARTA|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03642626"
652,"NCT03277729","A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03277729"
653,"NCT03484702","Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: JCAR017","Phase 2","null","https://ClinicalTrials.gov/show/NCT03484702"
654,"NCT02747732","Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL",,"Recruiting","No Results Available","Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6","Phase 2","null","https://ClinicalTrials.gov/show/NCT02747732"
655,"NCT01122472","Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP","REMARC","Active, not recruiting","No Results Available","Drug: Lenalidomide|Drug: Placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT01122472"
656,"NCT01030900","Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas",,"Active, not recruiting","No Results Available","Biological: campath|Biological: Rituximab|Drug: EPOCH","Phase 2","null","https://ClinicalTrials.gov/show/NCT01030900"
657,"NCT02168907","CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: 6,8-bis(benzylthio)octanoic acid|Drug: bendamustine hydrochloride|Biological: rituximab|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT02168907"
658,"NCT03093831","Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib","Phase 2","null","https://ClinicalTrials.gov/show/NCT03093831"
659,"NCT03079947","Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03079947"
660,"NCT02367040","Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)","CHRONOS-3","Recruiting","No Results Available","Drug: Copanlisib (BAY 80-6946)|Drug: Placebo|Drug: Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT02367040"
661,"NCT01680991","A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease",,"Completed","Has Results","Drug: Obinutuzumab","Phase 1","April 25, 2016","https://ClinicalTrials.gov/show/NCT01680991"
662,"NCT02981745","Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia",,"Recruiting","No Results Available","Drug: CT-1530","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02981745"
663,"NCT01955499","Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: Ibrutinib|Drug: Lenalidomide|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01955499"
664,"NCT03103971","huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT03103971"
665,"NCT01239875","Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Biological: dendritic cell vaccine therapy|Procedure: cryotherapy|Biological: pneumococcal polyvalent vaccine|Other: laboratory biomarker analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Biological: autologous dendritic cell-tumor fusion vaccine","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01239875"
666,"NCT03620578","DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL","HO152","Recruiting","No Results Available","Drug: DA-EPOCH-R followed by Nivolumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03620578"
667,"NCT02650414","CD22 Redirected Autologous T Cells for ALL",,"Recruiting","No Results Available","Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB","Phase 1","null","https://ClinicalTrials.gov/show/NCT02650414"
668,"NCT00720135","Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Biological: DI-Leu16-IL2 immunocytokine|Biological: rituximab|Other: flow cytometry|Other: immunohistochemistry staining method|Other: pharmacological study|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay|Genetic: reverse transcriptase-polymerase chain reaction","Phase 1","null","https://ClinicalTrials.gov/show/NCT00720135"
669,"NCT01055496","Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone","Phase 1","null","https://ClinicalTrials.gov/show/NCT01055496"
670,"NCT01045928","Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: lenalidomide|Biological: rituximab|Genetic: polymerase chain reaction|Genetic: nucleic acid sequencing|Genetic: polymorphism analysis|Other: flow cytometry|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01045928"
671,"NCT03019640","Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Drug: Cytarabine|Drug: Etoposide|Biological: Filgrastim|Drug: Lenalidomide|Drug: Melphalan|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03019640"
672,"NCT02253992","An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Biological: Urelumab|Biological: Nivolumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02253992"
673,"NCT03383952","A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia",,"Recruiting","No Results Available","Biological: ICAR19 CAR-T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03383952"
674,"NCT03398967","A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma",,"Recruiting","No Results Available","Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03398967"
675,"NCT00336843","Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: Zevalin-BuCyE","Phase 2","null","https://ClinicalTrials.gov/show/NCT00336843"
676,"NCT03166878","A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma",,"Recruiting","No Results Available","Biological: UCART019","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03166878"
677,"NCT00061425","Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG",,"Completed","No Results Available","Drug: radiolabeled epratuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00061425"
678,"NCT00542919","A Study for Patients With Non-Hodgkin's Lymphomas",,"Completed","No Results Available","Drug: enzastaurin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00542919"
679,"NCT00210379","Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: rituximab|Drug: CHOP|Drug: intrathecal methotrexate|Procedure: radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00210379"
680,"NCT02953509","Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: Hu5F9-G4|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02953509"
681,"NCT02106091","Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",,"Suspended","No Results Available","Drug: AFM11","Phase 1","null","https://ClinicalTrials.gov/show/NCT02106091"
682,"NCT03019055","Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",,"Recruiting","No Results Available","Biological: CAR-20/19-T","Phase 1","null","https://ClinicalTrials.gov/show/NCT03019055"
683,"NCT01626495","Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma","Pedi CART19","Completed","No Results Available","Biological: CART-19","Phase 1","null","https://ClinicalTrials.gov/show/NCT01626495"
684,"NCT02992223","Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02992223"
685,"NCT01647971","Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: Ublituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01647971"
686,"NCT03720496","Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy",,"Recruiting","No Results Available","Biological: CD19-TriCAR-T","Phase 1","null","https://ClinicalTrials.gov/show/NCT03720496"
687,"NCT03497533","Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19","Trident19-H","Recruiting","No Results Available","Biological: TriCAR-T-CD19","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03497533"
688,"NCT03375619","Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells",,"Recruiting","No Results Available","Other: Long-Term Follow-Up of Patients who Received CAR-20/19-T cells","","null","https://ClinicalTrials.gov/show/NCT03375619"
689,"NCT00081861","Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Avastin|Drug: Rituximab","Phase 2","August 26, 2009","https://ClinicalTrials.gov/show/NCT00081861"
690,"NCT00989586","Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Biological: milatuzumab|Biological: veltuzumab|Procedure: Correlative/Special Studies|Procedure: Quantitative T-, B-, and NK cell subsets|Procedure: Pharmacokinetics|Procedure: Human Anti-Human Antibodies|Biological: veltuzumab and milatuzumab","Phase 1|Phase 2","February 6, 2017","https://ClinicalTrials.gov/show/NCT00989586"
691,"NCT01545544","Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)","Lympho C","Unknown status","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01545544"
692,"NCT01200589","Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy","HOMER","Terminated","Has Results","Biological: Ofatumumab|Biological: Rituximab","Phase 3","May 16, 2018","https://ClinicalTrials.gov/show/NCT01200589"
693,"NCT02756247","A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",,"Active, not recruiting","No Results Available","Drug: Buparlisib|Drug: Ibrutinib","Phase 1","null","https://ClinicalTrials.gov/show/NCT02756247"
694,"NCT02401048","A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas",,"Active, not recruiting","No Results Available","Drug: Ibrutinib|Drug: MEDI4736","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02401048"
695,"NCT00397800","Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00397800"
696,"NCT03355859","Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Biological: JWCAR029","Phase 1","null","https://ClinicalTrials.gov/show/NCT03355859"
697,"NCT03344367","Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Biological: JWCAR029","Phase 1","null","https://ClinicalTrials.gov/show/NCT03344367"
698,"NCT03533283","An Open-Label Phase lB Study of RO7082859 and Atezolizumab in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: RO7082859|Drug: Atezolizumab|Drug: Obinutuzumab","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03533283"
699,"NCT02703272","A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: Rituximab|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: Vincristine|Drug: Idarubicin|Drug: Dexamethasone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02703272"
700,"NCT03601442","CTL019 Out of Specification MAP for ALL or DLBCL Patients",,"Available","No Results Available","Biological: CTL019","","null","https://ClinicalTrials.gov/show/NCT03601442"
701,"NCT00210340","A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis",,"Withdrawn","No Results Available","Drug: intrathecal rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00210340"
702,"NCT02072967","Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Other: Ribomustin|Other: rituximab","","null","https://ClinicalTrials.gov/show/NCT02072967"
703,"NCT03575351","A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","TRANSFORM","Recruiting","No Results Available","Drug: Standard of Care|Genetic: JCAR017","Phase 3","null","https://ClinicalTrials.gov/show/NCT03575351"
704,"NCT02240316","An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice",,"Active, not recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02240316"
705,"NCT01491841","IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma","BRP","Active, not recruiting","No Results Available","Drug: Bendamustine + Rituximab + Pixantrone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01491841"
706,"NCT02453087","A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Drug: DCDS0780A|Drug: Rituximab|Drug: Obinutuzumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02453087"
707,"NCT00863369","Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Biological: rituximab|Drug: bortezomib|Drug: gemcitabine hydrochloride|Other: questionnaire administration","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00863369"
708,"NCT02109224","Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",,"Terminated","No Results Available","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT02109224"
709,"NCT03598179","XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects",,"Recruiting","No Results Available","Biological: chimeric antigen receptor T cells","Phase 2","null","https://ClinicalTrials.gov/show/NCT03598179"
710,"NCT01760226","Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","DA-EPOCH-R","Completed","No Results Available","Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|Drug: Methotrexate|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Prednisone|Drug: G-CSF","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT01760226"
711,"NCT02568683","Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)",,"Completed","No Results Available","Drug: ENTO|Drug: VCR","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02568683"
712,"NCT00809341","R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Terminated","Has Results","Biological: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide|Drug: High-dose cyclophosphamide|Procedure: PET scan","Phase 2","September 25, 2018","https://ClinicalTrials.gov/show/NCT00809341"
713,"NCT00290498","Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger",,"Completed","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00290498"
714,"NCT00607854","Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","ZEVALLO","Completed","No Results Available","Drug: Ibritumomab Tiuxetan (Zevalin)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00607854"
715,"NCT01805375","A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies",,"Completed","No Results Available","Drug: DI-B4","Phase 1","null","https://ClinicalTrials.gov/show/NCT01805375"
716,"NCT03075696","A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: RO7082859|Drug: Obinutuzumab|Drug: Tocilizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03075696"
717,"NCT01992653","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Prednisolone|Drug: Prednisone|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01992653"
718,"NCT01691807","Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: ofatumumab|Drug: bendamustine","Phase 1","null","https://ClinicalTrials.gov/show/NCT01691807"
719,"NCT01549886","Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: Zevalin Regimen|Drug: Moxtezafin Gadolinium","Phase 2","null","https://ClinicalTrials.gov/show/NCT01549886"
720,"NCT01294579","Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)",,"Completed","Has Results","Biological: Ofatumumab|Drug: Bendamustine","Phase 2","August 9, 2018","https://ClinicalTrials.gov/show/NCT01294579"
721,"NCT01483664","Communication Skills Intervention to Promote Transition Into Survivorship",,"Active, not recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01483664"
722,"NCT02813837","Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies",,"Recruiting","No Results Available","Biological: CD19CART","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02813837"
723,"NCT03042247","Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03042247"
724,"NCT01840566","High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Biological: Pegfilgrastim|Biological: 19-28z T CELLS|Procedure: Autologous Stem Cell Transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT01840566"
725,"NCT00460109","Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: denileukin diftitox|Biological: rituximab","Phase 2","April 18, 2017","https://ClinicalTrials.gov/show/NCT00460109"
726,"NCT00073957","Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: cytarabine|Drug: liposomal cytarabine|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","January 23, 2018","https://ClinicalTrials.gov/show/NCT00073957"
727,"NCT01435720","Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)",,"Unknown status","No Results Available","Biological: SNS01-T","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01435720"
728,"NCT01108341","Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Drug: Bendamustine hydrochloride|Drug: Ofatumumab","Phase 2","August 28, 2012","https://ClinicalTrials.gov/show/NCT01108341"
729,"NCT00389818","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Phase 2","June 29, 2012","https://ClinicalTrials.gov/show/NCT00389818"
730,"NCT00303953","PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: belinostat","Phase 2","September 19, 2012","https://ClinicalTrials.gov/show/NCT00303953"
731,"NCT00549185","Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: SAR3419","Phase 1","null","https://ClinicalTrials.gov/show/NCT00549185"
732,"NCT00400907","Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9",,"Unknown status","No Results Available","Other: clinical observation|Procedure: management of therapy complications","","null","https://ClinicalTrials.gov/show/NCT00400907"
733,"NCT00911183","Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma",,"Unknown status","No Results Available","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: liposome-encapsulated doxorubicin citrate|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00911183"
734,"NCT00193479","Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab","Phase 2","February 21, 2014","https://ClinicalTrials.gov/show/NCT00193479"
735,"NCT00556699","A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: rituximab|Drug: SGN-40","Phase 1","null","https://ClinicalTrials.gov/show/NCT00556699"
736,"NCT03704714","Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Biological: Nivolumab|Drug: Prednisone|Other: Quality-of-Life Assessment|Biological: Rituximab|Drug: Vincristine Sulfate","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03704714"
737,"NCT03242902","To Decrease Fatigue With Light Therapy","SPARKLE","Recruiting","No Results Available","Device: Light therapy intensity 1|Device: Light therapy intensity 2","Phase 3","null","https://ClinicalTrials.gov/show/NCT03242902"
738,"NCT03261349","Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Drug: Ledipasvir and sofosbuvir","Phase 2","null","https://ClinicalTrials.gov/show/NCT03261349"
739,"NCT01829958","Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy",,"Recruiting","No Results Available","Drug: rituximab|Drug: prednisone|Behavioral: Geriatric Assessment","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01829958"
740,"NCT02180711","Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: acalabrutinib|Drug: rituximab (IV)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02180711"
741,"NCT00741871","A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies",,"Completed","No Results Available","Drug: SB1518","Phase 1","null","https://ClinicalTrials.gov/show/NCT00741871"
742,"NCT01665768","Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma",,"Active, not recruiting","No Results Available","Drug: Everolimus and Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01665768"
743,"NCT00001512","Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines",,"Completed","No Results Available","Drug: Id-KLH Vaccine|Drug: GM-CSF","Phase 1","null","https://ClinicalTrials.gov/show/NCT00001512"
744,"NCT01120834","Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: azacytidine|Drug: vorinostat","Phase 1|Phase 2","April 10, 2017","https://ClinicalTrials.gov/show/NCT01120834"
745,"NCT00577278","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Biological: rituximab|Drug: fludarabine phosphate|Drug: melphalan|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00577278"
746,"NCT00612183","Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma",,"Completed","No Results Available","Drug: bendamustine hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00612183"
747,"NCT01955668","AZD6738 First Time in Patient Multiple Ascending Dose Study",,"Completed","No Results Available","Drug: Administration of AZD6738","Phase 1","null","https://ClinicalTrials.gov/show/NCT01955668"
748,"NCT00101010","Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Biological: Filgrastim|Biological: Pegfilgrastim|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Pegylated liposomal doxorubicin hydrochloride|Drug: Prednisone|Drug: Vincristine Sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00101010"
749,"NCT02051257","Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Other: Laboratory Biomarker Analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT02051257"
750,"NCT01077518","Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen","COMPLEMENT A+B","Active, not recruiting","No Results Available","Drug: Ofatumumab and Bendamustine infusions (Arm A)|Drug: Bendamustine infusion (Arm B)","Phase 3","null","https://ClinicalTrials.gov/show/NCT01077518"
751,"NCT00278408","Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00278408"
752,"NCT00062296","Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Biological: rituximab|Drug: epirubicin hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00062296"
753,"NCT00974792","Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",,"Unknown status","No Results Available","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00974792"
754,"NCT00001572","Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype",,"Completed","No Results Available","Drug: Id-KLH Vaccine|Drug: QS-21 (Stimulation-QS-21) Drug","Phase 1","null","https://ClinicalTrials.gov/show/NCT00001572"
755,"NCT03233854","CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Phase 1","null","https://ClinicalTrials.gov/show/NCT03233854"
756,"NCT00695409","Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: ASCT|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","July 6, 2018","https://ClinicalTrials.gov/show/NCT00695409"
757,"NCT03114865","A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",,"Recruiting","No Results Available","Drug: Blinatumomab|Drug: Dexamethasone","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT03114865"
758,"NCT00765245","Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Drug: Lenalidomide|Drug: Rituximab","Phase 2","April 11, 2016","https://ClinicalTrials.gov/show/NCT00765245"
759,"NCT00989664","Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: Tositumomab and Iodine I 131 Tositumomab","Phase 2","April 10, 2012","https://ClinicalTrials.gov/show/NCT00989664"
760,"NCT00867529","Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",,"Completed","Has Results","Biological: rituximab|Procedure: peripheral blood stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 2","May 22, 2017","https://ClinicalTrials.gov/show/NCT00867529"
761,"NCT03220022","Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Filgrastim|Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","Phase 1","null","https://ClinicalTrials.gov/show/NCT03220022"
762,"NCT02017613","Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies","PI3K","Completed","No Results Available","Drug: RP6530","Phase 1","null","https://ClinicalTrials.gov/show/NCT02017613"
763,"NCT00498043","A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma","LNH2007-3B","Completed","No Results Available","Drug: R-CHOP14 induction regimen|Drug: R-ACVBP14 induction regimen","Phase 2","null","https://ClinicalTrials.gov/show/NCT00498043"
764,"NCT00079443","FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: romidepsin|Biological: rituximab|Drug: fludarabine phosphate|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00079443"
765,"NCT02572453","Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Onalespib","Phase 2","null","https://ClinicalTrials.gov/show/NCT02572453"
766,"NCT00875056","Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103)",,"Active, not recruiting","No Results Available","Drug: vorinostat","Phase 2","null","https://ClinicalTrials.gov/show/NCT00875056"
767,"NCT01980654","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma",,"Completed","No Results Available","Drug: Ibrutinib|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01980654"
768,"NCT01282424","Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma","DELTA","Completed","Has Results","Drug: Idelalisib","Phase 2","September 4, 2014","https://ClinicalTrials.gov/show/NCT01282424"
769,"NCT00944905","Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)",,"Completed","No Results Available","Biological: MDX-1203","Phase 1","null","https://ClinicalTrials.gov/show/NCT00944905"
770,"NCT02254772","A Phase I/II Study of Intratumoral Injection of SD-101",,"Completed","Has Results","Biological: Ipilimumab|Drug: SD-101|Radiation: Radiation therapy","Phase 1|Phase 2","September 29, 2017","https://ClinicalTrials.gov/show/NCT02254772"
771,"NCT03543813","PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",,"Recruiting","No Results Available","Drug: CX-2029","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03543813"
772,"NCT02332980","Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: Idelalisib|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02332980"
773,"NCT02242045","Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: Idelalisib","Phase 1","null","https://ClinicalTrials.gov/show/NCT02242045"
774,"NCT01030536","Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)",,"Completed","Has Results","Drug: CAT-8015 20 mcg/kg|Drug: CAT-8015 30 mcg/kg|Drug: CAT-8015 40 mcg/kg|Drug: CAT-8015 50 mcg/kg|Drug: CAT-8015 60 mcg/kg","Phase 1|Phase 2","April 9, 2018","https://ClinicalTrials.gov/show/NCT01030536"
775,"NCT00413959","VELCADE,Rituximab,Cyclophosphamide and Decadron","VRCD","Terminated","Has Results","Drug: VELCADE®|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Decadron","Phase 2","September 27, 2013","https://ClinicalTrials.gov/show/NCT00413959"
776,"NCT03605589","Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma",,"Recruiting","No Results Available","Drug: Blinatumomab|Drug: Pembrolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03605589"
777,"NCT01311232","Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01311232"
778,"NCT02659943","T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies",,"Active, not recruiting","No Results Available","Biological: Anti-CD19-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine","Phase 1","null","https://ClinicalTrials.gov/show/NCT02659943"
779,"NCT00968656","Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1","FISO PET/CT","Completed","No Results Available","Radiation: PET/CT|Other: Laboratory Testing|Other: Safety Testing|Other: Immunohistochemistry staining|Drug: F-18-ISO","Phase 1","null","https://ClinicalTrials.gov/show/NCT00968656"
780,"NCT00087425","Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Biological: rituximab|Drug: bryostatin 1","Phase 2","null","https://ClinicalTrials.gov/show/NCT00087425"
781,"NCT00543582","MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: MGCD0103 and Azacitidine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00543582"
782,"NCT00210327","VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy",,"Completed","No Results Available","Drug: Bortezomib (drug)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00210327"
783,"NCT01209130","A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: DCDT2980S|Drug: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01209130"
784,"NCT01290549","A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma",,"Completed","No Results Available","Drug: Polatuzumab Vedotin|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01290549"
785,"NCT00210392","VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy",,"Terminated","No Results Available","Drug: Bortezomib (drug)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00210392"
786,"NCT01851551","Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL",,"Completed","No Results Available","Drug: Vincristine Sulfate Liposome Injection plus rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01851551"
787,"NCT00210353","Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma",,"Active, not recruiting","No Results Available","Drug: chlorambucil (drug)|Drug: rituximab+chlorambucil|Drug: rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00210353"
788,"NCT00412321","A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease",,"Completed","No Results Available","Drug: CNTO 328","Phase 1","null","https://ClinicalTrials.gov/show/NCT00412321"
789,"NCT02257242","Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma","BRiM","Recruiting","No Results Available","Drug: Rituximab|Drug: Bendamustine|Drug: Vincristine sulfate liposome injection","Phase 1","null","https://ClinicalTrials.gov/show/NCT02257242"
790,"NCT00082784","Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms",,"Completed","No Results Available","Drug: Bortezomib|Drug: Alvocidib Hydrochloride|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00082784"
791,"NCT03265158","Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0","BMPB","Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03265158"
792,"NCT02885623","Role of CX3CR1-expressing Cells in Hematologic Malignancy",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02885623"
793,"NCT01088048","Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Ofatumumab|Drug: Fludarabine|Drug: Everolimus|Drug: Bortezomib|Drug: Chlorambucil|Drug: Lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01088048"
794,"NCT01479842","Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Drug: BTK inhibitor PCI-32765|Biological: rituximab|Drug: bendamustine hydrochloride|Other: pharmacogenomic studies|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01479842"
795,"NCT02914938","A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: ME-401|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02914938"
796,"NCT00523939","DepoCyt for Active Lymphomatous or Leukemic Meningitis",,"Terminated","Has Results","Drug: cytarabine liposome injection","Phase 2","March 14, 2011","https://ClinicalTrials.gov/show/NCT00523939"
797,"NCT00985699","S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: pharmacogenomic studies","","null","https://ClinicalTrials.gov/show/NCT00985699"
798,"NCT02498951","Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response",,"Recruiting","No Results Available","Procedure: Cognitive Assessment|Biological: Obinutuzumab|Other: Quality-of-Life Assessment","Phase 2","null","https://ClinicalTrials.gov/show/NCT02498951"
799,"NCT01791595","A Phase I Trial of AZD3965 in Patients With Advanced Cancer",,"Recruiting","No Results Available","Drug: AZD3965","Phase 1","null","https://ClinicalTrials.gov/show/NCT01791595"
800,"NCT03016000","Thalidomide Maintenance Treatment in DLBCL",,"Recruiting","No Results Available","Drug: Thalidomide|Other: Observation","Phase 3","null","https://ClinicalTrials.gov/show/NCT03016000"
801,"NCT03559439","CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies",,"Recruiting","No Results Available","Biological: CD19 CAR T","Phase 1","null","https://ClinicalTrials.gov/show/NCT03559439"
802,"NCT03000738","The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas",,"Not yet recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03000738"
803,"NCT00337259","Gemcitabine for Marginal Zone Lymphoma",,"Terminated","No Results Available","Drug: gemcitabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00337259"
804,"NCT02772198","T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies",,"Recruiting","No Results Available","Biological: CD19 CAR T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02772198"
805,"NCT01786135","A Safety Study of SGN-CD19A for B-Cell Lymphoma",,"Completed","No Results Available","Drug: SGN-CD19A","Phase 1","null","https://ClinicalTrials.gov/show/NCT01786135"
806,"NCT01562977","Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL","RGemOx","Completed","No Results Available","Drug: Rituximab, Gemcitabine, Oxaliplatin, Dexametasone","Phase 2","null","https://ClinicalTrials.gov/show/NCT01562977"
807,"NCT02646098","CD34+ Selected ASCT for Aggressive Lymphomas","SAAL","Active, not recruiting","No Results Available","Procedure: CD34+ cell selection","Phase 2","null","https://ClinicalTrials.gov/show/NCT02646098"
808,"NCT00054639","Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",,"Completed","Has Results","Biological: oblimersen sodium|Biological: rituximab|Other: laboratory biomarker analysis","Phase 2","February 21, 2011","https://ClinicalTrials.gov/show/NCT00054639"
809,"NCT03417414","Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?",,"Not yet recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03417414"
810,"NCT03106428","A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies",,"Recruiting","No Results Available","Drug: MEDI7247","Phase 1","null","https://ClinicalTrials.gov/show/NCT03106428"
811,"NCT03666988","First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)",,"Not yet recruiting","No Results Available","Drug: GSK3368715","Phase 1","null","https://ClinicalTrials.gov/show/NCT03666988"
812,"NCT02846935","p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies",,"Recruiting","No Results Available","Drug: Decitabine|Drug: Tetrahydrouridine","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT02846935"
813,"NCT00119392","Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Radiation: yttrium Y 90 ibritumomab tiuxetan|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: total-body irradiation","Phase 2","May 24, 2017","https://ClinicalTrials.gov/show/NCT00119392"
814,"NCT01352312","Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma",,"Terminated","No Results Available","Drug: Bendamustine|Drug: Pentostatin|Drug: Ofatumumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01352312"
815,"NCT03593109","Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma",,"Recruiting","No Results Available","Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT03593109"
816,"NCT03133221","1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",,"Recruiting","No Results Available","Drug: Zydelig","Phase 2","null","https://ClinicalTrials.gov/show/NCT03133221"
817,"NCT03564977","CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation",,"Recruiting","No Results Available","Biological: CD19-targeted CAR-T cells","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03564977"
818,"NCT00026182","Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Biological: recombinant interleukin-12|Other: laboratory biomarker analysis|Other: questionnaire administration|Procedure: quality-of-life assessment","Phase 2","null","https://ClinicalTrials.gov/show/NCT00026182"
819,"NCT01808599","Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma",,"Active, not recruiting","No Results Available","Drug: Chlorambucil|Drug: Rituximab i.v.|Drug: Rituximab s.c.","Phase 2","null","https://ClinicalTrials.gov/show/NCT01808599"
820,"NCT01119794","Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",,"Terminated","Has Results","Drug: Ofatumumab and Bortezomib","Phase 2","August 11, 2015","https://ClinicalTrials.gov/show/NCT01119794"
821,"NCT00089076","MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma",,"Terminated","Has Results","Biological: ipilimumab|Other: laboratory biomarker analysis","Phase 1|Phase 2","October 19, 2012","https://ClinicalTrials.gov/show/NCT00089076"
822,"NCT00051025","Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Drug: ONTAK","Phase 2","August 3, 2011","https://ClinicalTrials.gov/show/NCT00051025"
823,"NCT02650999","Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas",,"Recruiting","No Results Available","Drug: Pembrolizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02650999"
824,"NCT00823719","Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","Has Results","Drug: ofatumumab + ICE|Drug: ofatumumab + DHAP","Phase 2","September 5, 2012","https://ClinicalTrials.gov/show/NCT00823719"
825,"NCT03610724","Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients","BIANCA","Not yet recruiting","No Results Available","Biological: Tisagenlecleucel","Phase 2","null","https://ClinicalTrials.gov/show/NCT03610724"
826,"NCT02499003","GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma",,"Recruiting","No Results Available","Drug: Obinutuzumab and Pixantrone","Phase 2","null","https://ClinicalTrials.gov/show/NCT02499003"
827,"NCT02226965","PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)",,"Active, not recruiting","No Results Available","Drug: PNT2258","Phase 2","null","https://ClinicalTrials.gov/show/NCT02226965"
828,"NCT03241017","Durvalumab in DLBCL After Autologous Transplant","IDA-D","Withdrawn","No Results Available","Drug: Durvalumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03241017"
829,"NCT02652910","Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma","MeCAR","Recruiting","No Results Available","Drug: CD19.CAR-T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02652910"
830,"NCT03156101","A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects",,"Recruiting","No Results Available","Biological: BinD19","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03156101"
831,"NCT00110071","Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: iodine I 131 tositumomab|Other: laboratory biomarker analysis|Other: flow cytometry|Genetic: polymerase chain reaction","Phase 1","null","https://ClinicalTrials.gov/show/NCT00110071"
832,"NCT02987400","Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL",,"Recruiting","No Results Available","Drug: Venetoclax|Drug: Obinutuzumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02987400"
833,"NCT01431209","Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",,"Active, not recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Ruxolitinib Phosphate","Phase 2","null","https://ClinicalTrials.gov/show/NCT01431209"
834,"NCT03664635","MB-CART20.1 Lymphoma",,"Not yet recruiting","No Results Available","Biological: MB-CART20.1","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03664635"
835,"NCT00001582","Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00001582"
836,"NCT02417285","A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.",,"Recruiting","No Results Available","Drug: Obinutuzumab|Drug: CC-122","Phase 1","null","https://ClinicalTrials.gov/show/NCT02417285"
837,"NCT03265106","A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects",,"Recruiting","No Results Available","Biological: BinD19","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03265106"
838,"NCT01032681","EMD 521873 in Advanced Solid Tumors, MTD Finding",,"Completed","No Results Available","Biological: EMD 521873","Phase 1","null","https://ClinicalTrials.gov/show/NCT01032681"
839,"NCT00121199","Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma",,"Completed","Has Results","Biological: rituximab|Biological: bevacizumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","Phase 2","December 19, 2012","https://ClinicalTrials.gov/show/NCT00121199"
840,"NCT01165112","Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma","TREC","Active, not recruiting","Has Results","Drug: Bendamustine Hydrochloride|Drug: Carboplatin|Biological: Rituximab|Drug: Etoposide|Other: Laboratory Biomarker Analysis","Phase 1|Phase 2","May 25, 2017","https://ClinicalTrials.gov/show/NCT01165112"
841,"NCT00854568","Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL",,"Completed","No Results Available","Drug: CEOP regimen|Drug: CHOP regimen","Phase 3","null","https://ClinicalTrials.gov/show/NCT00854568"
842,"NCT02924402","Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies",,"Recruiting","No Results Available","Biological: XmAb13676","Phase 1","null","https://ClinicalTrials.gov/show/NCT02924402"
843,"NCT00937183","Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma",,"Unknown status","No Results Available","Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00937183"
844,"NCT03598608","Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",,"Not yet recruiting","No Results Available","Biological: pembrolizumab|Biological: MK-4280","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03598608"
845,"NCT01567709","Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma",,"Completed","No Results Available","Drug: Alisertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Vorinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT01567709"
846,"NCT03018626","R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL",,"Recruiting","No Results Available","Drug: Rituximab|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Vindesine|Drug: Bleomycin","Phase 3","null","https://ClinicalTrials.gov/show/NCT03018626"
847,"NCT03271515","Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL",,"Not yet recruiting","No Results Available","Biological: anti-CD19 anti-CD20 Bispecific CAR-T","Phase 1","null","https://ClinicalTrials.gov/show/NCT03271515"
848,"NCT02546739","Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL",,"Not yet recruiting","No Results Available","Biological: Anti-CD19-CAR","Phase 1","null","https://ClinicalTrials.gov/show/NCT02546739"
849,"NCT01660776","BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology","BMS_PD-L1","Active, not recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01660776"
850,"NCT02656147","Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL",,"Not yet recruiting","No Results Available","Biological: Anti-CD19-CAR γδT","Phase 1","null","https://ClinicalTrials.gov/show/NCT02656147"
851,"NCT03293173","Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis","Bio-CHIC","Recruiting","No Results Available","Combination Product: R-CHOEP|Combination Product: DA-EPOCH-R","Phase 2","null","https://ClinicalTrials.gov/show/NCT03293173"
852,"NCT01695941","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: Alisertib|Drug: Bortezomib|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01695941"
853,"NCT02364050","Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM",,"Active, not recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02364050"
854,"NCT02374424","Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients","GIOTTO","Terminated","No Results Available","Drug: GA101_DHAP","Phase 2","null","https://ClinicalTrials.gov/show/NCT02374424"
855,"NCT02081937","CART-19 Immunotherapy in Mantle Cell Lymphoma",,"Recruiting","No Results Available","Biological: anti-CD19-CAR vector-transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02081937"
856,"NCT03685786","CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT",,"Recruiting","No Results Available","Biological: CART19 cell and auto-HSCT","Phase 1","null","https://ClinicalTrials.gov/show/NCT03685786"
857,"NCT01141712","Autologous Transplant in HIV Patients (BMT CTN 0803)",,"Completed","Has Results","Procedure: Autologous transplant|Drug: BCNU|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan","Phase 2","March 28, 2017","https://ClinicalTrials.gov/show/NCT01141712"
858,"NCT01593696","Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma",,"Completed","No Results Available","Biological: Anti-CD19- CAR","Phase 1","null","https://ClinicalTrials.gov/show/NCT01593696"
859,"NCT01686321","Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma","B-R-ENDA","Unknown status","No Results Available","Drug: Bendamustine and subcutaneous rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01686321"
860,"NCT02624492","To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL",,"Completed","No Results Available","Drug: BI 836826|Drug: GemOx|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02624492"
861,"NCT00655837","Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL",,"Completed","No Results Available","Drug: SGN-40|Drug: rituximab|Drug: gemcitabine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00655837"
862,"NCT03276468","Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",,"Recruiting","No Results Available","Drug: Atezolizumab|Drug: Obinutuzumab|Drug: Venetoclax","Phase 2","null","https://ClinicalTrials.gov/show/NCT03276468"
863,"NCT01397591","Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",,"Terminated","Has Results","Biological: Ofatumumab|Drug: Bortezomib","Phase 2","July 30, 2014","https://ClinicalTrials.gov/show/NCT01397591"
864,"NCT03527147","Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)",,"Recruiting","No Results Available","Drug: AZD9150|Drug: Acalabrutinib|Drug: AZD6738","Phase 1","null","https://ClinicalTrials.gov/show/NCT03527147"
865,"NCT00529503","A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL",,"Terminated","No Results Available","Drug: SGN-40|Drug: placebo|Drug: rituximab|Drug: etoposide|Drug: carboplatin|Drug: ifosfamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00529503"
866,"NCT00568815","Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Drug: Rituximab combined with ESHAP","Phase 2","null","https://ClinicalTrials.gov/show/NCT00568815"
867,"NCT00003356","Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",,"Completed","No Results Available","Biological: aldesleukin|Biological: rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00003356"
868,"NCT00591630","Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation",,"Active, not recruiting","No Results Available","Drug: Zevalin|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Drug: Rituximab|Procedure: Stem Cell Transplant","Phase 2","null","https://ClinicalTrials.gov/show/NCT00591630"
869,"NCT01138579","Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation","STP-LYM-01","Terminated","No Results Available","Drug: FBTA05","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01138579"
870,"NCT00242996","Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: adjuvant therapy|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00242996"
871,"NCT00436280","Chemotherapy for Patients With Lymphoma",,"Completed","No Results Available","Drug: enzastaurin|Drug: gemcitabine|Drug: rituximab|Drug: oxaliplatin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00436280"
872,"NCT00093769","Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: bortezomib + rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00093769"
873,"NCT00001337","Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: EPOCH|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00001337"
874,"NCT00690560","Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00690560"
875,"NCT00007839","Beta Alethine in Treating Patients With Low-Grade Lymphoma",,"Unknown status","No Results Available","Drug: beta alethine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00007839"
876,"NCT00963274","Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",,"Completed","No Results Available","Drug: Bortezomib|Drug: Romidepsin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00963274"
877,"NCT00301301","A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Drug: Gemcitabine|Drug: Cisplatinum|Drug: Rituximab","","null","https://ClinicalTrials.gov/show/NCT00301301"
878,"NCT03588598","Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies",,"Recruiting","No Results Available","Drug: SHC014748M","Phase 1","null","https://ClinicalTrials.gov/show/NCT03588598"
879,"NCT00244985","Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: pegylated liposomal doxorubicin hydrochloride","Phase 1|Phase 2","July 14, 2017","https://ClinicalTrials.gov/show/NCT00244985"
880,"NCT02339922","Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT02339922"
881,"NCT00322218","Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R",,"Unknown status","No Results Available","Drug: Zevalin Therapeutic Regimen|Other: Observation","Phase 3","null","https://ClinicalTrials.gov/show/NCT00322218"
882,"NCT00278421","Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00278421"
883,"NCT00504751","Phase II Study of ""VIPER"" Chemotherapy in Rel/Ref DLBCL",,"Completed","Has Results","Drug: bortezomib, dexamethasone, ifosfamide|Drug: mesna, cisplatin, etoposide, rituximab","Phase 2","April 7, 2017","https://ClinicalTrials.gov/show/NCT00504751"
884,"NCT01671813","Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly",,"Withdrawn","No Results Available","Drug: brentuximab vedotin","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01671813"
885,"NCT01101581","Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",,"Unknown status","No Results Available","Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan|Drug: 90Y-epratuzumab tetraxetan|Drug: veltuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01101581"
886,"NCT01393756","Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma","R2-CHOP2","Completed","No Results Available","Drug: Lenalidomide and R-CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT01393756"
887,"NCT00361621","Ph II CHOP+Velcade in Mediastinal LBCL",,"Terminated","No Results Available","Drug: bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Radiation: Radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00361621"
888,"NCT01276717","Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma",,"Completed","No Results Available","Drug: Drug: Carfilzomib|Drug: Vorinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT01276717"
889,"NCT02339805","Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS","LymphoSeq","Completed","No Results Available","Other: next generation sequencing|Device: Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02339805"
890,"NCT03366272","Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","NIVEAU","Recruiting","No Results Available","Drug: Nivolumab|Drug: Rituximab|Drug: Gemcitabine|Device: Oxaliplatin","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT03366272"
891,"NCT01210287","Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP","IHBVRL","Unknown status","No Results Available","Drug: nucleoside analog reverse transcriptase inhibitor","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT01210287"
892,"NCT01421667","A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma",,"Completed","Has Results","Drug: brentuximab vedotin|Drug: rituximab","Phase 2","October 13, 2016","https://ClinicalTrials.gov/show/NCT01421667"
893,"NCT00028613","Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma",,"Completed","No Results Available","Radiation: iodine I 131 monoclonal antibody Lym-1","Phase 1","null","https://ClinicalTrials.gov/show/NCT00028613"
894,"NCT03483103","Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006)",,"Recruiting","No Results Available","Biological: lisocabtagene maraleucel","Phase 2","null","https://ClinicalTrials.gov/show/NCT03483103"
895,"NCT00007956","Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma",,"Completed","No Results Available","Biological: monoclonal antibody mono-dgA-RFB4","Phase 1","null","https://ClinicalTrials.gov/show/NCT00007956"
896,"NCT03463057","The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL","HO151DLBCL","Recruiting","No Results Available","Drug: Atezolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03463057"
897,"NCT00258336","Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: rituximab|Biological: sargramostim","Phase 2","null","https://ClinicalTrials.gov/show/NCT00258336"
898,"NCT00450385","Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)","R-CHOP","Terminated","Has Results","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Phase 2","June 23, 2017","https://ClinicalTrials.gov/show/NCT00450385"
899,"NCT01403636","A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia",,"Completed","No Results Available","Drug: SAR245409","Phase 2","null","https://ClinicalTrials.gov/show/NCT01403636"
900,"NCT01987505","MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma",,"Completed","Has Results","Drug: Rituximab","Phase 3","July 4, 2018","https://ClinicalTrials.gov/show/NCT01987505"
901,"NCT00002757","TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisolone|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00002757"
902,"NCT00039195","Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma",,"Completed","Has Results","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","August 10, 2016","https://ClinicalTrials.gov/show/NCT00039195"
903,"NCT00472056","Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies",,"Completed","Has Results","Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Drug: Rituximab","Phase 2","February 13, 2012","https://ClinicalTrials.gov/show/NCT00472056"
904,"NCT00054171","Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: aminolevulinic acid hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00054171"
905,"NCT00451178","An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only",,"Completed","No Results Available","Drug: enzastaurin|Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00451178"
906,"NCT00902018","Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)",,"Completed","No Results Available","Drug: Promacta (eltrombopag)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00902018"
907,"NCT00004198","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004198"
908,"NCT00004197","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004197"
909,"NCT00493454","Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas",,"Terminated","Has Results","Drug: Zevalin|Drug: Rituximab|Drug: ^111 In Ibritumomab Tiuxetan","Phase 2","May 31, 2013","https://ClinicalTrials.gov/show/NCT00493454"
910,"NCT00387959","Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Phase 2","February 1, 2016","https://ClinicalTrials.gov/show/NCT00387959"
911,"NCT02597387","Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs",,"Recruiting","No Results Available","Drug: Mitoxantrone HCL Liposome Injection","Phase 2","null","https://ClinicalTrials.gov/show/NCT02597387"
912,"NCT00041730","Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: Id-KLH","Phase 2","null","https://ClinicalTrials.gov/show/NCT00041730"
913,"NCT00425802","Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","Has Results","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Radiation: total-body irradiation","Phase 2","October 31, 2017","https://ClinicalTrials.gov/show/NCT00425802"
914,"NCT03225924","Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy",,"Recruiting","No Results Available","Drug: Entospletinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03225924"
915,"NCT00644371","Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","Z-RIC-Allo","Completed","No Results Available","Drug: Ibritumomab Tiuxetan (Zevalin)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00644371"
916,"NCT03418038","Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma",,"Recruiting","No Results Available","Dietary Supplement: Ascorbic Acid|Drug: Carboplatin|Drug: Cisplatin|Drug: Cytarabine|Drug: Dexamethasone|Drug: Etoposide|Drug: Gemcitabine Hydrochloride|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Other: Placebo|Other: Questionnaire Administration|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03418038"
917,"NCT01325194","CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","CHIC","Active, not recruiting","No Results Available","Drug: liposomal cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01325194"
918,"NCT00036426","Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: FavId (Id-KLH) active immunotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00036426"
919,"NCT00265928","Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: bortezomib|Drug: rituximab|Procedure: antibody therapy|Procedure: biological therapy|Procedure: enzyme inhibitor therapy|Procedure: monoclonal antibody therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00265928"
920,"NCT00307710","Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: Trivalent Baculovirus-expressed Influenza HA vaccine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00307710"
921,"NCT03123718","High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL",,"Not yet recruiting","No Results Available","Drug: Intrathecal methotrexate|Drug: High-dose intravenous methotrexate","Phase 3","null","https://ClinicalTrials.gov/show/NCT03123718"
922,"NCT00003963","Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",,"Completed","No Results Available","Biological: rituximab|Drug: vinorelbine ditartrate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003963"
923,"NCT00004039","Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma",,"Withdrawn","No Results Available","Biological: recombinant interferon alfa|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004039"
924,"NCT03144674","A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",,"Recruiting","No Results Available","Drug: INCB050465","Phase 2","null","https://ClinicalTrials.gov/show/NCT03144674"
925,"NCT00003397","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003397"
926,"NCT02481310","Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Drug: Prednisone|Biological: Rituximab|Drug: Therapeutic Hydrocortisone|Drug: Vincristine Sulfate","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02481310"
927,"NCT00080847","S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00080847"
928,"NCT01318317","Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Procedure: peripheral blood stem cell transplantation (PBSCT)|Biological: filgrastim|Genetic: polymerase chain reaction|Biological: rituximab|Biological: genetically engineered lymphocyte therapy|Other: laboratory biomarker analysis|Drug: plerixafor|Procedure: autologous hematopoietic stem cell transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01318317"
929,"NCT01713582","A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies (MK-8628-001)",,"Completed","Has Results","Drug: OTX015/MK-8628","Phase 1","October 1, 2018","https://ClinicalTrials.gov/show/NCT01713582"
930,"NCT00080886","Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00080886"
931,"NCT01796470","Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies",,"Completed","No Results Available","Drug: Entospletinib|Drug: Idelalisib","Phase 2","null","https://ClinicalTrials.gov/show/NCT01796470"
932,"NCT00324779","Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Biological: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00324779"
933,"NCT00004031","SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: CHOP regimen|Drug: carmustine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00004031"
934,"NCT00429065","Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.",,"Unknown status","No Results Available","Drug: Rituximab","","null","https://ClinicalTrials.gov/show/NCT00429065"
935,"NCT03460977","PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",,"Recruiting","No Results Available","Drug: PF-06821497","Phase 1","null","https://ClinicalTrials.gov/show/NCT03460977"
936,"NCT02981914","Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Drug: Pembrolizumab","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT02981914"
937,"NCT03498612","Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03498612"
938,"NCT02732275","A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas",,"Recruiting","No Results Available","Drug: DS-3201b","Phase 1","null","https://ClinicalTrials.gov/show/NCT02732275"
939,"NCT00002682","Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach",,"Completed","No Results Available","Drug: Amoxicillin|Drug: Bismuth Subsalicylate|Drug: Clarithromycin|Drug: Metronidazole Hydrochloride|Drug: Omeprazole|Drug: Tetracycline Hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002682"
940,"NCT02791217","Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool",,"Not yet recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02791217"
941,"NCT01087294","Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation",,"Recruiting","No Results Available","Procedure: Allogeneic stem cell transplant|Biological: Anti-CD19-chimeric-antigen-receptor- transduced T cell","Phase 1","null","https://ClinicalTrials.gov/show/NCT01087294"
942,"NCT02983097","Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","R²-DHAP","Terminated","No Results Available","Drug: Rituximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Dexamethasone|Drug: Cytarabine|Drug: Lenalidomide|Drug: PegFilgrastim|Procedure: peripheral stem cell collection","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02983097"
943,"NCT00498667","The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma",,"Withdrawn","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00498667"
944,"NCT00031642","Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation",,"Completed","No Results Available","Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00031642"
945,"NCT00022555","Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma",,"Completed","No Results Available","Drug: bryostatin 1|Drug: vincristine sulfate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00022555"
946,"NCT00491491","Zevalin-beam for Aggressive Lymphoma",,"Completed","No Results Available","Drug: ibritumomab tiuxetan|Procedure: BEAM chemotherapy and autologous stem-cell transplantation","Phase 3","null","https://ClinicalTrials.gov/show/NCT00491491"
947,"NCT00086944","Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: oblimersen sodium|Biological: rituximab|Drug: ifosfamide|Drug: carboplatin|Drug: etoposide|Biological: filgrastim|Biological: pegfilgrastim|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00086944"
948,"NCT00005601","Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cisplatin|Drug: cytarabine|Drug: dexamethasone|Drug: sargramostim","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005601"
949,"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)","SAGAN","Recruiting","No Results Available","Biological: CD19 CAR T Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01853631"
950,"NCT01775631","Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma",,"Completed","No Results Available","Biological: Urelumab|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01775631"
951,"NCT00005592","Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: 90-Y-ibritumomab tiuxetan|Biological: rituximab|Radiation: indium In 111 ibritumomab tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005592"
952,"NCT00058292","Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: Carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 1","null","https://ClinicalTrials.gov/show/NCT00058292"
953,"NCT00496873","Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",,"Completed","Has Results","Drug: Cytoxan|Drug: Nipent|Drug: Rituxan","Phase 2","August 23, 2016","https://ClinicalTrials.gov/show/NCT00496873"
954,"NCT00040950","Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: agatolimod sodium","Phase 1","null","https://ClinicalTrials.gov/show/NCT00040950"
955,"NCT00389051","A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: bendamustine hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00389051"
956,"NCT03309878","Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Biological: Mogamulizumab|Biological: Pembrolizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03309878"
957,"NCT00049036","Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: etoposide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: cyclophosphamide|Other: laboratory biomarker analysis","Phase 2","June 22, 2011","https://ClinicalTrials.gov/show/NCT00049036"
958,"NCT00726700","Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",,"Completed","No Results Available","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00726700"
959,"NCT00006241","Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Drug: chemotherapy|Procedure: in vitro-treated peripheral blood stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006241"
960,"NCT00274924","Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma",,"Active, not recruiting","Has Results","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine","Phase 2","February 24, 2014","https://ClinicalTrials.gov/show/NCT00274924"
961,"NCT00026351","Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Biological: rituximab|Drug: pentostatin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00026351"
962,"NCT00014664","Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: apolizumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00014664"
963,"NCT01541072","Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation","PALM2","Terminated","No Results Available","Drug: Pegfilgrastim|Drug: Filgrastim","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01541072"
964,"NCT01205737","A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects",,"Completed","No Results Available","Biological: TL011|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01205737"
965,"NCT00026429","Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: denileukin diftitox","Phase 2","null","https://ClinicalTrials.gov/show/NCT00026429"
966,"NCT01804686","A Long-term Extension Study of PCI-32765 (Ibrutinib)",,"Enrolling by invitation","No Results Available","Drug: PCI-32765 (Ibrutinib)","Phase 3","null","https://ClinicalTrials.gov/show/NCT01804686"
967,"NCT02793583","Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","UNITY-NHL","Recruiting","No Results Available","Drug: TGR-1202 + Ublituximab|Drug: TGR-1202|Drug: TGR-1202 + Ublituximab + Bendamustine","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT02793583"
968,"NCT02580552","Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL",,"Recruiting","No Results Available","Drug: MRG-106","Phase 1","null","https://ClinicalTrials.gov/show/NCT02580552"
969,"NCT01682044","Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma",,"Completed","Has Results","Biological: pegfilgrastim|Biological: rituximab|Other: flow cytometry|Procedure: biopsy|Other: immunohistochemistry staining method|Genetic: western blotting","Phase 2","October 9, 2017","https://ClinicalTrials.gov/show/NCT01682044"
970,"NCT03448393","CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies",,"Recruiting","No Results Available","Biological: CD19/CD22 CAR T-Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT03448393"
971,"NCT01722305","Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma",,"Active, not recruiting","No Results Available","Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Pomalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01722305"
972,"NCT02348216","A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)","ZUMA-1","Recruiting","No Results Available","Biological: axicabtagene ciloleucel","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02348216"
973,"NCT02342665","Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL",,"Active, not recruiting","No Results Available","Drug: Copanlisib (BAY80-6946)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02342665"
974,"NCT01281917","Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma",,"Completed","Has Results","Drug: Velcade|Drug: Temsirolimus","Phase 2","August 21, 2017","https://ClinicalTrials.gov/show/NCT01281917"
975,"NCT01939327","Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma","R2","Recruiting","No Results Available","Drug: Lenalidomide/Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01939327"
976,"NCT00994643","Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: Rituximab|Biological: Interleukin-2","Phase 2","October 6, 2017","https://ClinicalTrials.gov/show/NCT00994643"
977,"NCT01729104","Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma",,"Active, not recruiting","No Results Available","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01729104"
978,"NCT00077961","Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL",,"Terminated","No Results Available","Drug: CAMPATH (alemtuzumab)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00077961"
979,"NCT00709033","T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL","ATECRAB","Active, not recruiting","No Results Available","Biological: autologous or syngeneic PBTLs and EBV-CTLs","Phase 1","null","https://ClinicalTrials.gov/show/NCT00709033"
980,"NCT01962636","Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases",,"Recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Drug: Cyclosporine A|Drug: Mycophenylate mofetil|Biological: Umbilical cord blood","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01962636"
981,"NCT00055640","Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Genetic: microarray analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00055640"
982,"NCT02747043","Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab","JASMINE","Recruiting","No Results Available","Drug: ABP 798|Drug: Rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT02747043"
983,"NCT03154775","Study of Safety and Efficacy of C-CAR011 in B-NHL Patients",,"Recruiting","No Results Available","Biological: C-CAR011","Phase 1","null","https://ClinicalTrials.gov/show/NCT03154775"
984,"NCT01868035","Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP",,"Completed","Has Results","Drug: tositumomab and iodine I-131 tositumomab","Phase 2","September 12, 2013","https://ClinicalTrials.gov/show/NCT01868035"
985,"NCT03501576","Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma",,"Recruiting","No Results Available","Biological: Inactivated Influenza Vaccine","Phase 1","null","https://ClinicalTrials.gov/show/NCT03501576"
986,"NCT02594384","A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)","LAM-002A/NHL","Recruiting","No Results Available","Drug: LAM-002A|Drug: Rituximab|Drug: Atezolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02594384"
987,"NCT00024115","BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Withdrawn","No Results Available","Drug: BL22 immunotoxin|Procedure: antibody therapy|Procedure: biological response modifier therapy|Procedure: immunotoxin therapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT00024115"
988,"NCT00546377","Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",,"Completed","Has Results","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: pentostatin|Genetic: fluorescence in situ hybridization|Genetic: gene rearrangement analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: flow cytometry|Procedure: biopsy","Phase 1|Phase 2","May 12, 2016","https://ClinicalTrials.gov/show/NCT00546377"
989,"NCT02500407","A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",,"Recruiting","No Results Available","Drug: BTCT4465A (Mosunetuzumab) IV|Drug: Atezolizumab|Drug: BTCT4465A (Mosunetuzumab) SC","Phase 1","null","https://ClinicalTrials.gov/show/NCT02500407"
990,"NCT00003650","Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003650"
991,"NCT00481871","Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies",,"Completed","Has Results","Drug: Pralatrexate Injection|Drug: Gemcitabine Hydrochloride|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid","Phase 1|Phase 2","September 18, 2012","https://ClinicalTrials.gov/show/NCT00481871"
992,"NCT00138164","Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: denileukin diftitox","Phase 2","null","https://ClinicalTrials.gov/show/NCT00138164"
993,"NCT03207256","Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials",,"Enrolling by invitation","No Results Available","Drug: TGR-1202|Drug: TGR-1202 + Ublituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03207256"
994,"NCT01897012","Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas",,"Active, not recruiting","No Results Available","Drug: Alisertib|Other: Laboratory Biomarker Analysis|Drug: Romidepsin","Phase 1","null","https://ClinicalTrials.gov/show/NCT01897012"
995,"NCT00166439","Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma",,"Completed","No Results Available","Drug: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00166439"
996,"NCT00006669","Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: rituximab|Biological: sargramostim|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006669"
997,"NCT02950220","Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02950220"
998,"NCT02055820","A Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Drug: Venetoclax|Drug: Cyclophosphamide|Drug: Obinutuzumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02055820"
999,"NCT00028665","Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00028665"
1000,"NCT00807495","Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Alisertib","Phase 2","March 27, 2018","https://ClinicalTrials.gov/show/NCT00807495"
1001,"NCT03680586","Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma",,"Not yet recruiting","No Results Available","Radiation: Radiation Therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03680586"
1002,"NCT03474744","Copanlisib and Rituximab in Marginal Zone Lymphoma Patients",,"Not yet recruiting","No Results Available","Drug: Copanlisib","Phase 2","null","https://ClinicalTrials.gov/show/NCT03474744"
1003,"NCT03322865","Obinutuzumab in Marginal Zone Lymphoma",,"Not yet recruiting","No Results Available","Drug: Obinutuzumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03322865"
1004,"NCT03697512","MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","MALIBU","Not yet recruiting","No Results Available","Drug: Ibrutinib|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03697512"
1005,"NCT01007292","A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment",,"Completed","No Results Available","Drug: YM155|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01007292"
1006,"NCT01848652","Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.","MYLY","Terminated","No Results Available","Drug: infusion of MYOCET","Phase 2","null","https://ClinicalTrials.gov/show/NCT01848652"
1007,"NCT02568553","Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Biological: Blinatumomab|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT02568553"
1008,"NCT02142530","Carfilzomib Plus Belinostat in Relapsed/Refractory NHL",,"Completed","No Results Available","Drug: Carfilzomib|Drug: Belinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT02142530"
1009,"NCT00006695","Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: tositumomab and iodine I 131 tositumomab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006695"
1010,"NCT00042913","Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: epratuzumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00042913"
1011,"NCT01206777","Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies",,"Completed","Has Results","Drug: Rituximab","Phase 2","February 23, 2015","https://ClinicalTrials.gov/show/NCT01206777"
1012,"NCT00062114","Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00062114"
1013,"NCT00032019","Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00032019"
1014,"NCT02987127","Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02987127"
1015,"NCT03031483","Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma",,"Recruiting","No Results Available","Drug: clarithromycin and lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03031483"
1016,"NCT03211065","Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig",,"Active, not recruiting","No Results Available","Drug: 20% subcutaneous immunoglobulin","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT03211065"
1017,"NCT00089115","Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: rituximab|Biological: sargramostim","Phase 3","null","https://ClinicalTrials.gov/show/NCT00089115"
1018,"NCT00022685","Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: epratuzumab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00022685"
1019,"NCT01410513","Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: SAR245409","Phase 1","null","https://ClinicalTrials.gov/show/NCT01410513"
1020,"NCT00022932","Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP",,"Unknown status","No Results Available","Drug: Iodine-131 Anti-B1 Antibody","Phase 2","null","https://ClinicalTrials.gov/show/NCT00022932"
1021,"NCT00347971","Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: recombinant human interleukin 21 and rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00347971"
1022,"NCT03288415","SMZL Molecular Prognostic Index",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03288415"
1023,"NCT00562978","Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00562978"
1024,"NCT02945319","Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma",,"Not yet recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02945319"
1025,"NCT00022971","Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia",,"Terminated","No Results Available","Biological: Apolizumab|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00022971"
1026,"NCT00517049","A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)",,"Completed","No Results Available","Drug: PRO95780|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00517049"
1027,"NCT00064116","Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: CHOP regimen","Phase 3","null","https://ClinicalTrials.gov/show/NCT00064116"
1028,"NCT00006708","S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide","Phase 3","null","https://ClinicalTrials.gov/show/NCT00006708"
1029,"NCT01820910","Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment",,"Active, not recruiting","No Results Available","Drug: Doxycycline","Phase 2","null","https://ClinicalTrials.gov/show/NCT01820910"
1030,"NCT00562965","Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)",,"Terminated","Has Results","Drug: inotuzumab ozogamicin|Drug: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: prednisone/prednisolone|Drug: mitoxantrone|Drug: fludarabine|Drug: dexamethasone","Phase 3","January 9, 2018","https://ClinicalTrials.gov/show/NCT00562965"
1031,"NCT01516606","Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma","HD-K","Unknown status","No Results Available","Drug: clarithromycin, oral, high dose","Phase 2","null","https://ClinicalTrials.gov/show/NCT01516606"
1032,"NCT01427114","R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)",,"Active, not recruiting","No Results Available","Drug: rituximab, cyclophosphamide, vincristine, and prednisolone","Phase 2","null","https://ClinicalTrials.gov/show/NCT01427114"
1033,"NCT01514344","Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma","IRIS","Unknown status","No Results Available","Drug: intralesional rituximab|Biological: supplemental autologous serum","Phase 2","null","https://ClinicalTrials.gov/show/NCT01514344"
1034,"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL","O-ICE","Recruiting","No Results Available","Drug: Obinutuzumab|Drug: Liposomal ARA-C|Drug: Ifosfamide|Drug: Carboplatin|Drug: Etoposide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02393157"
1035,"NCT00012051","Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cisplatin|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: methotrexate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00012051"
1036,"NCT00923663","Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type",,"Unknown status","No Results Available","Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00923663"
1037,"NCT03583424","Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Procedure: Hematopoietic Cell Transplantation|Drug: Melphalan|Drug: Venetoclax","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03583424"
1038,"NCT01015248","Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma",,"Completed","No Results Available","Drug: Rituximab and Bendamustine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01015248"
1039,"NCT00400764","A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas",,"Terminated","Has Results","Drug: Dulanermin|Drug: Rituximab","Phase 1|Phase 2","October 7, 2011","https://ClinicalTrials.gov/show/NCT00400764"
1040,"NCT01302912","Lymphoma in the Orbit",,"Unknown status","No Results Available","Procedure: Lymphoma-Biopsy","","null","https://ClinicalTrials.gov/show/NCT01302912"
1041,"NCT01842672","Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia","MITCL","Recruiting","No Results Available","Drug: Clofarabine|Drug: Mitoxantrone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01842672"
1042,"NCT03229200","Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.",,"Enrolling by invitation","No Results Available","Drug: Ibrutinib","Phase 4","null","https://ClinicalTrials.gov/show/NCT03229200"
1043,"NCT01799889","Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies",,"Active, not recruiting","No Results Available","Drug: Entospletinib|Drug: Entospletinib SDD","Phase 2","null","https://ClinicalTrials.gov/show/NCT01799889"
1044,"NCT03226704","Leukapheresis for CAR-Therapy Manufacturing",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03226704"
1045,"NCT00656812","Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma",,"Completed","No Results Available","Drug: Rituximab|Drug: 2-CdA","Phase 2","null","https://ClinicalTrials.gov/show/NCT00656812"
1046,"NCT00244855","Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma",,"Completed","Has Results","Other: pharmacological study|Biological: rituximab|Drug: dexamethasone|Other: laboratory biomarker analysis","Phase 2","May 22, 2017","https://ClinicalTrials.gov/show/NCT00244855"
1047,"NCT00453102","Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma",,"Completed","Has Results","Drug: Rituximab|Drug: Ibritumomab Tiuxetan","Phase 2","January 1, 2016","https://ClinicalTrials.gov/show/NCT00453102"
1048,"NCT00373646","Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients",,"Completed","No Results Available","Drug: Thalidomide, Pharmion","Phase 2","null","https://ClinicalTrials.gov/show/NCT00373646"
1049,"NCT00377195","Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma",,"Active, not recruiting","No Results Available","Radiation: Involved Field Radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00377195"
1050,"NCT02701517","Cyclosporine Plus Methotrexate or Alemtuzumab",,"Terminated","No Results Available","Drug: Cyclosporine + METHOTREXATE|Drug: Cyclosporine + CAMPATH-1H","Phase 2","null","https://ClinicalTrials.gov/show/NCT02701517"
1051,"NCT01815749","Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Procedure: autologous hematopoietic stem cell transplantation|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01815749"
1052,"NCT01238146","Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Withdrawn","No Results Available","Drug: bendamustine hydrochloride|Drug: obatoclax mesylate|Biological: rituximab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01238146"
1053,"NCT00006383","Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: liposomal vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006383"
1054,"NCT00992446","Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",,"Completed","Has Results","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Bortezomib|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Drug: Melphalan|Drug: Rituximab|Drug: Vorinostat","Phase 2","May 10, 2017","https://ClinicalTrials.gov/show/NCT00992446"
1055,"NCT01285765","Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients",,"Active, not recruiting","No Results Available","Drug: RCHOP21","Phase 3","null","https://ClinicalTrials.gov/show/NCT01285765"
1056,"NCT02037256","Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant",,"Active, not recruiting","No Results Available","Drug: bortezomib|Biological: filgrastim|Procedure: autologous hematopoietic stem cell transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02037256"
1057,"NCT03162536","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",,"Recruiting","No Results Available","Drug: ARQ 531","Phase 1","null","https://ClinicalTrials.gov/show/NCT03162536"
1058,"NCT01959477","Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant",,"Completed","No Results Available","Drug: busulfan|Drug: etoposide|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Procedure: autologous hematopoietic stem cell transplantation","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT01959477"
1059,"NCT01769222","Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer",,"Terminated","Has Results","Biological: Ipilimumab|Radiation: Radiation therapy","Phase 1|Phase 2","March 3, 2017","https://ClinicalTrials.gov/show/NCT01769222"
1060,"NCT01769911","Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma",,"Withdrawn","No Results Available","Drug: carmustine|Drug: cytarabine|Drug: melphalan|Drug: etoposide|Drug: O6-benzylguanine|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Other: laboratory biomarker analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01769911"
1061,"NCT01805037","Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",,"Unknown status","No Results Available","Drug: brentuximab vedotin|Biological: rituximab|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01805037"
1062,"NCT00154440","Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation",,"Unknown status","No Results Available","Drug: proton pump inhibitor|Drug: clarithromycin|Drug: amoxicillin|Drug: metronidazole|Procedure: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00154440"
1063,"NCT01314014","Imexon for Relapsed Follicular and Aggressive Lymphomas","ULYM11011","Completed","Has Results","Drug: Imexon","Phase 2","July 1, 2014","https://ClinicalTrials.gov/show/NCT01314014"
1064,"NCT01116154","Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: lenalidomide|Drug: vorinostat|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01116154"
1065,"NCT01258998","Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma",,"Completed","Has Results","Drug: Akt inhibitor MK2206|Other: laboratory biomarker analysis","Phase 2","November 10, 2015","https://ClinicalTrials.gov/show/NCT01258998"
1066,"NCT01408043","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: plerixafor|Biological: filgrastim|Drug: etoposide|Procedure: leukapheresis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01408043"
1067,"NCT01129193","AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma",,"Completed","No Results Available","Other: Pharmacodynamic Studies|Other: Fatigue Inventory|Other: Pharmacogenomic studies|Drug: AR-42","Phase 1","null","https://ClinicalTrials.gov/show/NCT01129193"
1068,"NCT01177371","High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma",,"Completed","No Results Available","Drug: busulfan|Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Drug: methylprednisolone|Drug: methotrexate|Drug: cyclosporine","Phase 2","null","https://ClinicalTrials.gov/show/NCT01177371"
1069,"NCT00088881","Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",,"Terminated","Has Results","Biological: rituximab|Drug: prednisone|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: radiation therapy|Procedure: positron emission tomography","Phase 2","February 18, 2015","https://ClinicalTrials.gov/show/NCT00088881"
1070,"NCT00003196","Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma",,"Active, not recruiting","No Results Available","Drug: chemotherapy|Radiation: total-body irradiation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Biological: therapeutic allogeneic lymphocytes","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00003196"
1071,"NCT03424603","Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",,"Recruiting","No Results Available","Drug: STRO-001","Phase 1","null","https://ClinicalTrials.gov/show/NCT03424603"
1072,"NCT01748721","MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma",,"Completed","No Results Available","Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01748721"
1073,"NCT00601718","Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",,"Completed","Has Results","Drug: vorinostat|Biological: rituximab|Drug: ifosfamide|Drug: carboplatin|Drug: etoposide|Other: pharmacological study|Other: laboratory biomarker analysis|Genetic: gene expression analysis","Phase 1|Phase 2","May 25, 2017","https://ClinicalTrials.gov/show/NCT00601718"
1074,"NCT01419795","Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",,"Terminated","Has Results","Drug: lenalidomide|Biological: rituximab|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 2","March 21, 2017","https://ClinicalTrials.gov/show/NCT01419795"
1075,"NCT00005950","506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma",,"Terminated","No Results Available","Drug: nelarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005950"
1076,"NCT00499811","Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction",,"Completed","No Results Available","Drug: vorinostat|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00499811"
1077,"NCT00073918","Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: cyclophosphamide|Drug: etoposide|Radiation: iodine I 131 tositumomab|Procedure: quality-of-life assessment|Procedure: peripheral blood stem cell transplantation","Phase 2","January 27, 2017","https://ClinicalTrials.gov/show/NCT00073918"
1078,"NCT03044743","PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies",,"Recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Interleukin-2","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03044743"
1079,"NCT03479268","Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: Pevonedistat|Other: Pharmacokinetic Study|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT03479268"
1080,"NCT01110135","Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma",,"Completed","Has Results","Drug: bendamustine hydrochloride|Drug: dexamethasone|Biological: filgrastim|Procedure: leukapheresis|Other: laboratory biomarker analysis|Other: flow cytometry|Drug: etoposide","Phase 2","May 24, 2017","https://ClinicalTrials.gov/show/NCT01110135"
1081,"NCT02483000","Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies",,"Recruiting","No Results Available","Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Clearing Agent|Drug: Cytarabine|Drug: Etoposide|Radiation: Indium In 111-DOTA-Biotin|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacological Study|Radiation: Yttrium Y 90-DOTA-Biotin","Phase 1","null","https://ClinicalTrials.gov/show/NCT02483000"
1082,"NCT00860171","Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",,"Active, not recruiting","Has Results","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Radiation: Iodine I 131 Monoclonal Antibody BC8|Other: Laboratory Biomarker Analysis","Phase 1","October 12, 2017","https://ClinicalTrials.gov/show/NCT00860171"
1083,"NCT03646422","AEDV Registry of Primary Cutaneous Lymphoma",,"Recruiting","No Results Available","Other: Registry of patients (exposure is Cutaneous Lymphoma)","","null","https://ClinicalTrials.gov/show/NCT03646422"
1084,"NCT00769288","FAU in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: 2'-F-ara-deoxyuridine|Other: positron emission tomography|Other: laboratory biomarker analysis|Other: pharmacological study|Other: pharmacogenomic studies","Phase 1","null","https://ClinicalTrials.gov/show/NCT00769288"
1085,"NCT02153580","Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",,"Recruiting","No Results Available","Drug: cyclophosphamide|Other: laboratory biomarker analysis|Drug: Bendamustine Hydrochloride|Drug: Etoposide|Drug: Fludarabine Phosphate|Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT02153580"
1086,"NCT01523223","Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies",,"Unknown status","No Results Available","Biological: therapeutic allogeneic lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT01523223"
1087,"NCT02134782","Yoga Fatigue Study",,"Recruiting","No Results Available","Behavioral: Individualized Yoga Intervention Group|Other: iPad Activity Control Group","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02134782"
1088,"NCT03015896","Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Nivolumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03015896"
1089,"NCT02086591","A Phase II Study of Doxycycline in Relapsed NHL",,"Terminated","Has Results","Drug: Doxycycline","Phase 2","December 22, 2016","https://ClinicalTrials.gov/show/NCT02086591"
1090,"NCT01789255","Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies",,"Completed","Has Results","Drug: vorinostat|Drug: tacrolimus|Drug: cyclosporine|Drug: methotrexate|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 2","November 13, 2015","https://ClinicalTrials.gov/show/NCT01789255"
1091,"NCT01678443","Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies",,"Active, not recruiting","Has Results","Biological: indium In 111 anti-CD45 monoclonal antibody BC8|Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8|Procedure: peripheral blood stem cell transplantation","Phase 1","November 9, 2017","https://ClinicalTrials.gov/show/NCT01678443"
1092,"NCT02652715","Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Dietary Supplement: Salvia hispanica Seed","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02652715"
1093,"NCT01658319","Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies",,"Completed","No Results Available","Drug: fludarabine phosphate|Drug: methoxyamine|Other: laboratory biomarker analysis|Other: pharmacological study|Genetic: western blotting|Other: mass spectrometry|Genetic: DNA analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01658319"
1094,"NCT01839916","Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",,"Active, not recruiting","No Results Available","Biological: therapeutic allogeneic lymphocytes|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT01839916"
1095,"NCT01760655","Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies",,"Recruiting","No Results Available","Drug: Fludarabine phosphate|Drug: Thiotepa|Radiation: Total body irradiation|Biological: Therapeutic allogeneic lymphocytes|Drug: Cyclophosphamide|Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)|Procedure: Peripheral blood stem cell transplantation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Phase 2","null","https://ClinicalTrials.gov/show/NCT01760655"
1096,"NCT01652014","Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies",,"Withdrawn","No Results Available","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Procedure: double-unit umbilical cord blood transplantation|Radiation: total-body irradiation|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT01652014"
1097,"NCT00458731","Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",,"Completed","No Results Available","Biological: bevacizumab|Drug: cediranib maleate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00458731"
1098,"NCT01427881","Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies",,"Completed","Has Results","Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: busulfan|Procedure: allogeneic hematopoietic stem cell transplantation","Phase 2","May 19, 2017","https://ClinicalTrials.gov/show/NCT01427881"
1099,"NCT01273766","Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies",,"Completed","Has Results","Drug: deferasirox|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay","Phase 2","November 27, 2013","https://ClinicalTrials.gov/show/NCT01273766"
1100,"NCT01199562","Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant",,"Completed","No Results Available","Procedure: infection prophylaxis and management|Other: laboratory biomarker analysis|Other: flow cytometry|Genetic: DNA analysis|Genetic: RNA analysis|Procedure: management of therapy complications|Drug: ganciclovir|Drug: valganciclovir|Drug: foscarnet sodium|Procedure: antiviral therapy|Genetic: polymerase chain reaction|Genetic: protein expression analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01199562"
1101,"NCT01158274","RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors",,"Completed","No Results Available","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Drug: capecitabine|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01158274"
1102,"NCT01093586","Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",,"Completed","No Results Available","Procedure: double-unit umbilical cord blood transplantation|Other: cytogenetic analysis|Procedure: bone marrow aspiration|Other: fluorescence in situ hybridization|Drug: busulfan|Drug: cyclophosphamide|Drug: anti-thymocyte globulin|Drug: methylprednisolone|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: flow cytometry|Procedure: allogeneic hematopoietic stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT01093586"
1103,"NCT00058227","Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma",,"Completed","No Results Available","Drug: alvocidib|Drug: fludarabine phosphate|Biological: rituximab|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00058227"
1104,"NCT00890747","Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy",,"Completed","No Results Available","Drug: sunitinib malate|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00890747"
1105,"NCT00644189","Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma",,"Terminated","Has Results","Drug: Clofarabine","Phase 1|Phase 2","May 8, 2017","https://ClinicalTrials.gov/show/NCT00644189"
1106,"NCT00112593","Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer",,"Completed","Has Results","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Not Applicable","May 24, 2017","https://ClinicalTrials.gov/show/NCT00112593"
1107,"NCT00072514","Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",,"Completed","Has Results","Drug: gemcitabine hydrochloride|Drug: carboplatin|Drug: dexamethasone|Biological: rituximab","Phase 2","June 29, 2017","https://ClinicalTrials.gov/show/NCT00072514"
1108,"NCT00118352","Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",,"Completed","Has Results","Biological: alemtuzumab|Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Biological: graft versus host disease prophylaxis/therapy|Other: laboratory biomarker analysis","Phase 2","May 30, 2017","https://ClinicalTrials.gov/show/NCT00118352"
1109,"NCT00003210","Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease",,"Completed","No Results Available","Biological: recombinant interleukin-12|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003210"
1110,"NCT01261247","Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Active, not recruiting","Has Results","Drug: panobinostat|Other: laboratory biomarker analysis|Genetic: western blotting|Genetic: DNA analysis|Other: flow cytometry|Other: pharmacological study|Other: immunohistochemistry staining method","Phase 2","May 17, 2018","https://ClinicalTrials.gov/show/NCT01261247"
1111,"NCT00058305","Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation",,"Completed","No Results Available","Drug: bryostatin 1|Drug: vincristine sulfate|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00058305"
1112,"NCT00012298","Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Terminated","Has Results","Biological: rituximab|Biological: yttrium Y 90 ibritumomab tiuxetan|Biological: indium In 111 ibritumomab tiuxetan|Biological: oprelvekin|Biological: filgrastim","Phase 1|Phase 2","December 17, 2015","https://ClinicalTrials.gov/show/NCT00012298"
1113,"NCT00089011","Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer",,"Active, not recruiting","Has Results","Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis","Phase 2","May 22, 2017","https://ClinicalTrials.gov/show/NCT00089011"
1114,"NCT00006251","Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer",,"Active, not recruiting","No Results Available","Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Biological: donor lymphocytes|Procedure: peripheral blood stem cell transplantation|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00006251"
1115,"NCT00017472","Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia",,"Completed","No Results Available","Biological: apolizumab|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00017472"
1116,"NCT00005786","Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia",,"Terminated","No Results Available","Drug: arsenic trioxide|Other: laboratory biomarker analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00005786"
1117,"NCT00014235","Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies",,"Active, not recruiting","No Results Available","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00014235"
1118,"NCT00049504","Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer",,"Completed","Has Results","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: tacrolimus|Drug: mycophenolate mofetil|Genetic: polymerase chain reaction|Genetic: fluorescence in situ hybridization|Genetic: polymorphism analysis|Genetic: gene expression analysis|Radiation: total-body irradiation|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Phase 2","May 17, 2017","https://ClinicalTrials.gov/show/NCT00049504"
1119,"NCT00118170","Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function",,"Completed","No Results Available","Drug: sorafenib tosylate|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00118170"
1120,"NCT00006473","Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: oxaliplatin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006473"
1121,"NCT00068315","Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: bortezomib|Drug: fludarabine phosphate|Biological: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00068315"
1122,"NCT00918333","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",,"Active, not recruiting","Has Results","Drug: panobinostat|Drug: everolimus|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1|Phase 2","May 18, 2018","https://ClinicalTrials.gov/show/NCT00918333"
1123,"NCT00019708","Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: tanespimycin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00019708"
1124,"NCT00060112","Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",,"Terminated","No Results Available","Biological: oblimersen sodium|Drug: gemcitabine hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00060112"
1125,"NCT00101244","SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: ispinesib|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00101244"
1126,"NCT00293345","3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: gemcitabine hydrochloride|Drug: triapine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00293345"
1127,"NCT01251575","Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant",,"Recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Sirolimus|Radiation: Total-Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT01251575"
1128,"NCT00348985","PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: belinostat|Drug: bortezomib|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00348985"
1129,"NCT01035463","Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab",,"Active, not recruiting","No Results Available","Drug: lenalidomide|Biological: rituximab|Procedure: autologous hematopoietic stem cell transplantation|Drug: carmustine|Drug: etoposide|Drug: cytarabine|Drug: melphalan","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01035463"
1130,"NCT01075321","Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: everolimus|Drug: lenalidomide|Other: laboratory biomarker analysis|Genetic: polymorphism analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: fluorescence in situ hybridization","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01075321"
1131,"NCT03019666","Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",,"Recruiting","No Results Available","Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03019666"
1132,"NCT00275080","Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia",,"Completed","No Results Available","Drug: vorinostat|Drug: decitabine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00275080"
1133,"NCT00112723","Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",,"Terminated","Has Results","Drug: alvocidib","Phase 1|Phase 2","August 8, 2016","https://ClinicalTrials.gov/show/NCT00112723"
1134,"NCT00354185","PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma",,"Terminated","No Results Available","Drug: tanespimycin|Drug: belinostat|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00354185"
1135,"NCT00089271","17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: alvespimycin hydrochloride|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00089271"
1136,"NCT01460134","A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers",,"Completed","No Results Available","Drug: CDX-1127","Phase 1","null","https://ClinicalTrials.gov/show/NCT01460134"
1137,"NCT01588015","Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant",,"Active, not recruiting","No Results Available","Biological: tetanus-CMV fusion peptide vaccine|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01588015"
1138,"NCT00098891","MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: entinostat|Drug: isotretinoin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00098891"
1139,"NCT01529827","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",,"Active, not recruiting","Has Results","Drug: fludarabine phosphate|Drug: melphalan|Radiation: total-body irradiation|Drug: tacrolimus|Drug: mycophenolate mofetil|Drug: methotrexate|Other: laboratory biomarker analysis|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","July 2, 2017","https://ClinicalTrials.gov/show/NCT01529827"
1140,"NCT01558778","Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant",,"Withdrawn","No Results Available","Procedure: management of therapy complications|Procedure: musculoskeletal complications management/prevention","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01558778"
1141,"NCT01484015","Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia",,"Completed","No Results Available","Drug: cefepime hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT01484015"
1142,"NCT00096005","Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas",,"Terminated","No Results Available","Drug: tanespimycin|Drug: bortezomib|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00096005"
1143,"NCT01384513","A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies",,"Recruiting","No Results Available","Drug: Fludarabine|Drug: Busulfan|Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide (CY)|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Device: Allogeneic hematopoietic stem cell transplantation|Procedure: Peripheral blood stem cell transplantation (PBSCT)","Phase 2","null","https://ClinicalTrials.gov/show/NCT01384513"
1144,"NCT00077155","Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: cilengitide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00077155"
1145,"NCT01233921","Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer",,"Completed","Has Results","Biological: palifermin|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacological study","Not Applicable","April 2, 2014","https://ClinicalTrials.gov/show/NCT01233921"
1146,"NCT01159067","Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload",,"Terminated","No Results Available","Drug: deferasirox","Phase 2","null","https://ClinicalTrials.gov/show/NCT01159067"
1147,"NCT00891072","Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",,"Completed","No Results Available","Drug: R-(-)-gossypol acetic acid|Drug: paclitaxel|Drug: carboplatin|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00891072"
1148,"NCT00010192","Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: rituximab|Biological: aldesleukin|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00010192"
1149,"NCT01076270","Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",,"Terminated","Has Results","Drug: plerixafor|Biological: filgrastim|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Not Applicable","March 31, 2017","https://ClinicalTrials.gov/show/NCT01076270"
1150,"NCT01044745","Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",,"Active, not recruiting","No Results Available","Drug: rituximab|Drug: mycophenolate mofetil|Drug: tacrolimus|Drug: anti-thymocyte globulin|Procedure: allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis|Biological: graft versus host disease prophylaxis/therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: busulfan|Radiation: total-body irradiation|Biological: graft-versus-tumor induction therapy|Biological: immunosuppressive therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT01044745"
1151,"NCT00003970","Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: irinotecan hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003970"
1152,"NCT00004241","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma",,"Completed","No Results Available","Drug: tanespimycin|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004241"
1153,"NCT00856388","Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders",,"Active, not recruiting","Has Results","Drug: fludarabine phosphate|Drug: melphalan|Radiation: total-body irradiation|Procedure: allogeneic hematopoietic stem cell transplantation|Biological: anti-thymocyte globulin","Not Applicable","June 13, 2016","https://ClinicalTrials.gov/show/NCT00856388"
1154,"NCT00799461","Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications",,"Completed","No Results Available","Other: internet-based intervention|Other: questionnaire administration|Procedure: psychosocial assessment and care|Procedure: assessment of therapy complications|Procedure: management of therapy complications|Procedure: fatigue assessment and management|Other: counseling intervention","Phase 3","null","https://ClinicalTrials.gov/show/NCT00799461"
1155,"NCT00795769","Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant",,"Completed","Has Results","Drug: ondansetron|Other: survey administration|Procedure: management of therapy complications","Phase 2","May 23, 2017","https://ClinicalTrials.gov/show/NCT00795769"
1156,"NCT03000192","HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03000192"
1157,"NCT00536601","High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors",,"Completed","No Results Available","Drug: etoposide|Drug: cyclophosphamide|Drug: carmustine|Drug: melphalan|Drug: busulfan|Drug: carboplatin|Drug: thiotepa|Radiation: total-body irradiation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00536601"
1158,"NCT03302403","Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors",,"Not yet recruiting","No Results Available","Genetic: CAR-CD19 T cell|Genetic: CAR-BCMA T cell|Genetic: CAR-GPC3 T cell|Genetic: CAR-CLD18 T cell|Drug: Fludarabine|Drug: Cyclophosphamide","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03302403"
1159,"NCT00054483","Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction",,"Completed","No Results Available","Drug: bortezomib|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00054483"
1160,"NCT00489203","Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",,"Completed","No Results Available","Drug: beclomethasone dipropionate|Drug: placebo|Drug: tacrolimus|Drug: methotrexate|Procedure: allogeneic hematopoietic stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00489203"
1161,"NCT00408681","Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant","GVHD","Completed","Has Results","Drug: lithium carbonate|Other: laboratory biomarker analysis","Not Applicable","January 20, 2017","https://ClinicalTrials.gov/show/NCT00408681"
1162,"NCT00343798","A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies",,"Completed","No Results Available","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: ex-vivo umbilical cord blood expansion|Procedure: double-unit umbilical cord blood transplantation|Procedure: biopsy|Other: immunologic technique|Other: diagnostic laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00343798"
1163,"NCT03547115","A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies",,"Recruiting","No Results Available","Drug: Voruciclib","Phase 1","null","https://ClinicalTrials.gov/show/NCT03547115"
1164,"NCT00103272","17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer",,"Terminated","No Results Available","Drug: tanespimycin|Drug: bortezomib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00103272"
1165,"NCT01865617","Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Other: Laboratory Biomarker Analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01865617"
1166,"NCT00005799","Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer",,"Active, not recruiting","No Results Available","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: pharmacological study|Other: laboratory biomarker analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00005799"
1167,"NCT00078858","Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant",,"Active, not recruiting","No Results Available","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00078858"
1168,"NCT00025415","Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction",,"Completed","No Results Available","Drug: imatinib mesylate|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00025415"
1169,"NCT00040846","Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies",,"Active, not recruiting","Has Results","Biological: alemtuzumab|Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: mycophenolate mofetil|Drug: cyclosporine","Phase 2","March 16, 2017","https://ClinicalTrials.gov/show/NCT00040846"
1170,"NCT01953692","A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)",,"Active, not recruiting","No Results Available","Biological: Pembrolizumab|Drug: Lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01953692"
1171,"NCT00051597","A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies",,"Completed","No Results Available","Drug: SGN-30 (monoclonal antibody)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00051597"
1172,"NCT01787409","Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency",,"Recruiting","No Results Available","Dietary Supplement: Cholecalciferol|Other: Laboratory Biomarker Analysis","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01787409"
1173,"NCT00980304","R Retreatment in 1st Relapsed DLBCL",,"Unknown status","No Results Available","Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00980304"
1174,"NCT03272633","Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies",,"Not yet recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Irradiated Allogeneic Cells","Phase 2","null","https://ClinicalTrials.gov/show/NCT03272633"
1175,"NCT00626496","Family Study of Lymphoproliferative Disorders",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00626496"
1176,"NCT03037645","Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers",,"Recruiting","No Results Available","Drug: SNS-062","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03037645"
1177,"NCT01994382","Phase 1/2A Dose Escalation Study in CLL, SLL or NHL",,"Recruiting","No Results Available","Drug: Cerdulatinib (PRT062070)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01994382"
1178,"NCT03365791","PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",,"Recruiting","No Results Available","Biological: PDR001|Biological: LAG525","Phase 2","null","https://ClinicalTrials.gov/show/NCT03365791"
1179,"NCT03297424","A Study of PLX2853 in Advanced Malignancies.",,"Recruiting","No Results Available","Drug: PLX2853","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03297424"
1180,"NCT01744912","Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",,"Completed","No Results Available","Drug: Ublituximab|Drug: Lenalidomide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01744912"
1181,"NCT00038883","Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies",,"Completed","No Results Available","Drug: Campath-1H","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00038883"
1182,"NCT03269552","Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma",,"Recruiting","No Results Available","Drug: Carfilzomib|Other: Laboratory Biomarker Analysis|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT03269552"
1183,"NCT02532257","Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma",,"Active, not recruiting","No Results Available","Drug: Lenalidomide|Drug: Rituximab|Drug: Ibrutinib","Phase 2","null","https://ClinicalTrials.gov/show/NCT02532257"
1184,"NCT03676504","Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR",,"Recruiting","No Results Available","Biological: CD19.CAR T Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03676504"
1185,"NCT01720758","Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease","B-RAF V600E","Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01720758"
1186,"NCT03436771","Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product",,"Enrolling by invitation","No Results Available","Genetic: JCAR017|Genetic: JCARH125","","null","https://ClinicalTrials.gov/show/NCT03436771"
1187,"NCT02337985","Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: Prednisone|Biological: Rituximab|Drug: Etoposide|Drug: Doxorubicin Hydrochloride|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Biological: Filgrastim|Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02337985"
1188,"NCT01121757","Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma",,"Terminated","Has Results","Drug: azacitidine|Drug: lenalidomide","Phase 2","May 7, 2015","https://ClinicalTrials.gov/show/NCT01121757"
1189,"NCT02952508","Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies",,"Recruiting","No Results Available","Drug: CLR 131","Phase 2","null","https://ClinicalTrials.gov/show/NCT02952508"
1190,"NCT00566332","Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia",,"Completed","No Results Available","Drug: Chlorambucil|Drug: Fludarabine","Phase 3","null","https://ClinicalTrials.gov/show/NCT00566332"
1191,"NCT00310167","Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma","FoRT","Completed","No Results Available","Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00310167"
1192,"NCT00117156","Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: Fludarabine|Drug: Rituximab","Phase 2","October 6, 2014","https://ClinicalTrials.gov/show/NCT00117156"
1193,"NCT00772668","Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL",,"Terminated","Has Results","Drug: Rituximab|Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Prednisone","Not Applicable","February 21, 2013","https://ClinicalTrials.gov/show/NCT00772668"
1194,"NCT03035331","Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Procedure: Cryosurgery|Biological: Dendritic Cell Therapy|Biological: Pembrolizumab|Biological: Pneumococcal 13-valent Conjugate Vaccine|Other: Quality-of-Life Assessment","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03035331"
1195,"NCT03128359","High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant",,"Recruiting","No Results Available","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Procedure: Hematopoietic Cell Transplantation|Other: Laboratory Biomarker Analysis|Drug: Melphalan Hydrochloride|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Quality-of-Life Assessment|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT03128359"
1196,"NCT01921387","Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies",,"Active, not recruiting","Has Results","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","Phase 1|Phase 2","September 3, 2018","https://ClinicalTrials.gov/show/NCT01921387"
1197,"NCT02877082","Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients",,"Terminated","Has Results","Biological: Thymoglobulin|Drug: Bortezomib|Drug: Tacrolimus","Phase 2","April 30, 2018","https://ClinicalTrials.gov/show/NCT02877082"
1198,"NCT02928510","Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma",,"Recruiting","No Results Available","Procedure: Biospecimen Collection|Procedure: Colonoscopy|Procedure: Colposcopic Biopsy|Drug: Idelalisib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Procedure: Physical Examination|Procedure: Sigmoidoscopy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02928510"
1199,"NCT02278796","A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","BEB","Recruiting","No Results Available","Drug: BeEAM|Drug: BEAM","Phase 2","null","https://ClinicalTrials.gov/show/NCT02278796"
1200,"NCT02991898","Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies",,"Suspended","No Results Available","Biological: Infusion of Treg","Phase 2","null","https://ClinicalTrials.gov/show/NCT02991898"
1201,"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",,"Recruiting","No Results Available","Biological: HSCT with TBI Regimen|Biological: HSCT with Non-TBI Regimen","Phase 2","null","https://ClinicalTrials.gov/show/NCT03314974"
1202,"NCT02722668","UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep",,"Recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: MMF|Drug: Sirolimus|Radiation: TBI|Biological: Umbilical cord blood cell infusion|Biological: ATG","Phase 2","null","https://ClinicalTrials.gov/show/NCT02722668"
1203,"NCT00697346","Study of MLN8237 in Participants With Advanced Hematological Malignancies",,"Completed","No Results Available","Drug: Alisertib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00697346"
1204,"NCT01163201","T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies",,"Withdrawn","No Results Available","Biological: Treg cells|Biological: CD3+ Teff cells|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Umbilical cord blood transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01163201"
1205,"NCT02661035","Allo HSCT Using RIC for Hematological Diseases",,"Recruiting","No Results Available","Drug: Allopurinol|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: ATG|Radiation: TBI|Drug: Tacrolimus|Drug: MMF|Biological: Peripheral Blood Stem Cells|Biological: Related or Unrelated Bone Marrow Cells","Phase 2","null","https://ClinicalTrials.gov/show/NCT02661035"
1206,"NCT00880815","Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",,"Active, not recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Anti-Thymocyte Globulin|Drug: Bendamustine|Biological: Filgrastim|Drug: Fludarabine|Drug: Methotrexate|Biological: Rituximab|Drug: Tacrolimus","Phase 1","null","https://ClinicalTrials.gov/show/NCT00880815"
1207,"NCT01028716","Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT01028716"
1208,"NCT01459653","Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor","Monitor-GCSF","Completed","Has Results","","","July 7, 2015","https://ClinicalTrials.gov/show/NCT01459653"
1209,"NCT02376699","Safety Study of SEA-CD40 in Cancer Patients",,"Recruiting","No Results Available","Drug: IV SEA-CD40 monotherapy regimen|Drug: Pembrolizumab|Drug: SC SEA-CD40 monotherapy regimen","Phase 1","null","https://ClinicalTrials.gov/show/NCT02376699"
1210,"NCT02875548","Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study","TRuST","Recruiting","No Results Available","Drug: Tazemetostat","Phase 2","null","https://ClinicalTrials.gov/show/NCT02875548"
1211,"NCT01177397","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",,"Completed","No Results Available","Drug: CC-223","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01177397"
1212,"NCT00017381","Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Biological: filgrastim|Radiation: yttrium Y 90 ibritumomab tiuxetan|Procedure: peripheral blood stem cell transplantation","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT00017381"
1213,"NCT03263637","Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies",,"Recruiting","No Results Available","Drug: AZD4573","Phase 1","null","https://ClinicalTrials.gov/show/NCT03263637"
1214,"NCT00093314","HuMax-CD20 in Chronic Lymphocytic Leukemia",,"Withdrawn","No Results Available","Drug: HuMax-CD20","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00093314"
1215,"NCT03246906","Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation",,"Recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Mycophenolate Mofetil|Drug: Sirolimus","Phase 2","null","https://ClinicalTrials.gov/show/NCT03246906"
1216,"NCT03538028","A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",,"Recruiting","No Results Available","Biological: INCAGN02385","Phase 1","null","https://ClinicalTrials.gov/show/NCT03538028"
1217,"NCT02227108","Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma",,"Terminated","Has Results","Drug: Moxetumomab Pasudotox","Phase 2","February 27, 2017","https://ClinicalTrials.gov/show/NCT02227108"
1218,"NCT01231412","Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant",,"Completed","Has Results","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Sirolimus|Radiation: Total-Body Irradiation","Phase 3","December 4, 2017","https://ClinicalTrials.gov/show/NCT01231412"
1219,"NCT00789776","Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer",,"Active, not recruiting","Has Results","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Biological: Natural Killer Cell Therapy|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Phase 1|Phase 2","July 12, 2018","https://ClinicalTrials.gov/show/NCT00789776"
1220,"NCT03207867","A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: NIR178|Drug: PDR001","Phase 2","null","https://ClinicalTrials.gov/show/NCT03207867"
1221,"NCT00864227","Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)",,"Completed","Has Results","Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|Biological: GVHD prophylaxis","Phase 2","August 28, 2015","https://ClinicalTrials.gov/show/NCT00864227"
1222,"NCT00849147","Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)",,"Completed","Has Results","Biological: Haploidentical Bone Marrow Transplantation|Biological: GVHD prophylaxis","Phase 2","September 7, 2015","https://ClinicalTrials.gov/show/NCT00849147"
1223,"NCT03458260","Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Pixantrone|Other: Ifosfamide|Other: Etoposide|Other: Rituximab|Procedure: Transplant","Phase 2","null","https://ClinicalTrials.gov/show/NCT03458260"
1224,"NCT00075478","Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",,"Completed","Has Results","Procedure: Total-Body Irradiation|Drug: Fludarabine Phosphate|Drug: Mycophenolate Mofetil|Drug: Cyclosporine|Procedure: Peripheral Blood Stem Cell Transplantation","Phase 3","May 19, 2014","https://ClinicalTrials.gov/show/NCT00075478"
1225,"NCT01527045","Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies",,"Recruiting","No Results Available","Drug: Atorvastatin Calcium|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT01527045"
1226,"NCT01326702","Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",,"Completed","No Results Available","Drug: Bendamustine Hydrochloride|Other: Pharmacological Study|Biological: Rituximab|Drug: Veliparib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01326702"
1227,"NCT01793233","Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas",,"Active, not recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","","null","https://ClinicalTrials.gov/show/NCT01793233"
1228,"NCT01000753","Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Other: Cytology Specimen Collection Procedure","","null","https://ClinicalTrials.gov/show/NCT01000753"
1229,"NCT00608361","Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",,"Completed","No Results Available","Drug: Dasatinib|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00608361"
1230,"NCT03364231","Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: Umbralisib","Phase 2","null","https://ClinicalTrials.gov/show/NCT03364231"
1231,"NCT01583699","Endomicroscopy and Gastric MALT-lymphoma",,"Completed","No Results Available","Procedure: Confocal laser endomicroscopy|Device: Confocal Laser Endomicroscope","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01583699"
1232,"NCT01938001","Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)","AUGMENT","Active, not recruiting","No Results Available","Drug: Rituximab|Drug: Lenalidomide|Drug: Placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT01938001"
1233,"NCT03105336","A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","ZUMA-5","Recruiting","No Results Available","Biological: axicabtagene ciloleucel|Drug: Cyclophosphamide|Drug: Fludarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT03105336"
1234,"NCT01264822","Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori",,"Completed","No Results Available","Drug: Rabeprazole Sodium","","null","https://ClinicalTrials.gov/show/NCT01264822"
1235,"NCT01701232","Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT01701232"
1236,"NCT00373906","Velcade in MALT Lymphoma Patients",,"Completed","No Results Available","Drug: Bortezomib (Velcade)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00373906"
1237,"NCT02424968","CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma",,"Recruiting","No Results Available","Biological: Anti-Thymocyte Globulin|Drug: Cyclosporine|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Biological: Therapeutic Allogeneic Lymphocytes|Radiation: Total Nodal Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT02424968"
1238,"NCT00327132","Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome",,"Completed","No Results Available","Drug: Omeprazole, Amoxicillin, Clarithromycin","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00327132"
1239,"NCT01500538","A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)","VEIL","Terminated","No Results Available","Drug: Eltrombopag and Vorinostat","Phase 2","null","https://ClinicalTrials.gov/show/NCT01500538"
1240,"NCT01460602","Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma",,"Terminated","No Results Available","Drug: MTD of Velcade, Nipent and Rituxan established in Part 1","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01460602"
1241,"NCT02440685","A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",,"Terminated","No Results Available","Drug: ASN002 Dose Escalation|Drug: ASN002 RD","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02440685"
1242,"NCT01254578","Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers",,"Completed","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01254578"
1243,"NCT02599194","18F-FSPG PET/CT for Cancer Patients on Therapy",,"Suspended","No Results Available","Procedure: Computed Tomography|Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392|Procedure: Positron Emission Tomography|Procedure: Magnetic Resonance Imaging","Phase 2","null","https://ClinicalTrials.gov/show/NCT02599194"
1244,"NCT00546793","Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL",,"Completed","No Results Available","Biological: veltuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00546793"
1245,"NCT02208037","Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)",,"Completed","No Results Available","Drug: Tacrolimus (ARM with Methotrexate)|Drug: Tacrolimus (ARM with MMF and Cyclophosphamide)|Drug: Methotrexate (ARM with Maraviroc)|Drug: Methotrexate (ARM with Bortezomib)|Drug: Maraviroc|Drug: Bortezomib|Drug: Mycophenolate mofetil|Drug: Cyclophosphamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02208037"
1246,"NCT02847130","Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology",,"Recruiting","No Results Available","Other: Informational Intervention|Other: Interview|Other: Medical Chart Review|Other: Questionnaire Administration","","null","https://ClinicalTrials.gov/show/NCT02847130"
1247,"NCT03195010","Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia",,"Enrolling by invitation","No Results Available","Biological: Platelet Transfusion","Phase 2","null","https://ClinicalTrials.gov/show/NCT03195010"
1248,"NCT03333486","Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT03333486"
1249,"NCT00933985","Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",,"Terminated","No Results Available","Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: obatoclax mesylate|Drug: liposomal vincristine sulfate|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00933985"
1250,"NCT01053494","Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer",,"Completed","No Results Available","Procedure: massage therapy|Other: questionnaire administration|Procedure: quality-of-life assessment|Other: intervention by caregiver|Procedure: standard follow-up care","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01053494"
1251,"NCT03078855","A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma","ILyAD","Recruiting","No Results Available","Dietary Supplement: Vitamin D|Biological: Rituximab|Other: Placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT03078855"
1252,"NCT02576275","A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",,"Withdrawn","No Results Available","Drug: Duvelisib|Drug: Placebo|Drug: Rituximab|Drug: Bendamustine","Phase 3","null","https://ClinicalTrials.gov/show/NCT02576275"
1253,"NCT00323323","CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas",,"Completed","No Results Available","Drug: CHOP|Drug: Alemtuzumab|Procedure: Plasma Samples","Phase 1","null","https://ClinicalTrials.gov/show/NCT00323323"
1254,"NCT00801281","First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.","PLRG4","Completed","No Results Available","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone 1|Drug: Prednisone 2","Phase 3","null","https://ClinicalTrials.gov/show/NCT00801281"
1255,"NCT01306643","Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",,"Completed","Has Results","Drug: Idelalisib","Phase 1|Phase 2","December 21, 2016","https://ClinicalTrials.gov/show/NCT01306643"
1256,"NCT00695786","Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: Lenalidomide|Biological: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00695786"
1257,"NCT00923507","Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00923507"
1258,"NCT00991211","Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",,"Completed","No Results Available","Drug: Bendamustine|Drug: Standard chemotherapy CHOP + Ritiximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00991211"
1259,"NCT00253630","Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma",,"Completed","Has Results","Other: Laboratory Biomarker Analysis|Drug: Vorinostat","Phase 2","March 6, 2018","https://ClinicalTrials.gov/show/NCT00253630"
1260,"NCT03010358","Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Entospletinib|Other: Laboratory Biomarker Analysis|Biological: Obinutuzumab|Other: Pharmacological Study","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03010358"
1261,"NCT02258555","Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma",,"Terminated","No Results Available","Drug: GS-9901","Phase 1","null","https://ClinicalTrials.gov/show/NCT02258555"
1262,"NCT00877214","Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas","MAINTAIN","Active, not recruiting","No Results Available","Drug: Rituximab|Drug: Rituximab / observation","Phase 3","null","https://ClinicalTrials.gov/show/NCT00877214"
1263,"NCT00180895","Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL",,"Terminated","No Results Available","Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00180895"
1264,"NCT01292135","Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)",,"Completed","Has Results","Drug: PCI-32765","Phase 1","July 24, 2014","https://ClinicalTrials.gov/show/NCT01292135"
1265,"NCT01381692","Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma",,"Active, not recruiting","No Results Available","Drug: Bortezomib|Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Biological: Rituximab|Drug: Temsirolimus","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01381692"
1266,"NCT00538187","Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma",,"Terminated","No Results Available","Drug: obatoclax mesylate|Drug: bortezomib|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00538187"
1267,"NCT00438880","Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",,"Completed","Has Results","Drug: Agatolimod Sodium|Radiation: Indium In-111 Ibritumomab Tiuxetan|Other: Laboratory Biomarker Analysis|Procedure: Radionuclide Imaging|Biological: Rituximab|Procedure: Single Photon Emission Computed Tomography|Radiation: Yttrium Y-90 Ibritumomab Tiuxetan","Phase 1|Phase 2","September 1, 2014","https://ClinicalTrials.gov/show/NCT00438880"
1268,"NCT00711828","Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma",,"Active, not recruiting","Has Results","Drug: Bortezomib|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Dexamethasone|Other: Questionnaire Administration|Other: Quality-of-Life Assessment","Phase 2","January 27, 2015","https://ClinicalTrials.gov/show/NCT00711828"
1269,"NCT03432741","Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",,"Recruiting","No Results Available","Drug: Belinostat|Drug: Carfilzomib|Biological: Daratumumab|Drug: Fludeoxyglucose F-18|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: Obinutuzumab|Biological: Pembrolizumab|Procedure: Positron Emission Tomography|Biological: Rituximab|Drug: Romidepsin|Other: Saline|Biological: Trastuzumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03432741"
1270,"NCT01728207","Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL",,"Unknown status","No Results Available","Drug: IMMU-114","Phase 1","null","https://ClinicalTrials.gov/show/NCT01728207"
1271,"NCT03219723","Drug Use Surveillance of Takecab for ""Supplement to Helicobacter Pylori Eradication""",,"Completed","No Results Available","Drug: Vonoprazan|Drug: Amoxicillin hydrate|Drug: Clarithromycin|Drug: Metronidazole","","null","https://ClinicalTrials.gov/show/NCT03219723"
1272,"NCT01076543","Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Temsirolimus","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01076543"
1273,"NCT00082888","Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma",,"Active, not recruiting","Has Results","Other: Laboratory Biomarker Analysis|Drug: Tipifarnib","Phase 2","December 7, 2011","https://ClinicalTrials.gov/show/NCT00082888"
1274,"NCT00359411","Genetic Studies of X-linked Lymphoproliferative Disease",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00359411"
1275,"NCT01421524","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",,"Active, not recruiting","No Results Available","Drug: CC-122","Phase 1","null","https://ClinicalTrials.gov/show/NCT01421524"
1276,"NCT02996773","Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine",,"Recruiting","No Results Available","Drug: Bendamustine|Drug: Cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02996773"
1277,"NCT01474681","Safety and Tolerability of HSC835 in Patients With Hematological Malignancies",,"Completed","Has Results","Biological: HSC835","Phase 1|Phase 2","May 12, 2017","https://ClinicalTrials.gov/show/NCT01474681"
1278,"NCT01231919","MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia",,"Completed","No Results Available","Drug: Akt inhibitor MK2206|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01231919"
1279,"NCT01700946","Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma",,"Recruiting","No Results Available","Drug: dexamethasone|Drug: vincristine sulfate|Biological: rituximab|Drug: clofarabine|Drug: cyclophosphamide|Drug: etoposide|Biological: aldesleukin|Drug: pegaspargase|Drug: methotrexate|Drug: mercaptopurine|Drug: cytarabine|Drug: mitoxantrone|Drug: teniposide|Drug: vinblastine|Biological: natural killer cell infusion|Other: laboratory biomarker analysis|Drug: therapeutic hydrocortisone|Procedure: allogeneic hematopoietic stem cell transplantation|Device: CliniMACS","Phase 2","null","https://ClinicalTrials.gov/show/NCT01700946"
1280,"NCT00723099","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",,"Active, not recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00723099"
1281,"NCT00719888","Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Cyclosporine|Procedure: Double-Unit Umbilical Cord Blood Transplantation|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00719888"
1282,"NCT00105001","Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",,"Completed","Has Results","Drug: Fludarabine Phosphate|Radiation: Total-Body Irradiation|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: Sirolimus","Phase 2","September 15, 2015","https://ClinicalTrials.gov/show/NCT00105001"
1283,"NCT01232556","A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy",,"Terminated","Has Results","Drug: Inotuzumab ozogamicin|Drug: Rituximab|Drug: rituximab + gemcitabine|Drug: rituximab +bendamustine","Phase 3","August 21, 2018","https://ClinicalTrials.gov/show/NCT01232556"
1284,"NCT02203526","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: TEDDI|Biological: Rituximab (R)|Drug: Cytarabine|Drug: TEDD","Phase 1","null","https://ClinicalTrials.gov/show/NCT02203526"
1285,"NCT00052923","Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00052923"
1286,"NCT01300026","AMG 319 Lymphoid Malignancy FIH",,"Completed","No Results Available","Drug: AMG 319","Phase 1","null","https://ClinicalTrials.gov/show/NCT01300026"
1287,"NCT02145039","Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases",,"Active, not recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Biological: Haploidentical stem cell transplant","Not Applicable","null","https://ClinicalTrials.gov/show/NCT02145039"
1288,"NCT03310619","A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)","PLATFORM","Recruiting","No Results Available","Biological: JCAR017|Drug: Durvalumab|Drug: CC-122","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03310619"
1289,"NCT02992483","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",,"Recruiting","No Results Available","Drug: MIK665","Phase 1","null","https://ClinicalTrials.gov/show/NCT02992483"
1290,"NCT03666000","Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL",,"Not yet recruiting","No Results Available","Genetic: PBCAR0191|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03666000"
1291,"NCT00187161","Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL",,"Completed","No Results Available","Drug: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00187161"
1292,"NCT03536039","RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor","INGRID","Recruiting","No Results Available","Drug: NGR-hTNF|Other: RITUXIMAB|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT03536039"
1293,"NCT03600363","A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients",,"Not yet recruiting","No Results Available","Drug: Metformin|Drug: Placebos","Phase 2","null","https://ClinicalTrials.gov/show/NCT03600363"
1294,"NCT00582725","R-CHOP + GM-CSF for Previously Untreated LCL in Elderly",,"Completed","No Results Available","Drug: R-CHOP+GM-CSF","Phase 2","null","https://ClinicalTrials.gov/show/NCT00582725"
1295,"NCT03238651","A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)",,"Recruiting","No Results Available","Drug: TAK-659","Phase 1","null","https://ClinicalTrials.gov/show/NCT03238651"
1296,"NCT03298828","CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma",,"Not yet recruiting","No Results Available","Biological: CD19 CAR and PD-1 knock out engineered T-cells|Biological: CD19 CAR T-cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03298828"
1297,"NCT00006436","EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection",,"Recruiting","No Results Available","Biological: Rituximab|Biological: filgrastim|Drug: EPOCH","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006436"
1298,"NCT02669017","Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)",,"Active, not recruiting","No Results Available","Drug: ADCT-402","Phase 1","null","https://ClinicalTrials.gov/show/NCT02669017"
1299,"NCT02996617","PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia",,"Recruiting","No Results Available","Drug: rhG-CSF regimen|Drug: Pegylated rhG-CSF regimen","Phase 4","null","https://ClinicalTrials.gov/show/NCT02996617"
1300,"NCT02883517","Cell-free Circulating DNA in Primary Cutaneous Lymphomas","MATULILA","Recruiting","No Results Available","Genetic: Cytogenetic and molecular studies","","null","https://ClinicalTrials.gov/show/NCT02883517"
1301,"NCT02846584","a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies",,"Active, not recruiting","No Results Available","Biological: CD19 or CD20 CAR T cells briging HSCT","Phase 2","null","https://ClinicalTrials.gov/show/NCT02846584"
1302,"NCT01786096","A Safety Study of SGN-CD19A for Leukemia and Lymphoma",,"Completed","No Results Available","Drug: SGN-CD19A","Phase 1","null","https://ClinicalTrials.gov/show/NCT01786096"
1303,"NCT02743546","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma",,"Withdrawn","No Results Available","Drug: Duvortuxizumab|Drug: Ibrutinib","Phase 1","null","https://ClinicalTrials.gov/show/NCT02743546"
1304,"NCT00691652","Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",,"Terminated","Has Results","Biological: rituximab|Drug: clofarabine|Genetic: DNA methylation analysis|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymerase chain reaction|Other: high performance liquid chromatography|Other: laboratory biomarker analysis","Phase 1|Phase 2","September 16, 2011","https://ClinicalTrials.gov/show/NCT00691652"
1305,"NCT03154710","Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response",,"Recruiting","No Results Available","Device: SENTINEL","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03154710"
1306,"NCT03357627","A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: TAK-659|Drug: Venetoclax","Phase 1","null","https://ClinicalTrials.gov/show/NCT03357627"
1307,"NCT00471367","Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877",,"Terminated","No Results Available","Drug: AZD4877","Phase 1","null","https://ClinicalTrials.gov/show/NCT00471367"
1308,"NCT02763254","Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas","CIVIC","Recruiting","No Results Available","Biological: CMD-003","Phase 2","null","https://ClinicalTrials.gov/show/NCT02763254"
1309,"NCT02626455","Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","CHRONOS-4","Recruiting","No Results Available","Drug: Copanlisib (BAY 80-6946)|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Bendamustine|Drug: Prednisone","Phase 3","null","https://ClinicalTrials.gov/show/NCT02626455"
1310,"NCT00057811","Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma",,"Completed","Has Results","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: methotrexate|Drug: rasburicase|Drug: leucovorin calcium|Drug: prednisone|Drug: methylprednisolone|Biological: filgrastim|Biological: rituximab|Drug: cytarabine|Drug: etoposide|Drug: vincristine sulfate|Drug: hydrocortisone sodium succinate|Other: laboratory biomarker analysis","Phase 2","August 22, 2014","https://ClinicalTrials.gov/show/NCT00057811"
1311,"NCT02973191","A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia","ORBIT","Withdrawn","No Results Available","Drug: JCAR015","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02973191"
1312,"NCT02685670","Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma","MatchCART","Recruiting","No Results Available","Biological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02685670"
1313,"NCT01029366","CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",,"Completed","Has Results","Biological: CART-19","Phase 1","February 28, 2017","https://ClinicalTrials.gov/show/NCT01029366"
1314,"NCT03097770","Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",,"Recruiting","No Results Available","Biological: anti-CD19/20-CAR vector-transduced T cells","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03097770"
1315,"NCT03185494","Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",,"Recruiting","No Results Available","Biological: anti-CD19/22-CAR vector-transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03185494"
1316,"NCT00033423","Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 1","null","https://ClinicalTrials.gov/show/NCT00033423"
1317,"NCT01841021","Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30",,"Terminated","Has Results","Drug: Brentuximab vedotin","Not Applicable","January 19, 2017","https://ClinicalTrials.gov/show/NCT01841021"
1318,"NCT01105247","Safety of PCI-32765 in Chronic Lymphocytic Leukemia",,"Completed","Has Results","Drug: PCI-32765","Phase 1|Phase 2","March 31, 2014","https://ClinicalTrials.gov/show/NCT01105247"
1319,"NCT01864889","Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19","CART19","Unknown status","No Results Available","Biological: anti-CD19-CAR vector-transduced T cells","Not Applicable","null","https://ClinicalTrials.gov/show/NCT01864889"
1320,"NCT00275431","Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies",,"Completed","No Results Available","Drug: AT-101","Phase 2","null","https://ClinicalTrials.gov/show/NCT00275431"
1321,"NCT00003163","Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers",,"Unknown status","No Results Available","Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003163"
1322,"NCT00295932","Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: bortezomib|Drug: cyclophosphamide|Drug: prednisone","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00295932"
1323,"NCT00004086","Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer",,"Unknown status","No Results Available","Biological: filgrastim|Drug: cisplatin|Drug: cytarabine|Drug: etoposide|Drug: ifosfamide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 LL2 IgG|Radiation: yttrium Y 90 epratuzumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004086"
1324,"NCT01686165","Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL",,"Completed","Has Results","Drug: belinostat|Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","July 31, 2018","https://ClinicalTrials.gov/show/NCT01686165"
1325,"NCT02454270","A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies",,"Completed","No Results Available","Drug: Part 1 (Dose Escalation): Duvortuxizumab|Drug: Part 2 (Dose Expansion): Duvortuxizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT02454270"
1326,"NCT00003874","Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",,"Completed","No Results Available","Biological: monoclonal antibody CD19|Biological: monoclonal antibody CD20|Procedure: in vitro-treated peripheral blood stem cell transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00003874"
1327,"NCT00274794","VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00274794"
1328,"NCT03629873","Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects",,"Recruiting","No Results Available","Drug: Chidamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT03629873"
1329,"NCT00837174","Relapsed and/or Refractory Non-Hodgkin Lymphoma Study","COMBOSTAT","Withdrawn","No Results Available","Drug: Vorinostat in combination with Bortezomib","Phase 2","null","https://ClinicalTrials.gov/show/NCT00837174"
1330,"NCT00058461","Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia",,"Terminated","No Results Available","Drug: ifosfamide|Drug: etoposide|Biological: rituximab|Drug: carboplatin|Biological: filgrastim|Drug: methotrexate|Drug: cytarabine|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00058461"
1331,"NCT02733042","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","FUSION NHL 001","Active, not recruiting","No Results Available","Drug: Durvalumab|Drug: Lenalidomide|Drug: Rituximab|Drug: Ibrutinib|Drug: Bendamustine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02733042"
1332,"NCT03321123","MB-CART19.1 in Patients With R/R ALL",,"Not yet recruiting","No Results Available","Drug: MB-CART19.1","Phase 2","null","https://ClinicalTrials.gov/show/NCT03321123"
1333,"NCT02181218","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",,"Recruiting","No Results Available","Drug: Romidepsin|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Dexamethasone|Drug: Pegfilgrastim","Phase 1","null","https://ClinicalTrials.gov/show/NCT02181218"
1334,"NCT00100737","Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin’s Lymphoma (NHL)",,"Terminated","No Results Available","Drug: interleukin-2|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00100737"
1335,"NCT00199082","Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults",,"Completed","No Results Available","Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone/Prednisolone|Drug: VP16|Drug: Ifosfamide|Drug: Methotrexate|Drug: G-CSF|Drug: Rituximab|Drug: Vincristine/Vindesine|Procedure: Irradiation (in specific conditions)","Phase 4","null","https://ClinicalTrials.gov/show/NCT00199082"
1336,"NCT00566228","Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma",,"Completed","Has Results","Procedure: autologous hematopoietic stem cell transplantation|Procedure: leukapheresis","Phase 3","July 9, 2018","https://ClinicalTrials.gov/show/NCT00566228"
1337,"NCT00590941","Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma",,"Completed","No Results Available","Procedure: Blood draw","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00590941"
1338,"NCT00289562","Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Drug: forodesine hydrochloride (BCX-1777)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00289562"
1339,"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients",,"Recruiting","No Results Available","Drug: Etoposide|Drug: BCNU|Drug: AraC|Drug: Melphalan|Procedure: Peripheral blood stem cell transplantation|Biological: G-CSF|Drug: Cyclophosphamide|Radiation: Total Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT03125642"
1340,"NCT02924753","The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).",,"Recruiting","No Results Available","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19 cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02924753"
1341,"NCT00003151","Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma",,"Completed","No Results Available","Dietary Supplement: bismuth subcitrate|Drug: amoxicillin|Drug: clarithromycin|Drug: metronidazole hydrochloride|Drug: omeprazole|Drug: tetracycline hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003151"
1342,"NCT02746952","Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia","CALM","Recruiting","No Results Available","Biological: UCART19","Phase 1","null","https://ClinicalTrials.gov/show/NCT02746952"
1343,"NCT00126646","BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: BL22 immunotoxin|Procedure: antibody-drug conjugate therapy|Procedure: immunotoxin therapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT00126646"
1344,"NCT02819583","CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",,"Recruiting","No Results Available","Biological: PCAR-019 (anti-CD19 CAR-T cells)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02819583"
1345,"NCT02851589","Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",,"Recruiting","No Results Available","Biological: PCAR-019 (anti-CD19 CAR-T cells)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02851589"
1346,"NCT02892695","PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma",,"Recruiting","No Results Available","Biological: anti-CD19 CAR-NK cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02892695"
1347,"NCT01860937","T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia",,"Active, not recruiting","No Results Available","Procedure: leukapheresis or collection of PBMCs|Drug: cyclophosphamide based chemotherapy regimens|Biological: modified T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT01860937"
1348,"NCT00052416","Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: thalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00052416"
1349,"NCT03671460","CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.",,"Recruiting","No Results Available","Biological: CD19 CAR-T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03671460"
1350,"NCT00005580","Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: bryostatin 1|Drug: fludarabine phosphate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005580"
1351,"NCT00002908","Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Drug: bryostatin 1|Drug: vincristine sulfate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002908"
1352,"NCT00006252","Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma",,"Completed","No Results Available","Drug: fludarabine phosphate|Drug: Cyclophosphamide|Biological: PBSC|Drug: G-CSF|Biological: Donor lymphocytes","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006252"
1353,"NCT03599375","Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia",,"Not yet recruiting","No Results Available","Biological: CD19-targeted CART cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03599375"
1354,"NCT01735604","Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",,"Unknown status","No Results Available","Biological: anti-CD20-CAR vector-transduced autologous T cells|Other: genetically engineered lymphocyte therapy","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01735604"
1355,"NCT00671112","Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma",,"Terminated","No Results Available","Drug: Bortezomib|Drug: Everolimus","Phase 1","null","https://ClinicalTrials.gov/show/NCT00671112"
1356,"NCT01181271","Tandem Auto-Allo Transplant for Lymphoma",,"Completed","Has Results","Drug: Busulfan (conditioning for AUTO transplant)|Drug: Etoposide (conditioning for AUTO transplant)|Drug: Cyclophosphamide (conditioning for AUTO transplant)|Drug: Mesna (prior to AUTO transplant)|Other: autologous (auto) peripheral blood stem cell transplantation|Drug: Neupogen|Drug: Fludarabine (conditioning for ALLO Transplant)|Drug: Busulfan (conditioning for ALLO Transplant)|Other: non-myeloablative allogeneic (allo) transplant|Drug: Tacrolimus|Drug: Sirolimus|Drug: Methotrexate","Phase 2","March 9, 2017","https://ClinicalTrials.gov/show/NCT01181271"
1357,"NCT03614858","CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.",,"Recruiting","No Results Available","Biological: CART-19/22","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03614858"
1358,"NCT00511043","PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma",,"Terminated","No Results Available","Drug: PTK787","Phase 2","null","https://ClinicalTrials.gov/show/NCT00511043"
1359,"NCT03574168","CD19-CAR-T Cells in Patients With R/R B-ALL",,"Recruiting","No Results Available","Biological: CD19-CAR-T Cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT03574168"
1360,"NCT02216890","Safety Study of SGN-CD70A in Cancer Patients",,"Completed","No Results Available","Drug: SGN-CD70A","Phase 1","null","https://ClinicalTrials.gov/show/NCT02216890"
1361,"NCT03160079","Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts",,"Recruiting","No Results Available","Drug: blinatumomab|Drug: pembrolizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03160079"
1362,"NCT00889408","DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",,"Completed","No Results Available","Biological: DT2219ARL","Phase 1","null","https://ClinicalTrials.gov/show/NCT00889408"
1363,"NCT02808442","Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia","PALL","Recruiting","No Results Available","Biological: UCART19","Phase 1","null","https://ClinicalTrials.gov/show/NCT02808442"
1364,"NCT00962507","Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",,"Completed","No Results Available","Drug: everolimus|Drug: panobinostat|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00962507"
1365,"NCT03289455","CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL","AMELIA","Recruiting","No Results Available","Biological: AUTO3 (CD19/22 CAR T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03289455"
1366,"NCT00101205","Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma",,"Terminated","No Results Available","Drug: oxaliplatin|Drug: etoposide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00101205"
1367,"NCT02432235","Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: ADCT-301","Phase 1","null","https://ClinicalTrials.gov/show/NCT02432235"
1368,"NCT00612716","Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",,"Recruiting","No Results Available","Drug: busulfan|Drug: cyclophosphamide|Biological: Stem cell infusion|Radiation: Total body irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00612716"
1369,"NCT01540578","Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT01540578"
1370,"NCT00474929","Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma",,"Active, not recruiting","Has Results","Drug: RAD001|Drug: Sorafenib","Phase 1|Phase 2","July 7, 2016","https://ClinicalTrials.gov/show/NCT00474929"
1371,"NCT00577798","Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin",,"Unknown status","No Results Available","Drug: doxorubicin hydrochloride|Procedure: contrast-enhanced magnetic resonance imaging","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00577798"
1372,"NCT01609816","Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Dasatinib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01609816"
1373,"NCT00470405","Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: oxaliplatin|Drug: pemetrexed disodium","Phase 1","null","https://ClinicalTrials.gov/show/NCT00470405"
1374,"NCT02167360","Study of Efficacy and Safety of CTL019 in Adult ALL Patients",,"Withdrawn","No Results Available","Drug: CTL019","Phase 2","null","https://ClinicalTrials.gov/show/NCT02167360"
1375,"NCT01279707","Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)","MARALL","Unknown status","No Results Available","Biological: humanised monoclonal antibody, veltuzumab|Biological: humanised monoclonal antibody epratuzumab|Biological: humanised monoclonal antibodies veltuzumab and epratuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01279707"
1376,"NCT00734890","Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Biological: bevacizumab|Drug: vandetanib|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00734890"
1377,"NCT00822432","Coproporphyrine Isomers and Methotrexate Elimination","COMETH","Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00822432"
1378,"NCT00562380","AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma",,"Completed","No Results Available","Biological: ganitumab|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Phase 1","null","https://ClinicalTrials.gov/show/NCT00562380"
1379,"NCT02228096","Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients",,"Active, not recruiting","No Results Available","Biological: CTL019 T-cells","Phase 2","null","https://ClinicalTrials.gov/show/NCT02228096"
1380,"NCT00646139","KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment",,"Completed","No Results Available","Drug: Src kinase inhibitor KX2-391|Other: immunoenzyme technique|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00646139"
1381,"NCT00048737","Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies",,"Completed","Has Results","Drug: Zevalin Radioimmunotherapy|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: Allogeneic Stem Cell Transplantation","Phase 1|Phase 2","June 13, 2013","https://ClinicalTrials.gov/show/NCT00048737"
1382,"NCT00956475","Quality of Life in Younger Leukemia and Lymphoma Survivors",,"Completed","No Results Available","Behavioral: telephone-based intervention|Other: questionnaire administration|Procedure: assessment of therapy complications|Procedure: fatigue assessment and management|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","","null","https://ClinicalTrials.gov/show/NCT00956475"
1383,"NCT00003166","Bryostatin and Vincristine in B-Cell Malignancies",,"Completed","No Results Available","Drug: bryostatin 1|Drug: vincristine sulfate|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003166"
1384,"NCT01643603","Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",,"Recruiting","No Results Available","Drug: Dasatinib|Other: laboratory biomarker analysis","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01643603"
1385,"NCT00003341","Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy",,"Completed","No Results Available","Biological: epoetin alfa|Procedure: quality-of-life assessment","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003341"
1386,"NCT03509961","The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With ALL",,"Recruiting","No Results Available","Diagnostic Test: NGS-MRD|Drug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen","Phase 2","null","https://ClinicalTrials.gov/show/NCT03509961"
1387,"NCT02617004","Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults","GRAALL-2014/B","Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02617004"
1388,"NCT00818961","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",,"Terminated","Has Results","Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation","Phase 2","December 18, 2013","https://ClinicalTrials.gov/show/NCT00818961"
1389,"NCT03610438","Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia","ALL2418","Not yet recruiting","No Results Available","Drug: Inotuzumab Ozogamicin (IO)","Phase 2","null","https://ClinicalTrials.gov/show/NCT03610438"
1390,"NCT03472573","Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Drug: Palbociclib|Drug: Dexamethasone","Phase 1","null","https://ClinicalTrials.gov/show/NCT03472573"
1391,"NCT01118013","Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",,"Terminated","Has Results","Biological: anti-thymocyte globulin|Biological: donor lymphocytes|Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: tacrolimus|Other: reduced-intensity transplant conditioning procedure|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","March 24, 2017","https://ClinicalTrials.gov/show/NCT01118013"
1392,"NCT01137643","Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer",,"Recruiting","No Results Available","Other: biologic sample preservation procedure|Other: cytology specimen collection procedure","","null","https://ClinicalTrials.gov/show/NCT01137643"
1393,"NCT01137825","Registry of Older Patients With Cancer",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01137825"
1394,"NCT01116232","Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",,"Terminated","Has Results","Biological: anti-thymocyte globulin|Biological: rituximab|Drug: sirolimus|Drug: tacrolimus|Other: laboratory biomarker analysis|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: management of therapy complications|Procedure: peripheral blood stem cell transplantation","Phase 2","December 13, 2013","https://ClinicalTrials.gov/show/NCT01116232"
1395,"NCT01101412","Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies",,"Withdrawn","No Results Available","Drug: Edetate Calcium Disodium|Drug: Ethanol|Drug: Trimethoprim-sulfamethoxazole|Other: Hypertonic Saline","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01101412"
1396,"NCT00827099","Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer",,"Terminated","Has Results","Biological: anti-thymocyte globulin|Drug: fludarabine phosphate|Drug: Melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: umbilical cord blood transplantation","Phase 2","August 3, 2011","https://ClinicalTrials.gov/show/NCT00827099"
1397,"NCT00799136","A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL","CATCH","Completed","No Results Available","Drug: R-EPOCH and cART","Phase 2","null","https://ClinicalTrials.gov/show/NCT00799136"
1398,"NCT00534118","Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant",,"Active, not recruiting","No Results Available","Biological: donor lymphocytes","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00534118"
1399,"NCT00993694","Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone",,"Completed","No Results Available","Drug: chemotherapy|Drug: dapsone|Other: medical chart review|Procedure: assessment of therapy complications","","null","https://ClinicalTrials.gov/show/NCT00993694"
1400,"NCT00952185","Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers",,"Terminated","No Results Available","Other: cytology specimen collection procedure|Other: fluorescent antibody technique|Procedure: assessment of therapy complications","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00952185"
1401,"NCT00935090","3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer",,"Recruiting","No Results Available","Device: 3'-deoxy-3'-[18F]fluorothymidine","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00935090"
1402,"NCT00900120","Collecting and Storing Blood Samples From Patients With Cancer",,"Withdrawn","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00900120"
1403,"NCT00899951","Studying Fentanyl in Patients With Cancer",,"Terminated","No Results Available","Drug: fentanyl citrate|Other: pharmacological study","","null","https://ClinicalTrials.gov/show/NCT00899951"
1404,"NCT00800150","Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment",,"Terminated","No Results Available","Drug: fludarabine phosphate|Drug: melphalan|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Radiation: intensity-modulated radiation therapy|Radiation: tomotherapy|Radiation: total marrow irradiation|Radiation: total nodal irradiation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00800150"
1405,"NCT00416312","Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","Has Results","Device: Patient-specific dosimetry|Device: conventional dosimetry","","August 27, 2018","https://ClinicalTrials.gov/show/NCT00416312"
1406,"NCT02215629","Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia",,"Withdrawn","No Results Available","Drug: VS-4718","Phase 1","null","https://ClinicalTrials.gov/show/NCT02215629"
1407,"NCT00823524","Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Biological: donor natural killer cell infusion","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00823524"
1408,"NCT01974479","Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia",,"Suspended","No Results Available","Biological: anti-CD19 redirected NK cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT01974479"
1409,"NCT00770419","Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers",,"Withdrawn","No Results Available","Other: medical chart review|Other: questionnaire administration|Procedure: psychosocial assessment and care","","null","https://ClinicalTrials.gov/show/NCT00770419"
1410,"NCT00750009","Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial",,"Completed","No Results Available","Other: educational intervention","Phase 3","null","https://ClinicalTrials.gov/show/NCT00750009"
1411,"NCT02535364","Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)","ROCKET","Terminated","Has Results","Biological: JCAR015 (CD19-targeted CAR T cells)","Phase 2","July 19, 2018","https://ClinicalTrials.gov/show/NCT02535364"
1412,"NCT00726830","Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",,"Terminated","Has Results","Drug: methadone hydrochloride|Drug: morphine sulfate|Drug: oxycodone hydrochloride","Not Applicable","December 6, 2012","https://ClinicalTrials.gov/show/NCT00726830"
1413,"NCT00719563","American Ginseng in Treating Patients With Fatigue Caused by Cancer",,"Completed","Has Results","Drug: American ginseng|Other: placebo","Phase 3","August 6, 2014","https://ClinicalTrials.gov/show/NCT00719563"
1414,"NCT00666211","Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain",,"Completed","Has Results","Other: educational intervention|Other: Titrated pain management|Other: questionnaire administration","Phase 3","September 6, 2012","https://ClinicalTrials.gov/show/NCT00666211"
1415,"NCT01316744","Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain",,"Unknown status","No Results Available","Drug: ketamine hydrochloride|Other: pharmacogenomic studies|Other: questionnaire administration|Procedure: assessment of therapy complications|Procedure: quality-of-life assessment","Phase 3","null","https://ClinicalTrials.gov/show/NCT01316744"
1416,"NCT00521430","Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: methylprednisolone|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00521430"
1417,"NCT00589563","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer",,"Completed","Has Results","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: hematopoietic stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Phase 2","August 12, 2014","https://ClinicalTrials.gov/show/NCT00589563"
1418,"NCT00383565","FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Terminated","Has Results","Drug: romidepsin","Phase 2","August 22, 2012","https://ClinicalTrials.gov/show/NCT00383565"
1419,"NCT00499668","Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer",,"Withdrawn","No Results Available","Drug: aprepitant|Drug: ondansetron hydrochloride","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00499668"
1420,"NCT01685021","Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)",,"Terminated","Has Results","Drug: MOR00208 (formerly Xmab5574)","Phase 2","February 21, 2018","https://ClinicalTrials.gov/show/NCT01685021"
1421,"NCT02588456","Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia",,"Terminated","No Results Available","Biological: CART22 cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02588456"
1422,"NCT00006362","PS-341 in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: bortezomib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00006362"
1423,"NCT00237627","Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer",,"Completed","No Results Available","Drug: PS-341|Drug: Doxil|Drug: Velcade","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00237627"
1424,"NCT00899496","Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants",,"Completed","No Results Available","Other: immunological diagnostic method|Other: physiologic testing","","null","https://ClinicalTrials.gov/show/NCT00899496"
1425,"NCT00001237","Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas",,"Completed","No Results Available","Drug: granulocyte-macrophage colony stimulating factor (GM-CSF)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00001237"
1426,"NCT03504644","Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Venetoclax|Drug: Vincristine Liposomal","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03504644"
1427,"NCT01044069","Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19",,"Active, not recruiting","No Results Available","Biological: gene-modified T cells targeted","Phase 1","null","https://ClinicalTrials.gov/show/NCT01044069"
1428,"NCT03467256","CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL",,"Recruiting","No Results Available","Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Tocilizumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03467256"
1429,"NCT03698552","ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Biological: ADCT-602","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03698552"
1430,"NCT03000335","Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03000335"
1431,"NCT02374333","Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy",,"Recruiting","No Results Available","Biological: huCART19","Phase 1","null","https://ClinicalTrials.gov/show/NCT02374333"
1432,"NCT00293488","SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma",,"Completed","No Results Available","Drug: polyamine analogue PG11047","Phase 1","null","https://ClinicalTrials.gov/show/NCT00293488"
1433,"NCT00081809","A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma",,"Completed","No Results Available","Drug: autologous human tumor-derived HSPPC-96","Phase 2","null","https://ClinicalTrials.gov/show/NCT00081809"
1434,"NCT01475058","CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",,"Completed","No Results Available","Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01475058"
1435,"NCT00898872","SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial",,"Completed","No Results Available","Other: cryopreservation","","null","https://ClinicalTrials.gov/show/NCT00898872"
1436,"NCT03595917","ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML",,"Recruiting","No Results Available","Drug: ABL001|Drug: Dasatinib|Drug: Prednisone","Phase 1","null","https://ClinicalTrials.gov/show/NCT03595917"
1437,"NCT00002829","Bone Marrow Transplantation in Treating Patients With Lymphoma",,"Completed","No Results Available","Biological: Recombinant Interferon Alfa|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Mesna|Procedure: Bone Marrow Transplantation|Radiation: Radiation Therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002829"
1438,"NCT01429025","Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Biological: rituximab|Drug: bendamustine|Drug: lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01429025"
1439,"NCT00784927","Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: cyclophosphamide|Drug: dexamethasone|Drug: lenalidomide","Phase 2","February 8, 2016","https://ClinicalTrials.gov/show/NCT00784927"
1440,"NCT00176475","Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",,"Terminated","No Results Available","Biological: rituximab|Biological: therapeutic allogeneic lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT00176475"
1441,"NCT00897923","Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Procedure: radionuclide imaging|Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells|Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes","","null","https://ClinicalTrials.gov/show/NCT00897923"
1442,"NCT00720876","Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: vorinostat","Phase 2","July 6, 2018","https://ClinicalTrials.gov/show/NCT00720876"
1443,"NCT00949741","Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients","CFM","Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00949741"
1444,"NCT00381680","Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia",,"Completed","Has Results","Drug: vincristine sulfate|Drug: prednisone|Drug: doxorubicin hydrochloride|Drug: pegaspargase|Drug: cytarabine|Drug: methotrexate|Drug: dexamethasone|Drug: etoposide|Drug: cyclophosphamide|Drug: leucovorin calcium|Biological: filgrastim|Drug: asparaginase|Drug: mercaptopurine","Phase 3","May 12, 2017","https://ClinicalTrials.gov/show/NCT00381680"
1445,"NCT01207388","Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)","BLAST","Active, not recruiting","Has Results","Drug: Blinatumomab","Phase 2","February 12, 2015","https://ClinicalTrials.gov/show/NCT01207388"
1446,"NCT01307267","A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",,"Active, not recruiting","No Results Available","Drug: PF-05082566|Drug: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01307267"
1447,"NCT02721407","Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients","MendCART","Recruiting","No Results Available","Drug: Retroviral vector-transduced autologous T cells to express CD22-specific CARs","Phase 1","null","https://ClinicalTrials.gov/show/NCT02721407"
1448,"NCT01505699","Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Genetic: RNA analysis|Genetic: cytogenetic analysis|Genetic: microarray analysis|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT01505699"
1449,"NCT02303392","Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: Selinexor|Drug: Ibrutinib|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT02303392"
1450,"NCT00278161","Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00278161"
1451,"NCT00589381","Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: fenretinide lipid matrix","Phase 1","null","https://ClinicalTrials.gov/show/NCT00589381"
1452,"NCT00392691","Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",,"Completed","No Results Available","Drug: ibritumomab tiuxetan|Drug: rituximab|Drug: melphalan|Drug: vinorelbine tartrate / G-CSF|Procedure: autologous hematopoietic stem cell harvesting and transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00392691"
1453,"NCT01719250","Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",,"Completed","No Results Available","Drug: Buparlisib|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT01719250"
1454,"NCT00504205","MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma",,"Terminated","No Results Available","Drug: multitargeted receptor tyrosine kinase inhibitor MP470|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: positron emission tomography","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00504205"
1455,"NCT00551239","Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma",,"Unknown status","No Results Available","Biological: rituximab|Drug: fludarabine phosphate|Drug: pixantrone dimaleate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00551239"
1456,"NCT00238433","Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: filgrastim|Drug: busulfan|Drug: melphalan|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Phase 2","May 11, 2017","https://ClinicalTrials.gov/show/NCT00238433"
1457,"NCT00004107","Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia",,"Completed","No Results Available","Biological: filgrastim|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody MN-14|Radiation: yttrium Y 90 epratuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00004107"
1458,"NCT00436618","Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment",,"Completed","Has Results","Drug: Everolimus","Phase 2","July 30, 2013","https://ClinicalTrials.gov/show/NCT00436618"
1459,"NCT00110149","Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",,"Terminated","Has Results","Biological: rituximab|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 2","November 21, 2017","https://ClinicalTrials.gov/show/NCT00110149"
1460,"NCT00278382","Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: sorafenib tosylate|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00278382"
1461,"NCT00416923","Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",,"Completed","No Results Available","Biological: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00416923"
1462,"NCT00002779","Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: fludarabine phosphate|Drug: octreotide acetate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002779"
1463,"NCT00003663","Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma",,"Withdrawn","No Results Available","Biological: rituximab|Drug: dexamethasone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003663"
1464,"NCT00003605","Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma",,"Withdrawn","No Results Available","Biological: rituximab|Drug: cyclophosphamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003605"
1465,"NCT00002725","Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: bryostatin 1|Drug: chemotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002725"
1466,"NCT00183976","Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas",,"Terminated","No Results Available","Drug: Pegylated Liposomal Doxorubicin (Doxil) and Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00183976"
1467,"NCT00004260","Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: recombinant interleukin-12|Biological: rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004260"
1468,"NCT00005613","Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease","CBV","Completed","No Results Available","Drug: cyclophosphamide|Drug: etoposide|Drug: BCNU","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005613"
1469,"NCT00003639","Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: recombinant interferon alfa|Drug: chlorambucil|Drug: dexamethasone|Drug: idarubicin","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003639"
1470,"NCT00003143","Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation",,"Completed","No Results Available","Drug: Amifostine|Drug: DHAP","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003143"
1471,"NCT00004101","Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: apolizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004101"
1472,"NCT00004112","Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00004112"
1473,"NCT00002481","Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002481"
1474,"NCT00003337","Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Procedure: immunoscintigraphy|Radiation: technetium Tc 99m epratuzumab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003337"
1475,"NCT00021372","Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: estramustine phosphate sodium|Drug: paclitaxel","Phase 2","null","https://ClinicalTrials.gov/show/NCT00021372"
1476,"NCT00003338","Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Procedure: immunoscintigraphy|Radiation: technetium Tc 99m epratuzumab","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT00003338"
1477,"NCT00003615","Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: denileukin diftitox","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003615"
1478,"NCT00007852","Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00007852"
1479,"NCT00075946","Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma",,"Active, not recruiting","Has Results","Biological: rituximab","Phase 3","June 22, 2015","https://ClinicalTrials.gov/show/NCT00075946"
1480,"NCT00098566","Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00098566"
1481,"NCT00109824","Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: decitabine|Drug: valproic acid|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00109824"
1482,"NCT00003924","Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: recombinant interferon alfa","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003924"
1483,"NCT00003245","Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: irinotecan hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003245"
1484,"NCT00004908","Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004908"
1485,"NCT00898612","Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant",,"Withdrawn","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00898612"
1486,"NCT00390117","AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: CDKI AT7519|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00390117"
1487,"NCT00443976","Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: Aurora kinase inhibitor AT9283","Phase 1","null","https://ClinicalTrials.gov/show/NCT00443976"
1488,"NCT00008021","Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: filgrastim|Biological: monoclonal antibody Lym-1|Drug: cyclosporine|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody Lym-1|Radiation: yttrium Y 90 monoclonal antibody Lym-1","Phase 1","null","https://ClinicalTrials.gov/show/NCT00008021"
1489,"NCT00005998","Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease",,"Withdrawn","No Results Available","Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: filgrastim|Drug: mitoxantrone hydrochloride|Drug: retrovirus vector LN|Procedure: in vitro-treated peripheral blood stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005998"
1490,"NCT00352443","S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: everolimus|Drug: lapatinib ditosylate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00352443"
1491,"NCT00047164","Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy",,"Completed","No Results Available","Biological: ipilimumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00047164"
1492,"NCT00009776","Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: monoclonal antibody Lym-1|Drug: cyclosporine|Drug: paclitaxel|Radiation: indium In 111 monoclonal antibody Lym-1|Radiation: yttrium Y 90 monoclonal antibody Lym-1","Phase 1","null","https://ClinicalTrials.gov/show/NCT00009776"
1493,"NCT00002697","Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: sargramostim|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002697"
1494,"NCT00052936","Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00052936"
1495,"NCT00004192","Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: cytarabine|Drug: etoposide|Drug: methylprednisolone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004192"
1496,"NCT00005993","Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer",,"Terminated","No Results Available","Drug: aldesleukin|Drug: filgrastim|Drug: recombinant human stem cell factor|Procedure: peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005993"
1497,"NCT00057954","Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma",,"Terminated","Has Results","Procedure: Extracorporeal Photopheresis|Drug: Pentostatin|Radiation: Total body irradiation (TBI)|Procedure: Allogeneic bone marrow transplantation|Drug: Cyclosporin (CSA)|Drug: Mycophenolate mofetil (MMF)|Drug: Methotrexate (MTX)","Phase 2","February 8, 2013","https://ClinicalTrials.gov/show/NCT00057954"
1498,"NCT00006039","Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: pegylated interferon alfa","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006039"
1499,"NCT00004084","Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",,"Completed","No Results Available","Radiation: indium In 111 LL2 IgG|Radiation: yttrium Y 90 epratuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00004084"
1500,"NCT00896662","Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202",,"Completed","No Results Available","Other: immunologic technique|Other: laboratory biomarker analysis|Other: pharmacological study","","null","https://ClinicalTrials.gov/show/NCT00896662"
1501,"NCT00006373","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: etoposide|Drug: ifosfamide|Drug: topotecan hydrochloride|Procedure: autologous bone marrow transplantation|Drug: Mesna","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006373"
1502,"NCT00003414","Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease",,"Completed","No Results Available","Biological: aldesleukin|Biological: recombinant interferon gamma|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003414"
1503,"NCT00450944","Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia",,"Unknown status","No Results Available","Biological: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins","Phase 1","null","https://ClinicalTrials.gov/show/NCT00450944"
1504,"NCT02810223","Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia",,"Unknown status","No Results Available","Biological: CART-19","Phase 1","null","https://ClinicalTrials.gov/show/NCT02810223"
1505,"NCT00045500","UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: 7-hydroxystaurosporine|Drug: prednisone","Phase 1","null","https://ClinicalTrials.gov/show/NCT00045500"
1506,"NCT00045266","VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: ziv-aflibercept","Phase 1","null","https://ClinicalTrials.gov/show/NCT00045266"
1507,"NCT00088868","17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma",,"Completed","No Results Available","Drug: alvespimycin hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00088868"
1508,"NCT00036946","VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: ziv-aflibercept","Phase 1","null","https://ClinicalTrials.gov/show/NCT00036946"
1509,"NCT00791011","Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat",,"Completed","No Results Available","Drug: AMG 655|Other: Vorinostat|Other: Bortezomib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00791011"
1510,"NCT00002552","Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma",,"Completed","No Results Available","Biological: filgrastim|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: perfosfamide|Drug: therapeutic hydrocortisone|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002552"
1511,"NCT00002946","Penclomedine in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: penclomedine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002946"
1512,"NCT00004057","Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: L-778,123|Drug: paclitaxel","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004057"
1513,"NCT00002909","Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: chemotherapy|Drug: oral sodium phenylbutyrate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002909"
1514,"NCT00018954","Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00018954"
1515,"NCT00023816","Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Unknown status","No Results Available","Drug: carbendazim","Phase 1","null","https://ClinicalTrials.gov/show/NCT00023816"
1516,"NCT00007865","Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00007865"
1517,"NCT00004907","Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00004907"
1518,"NCT00027937","Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Biological: aldesleukin|Biological: filgrastim|Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: in vitro-treated peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00027937"
1519,"NCT02129062","Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia",,"Terminated","Has Results","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis","Phase 2","January 16, 2017","https://ClinicalTrials.gov/show/NCT02129062"
1520,"NCT02101853","Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Biological: Blinatumomab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Mitoxantrone Hydrochloride|Drug: Pegaspargase|Other: Pharmacological Study|Drug: Therapeutic Hydrocortisone|Drug: Thioguanine|Drug: Vincristine Sulfate","Phase 3","null","https://ClinicalTrials.gov/show/NCT02101853"
1521,"NCT00891137","Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy",,"Completed","No Results Available","Biological: human myeloid progenitor cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT00891137"
1522,"NCT00002765","Immunotoxin in Treating Patients With Leukemia or Lymphoma",,"Completed","No Results Available","Biological: LMB-2 immunotoxin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002765"
1523,"NCT00004075","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery",,"Completed","No Results Available","Drug: tanespimycin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004075"
1524,"NCT00324597","AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Unknown status","No Results Available","Drug: gemcitabine hydrochloride|Drug: motesanib diphosphate|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00324597"
1525,"NCT00082823","Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: ziv-aflibercept","Phase 1","null","https://ClinicalTrials.gov/show/NCT00082823"
1526,"NCT00083213","Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: ziv-aflibercept","Phase 1","null","https://ClinicalTrials.gov/show/NCT00083213"
1527,"NCT00049400","S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction",,"Completed","No Results Available","Drug: BMS-247550","Phase 1","null","https://ClinicalTrials.gov/show/NCT00049400"
1528,"NCT00004002","PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: bortezomib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004002"
1529,"NCT00005787","Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: epoetin alfa|Biological: filgrastim|Biological: recombinant flt3 ligand|Biological: recombinant interleukin-3|Biological: sargramostim|Procedure: in vitro-treated peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005787"
1530,"NCT00019838","UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia",,"Completed","No Results Available","Drug: 7-hydroxystaurosporine|Drug: fludarabine phosphate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00019838"
1531,"NCT00047021","Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma",,"Completed","No Results Available","Biological: sargramostim|Drug: cytarabine|Drug: mitoxantrone hydrochloride","Phase 2","null","https://ClinicalTrials.gov/show/NCT00047021"
1532,"NCT00005021","Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Drug: carboplatin|Drug: paclitaxel|Drug: topotecan hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005021"
1533,"NCT00016172","ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: pegylated liposomal doxorubicin hydrochloride|Drug: picoplatin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00016172"
1534,"NCT00003368","Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis",,"Completed","No Results Available","Drug: irinotecan hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003368"
1535,"NCT01490723","Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)",,"Active, not recruiting","No Results Available","Drug: Rituximab|Drug: 111In Ibritumomab|Procedure: Planar Scintigraphy Imaging|Drug: 90Y IbritumomabTiuxetan|Drug: Fludarabine|Drug: Bendamustine|Drug: Thymoglobulin|Drug: Tacrolimus|Drug: Methotrexate|Drug: Mycophenolate|Drug: G-CSF|Procedure: Stem Cell Transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT01490723"
1536,"NCT00659568","Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma",,"Completed","No Results Available","Drug: metformin hydrochloride|Drug: temsirolimus","Phase 1","null","https://ClinicalTrials.gov/show/NCT00659568"
1537,"NCT00002625","Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: topotecan hydrochloride|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002625"
1538,"NCT00003056","Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation",,"Terminated","No Results Available","Drug: cyclosporine|Drug: cyclosporine and methotrexate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003056"
1539,"NCT00020579","MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: entinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT00020579"
1540,"NCT02520895","Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia","RIPAL","Completed","No Results Available","Biological: blood samplings","","null","https://ClinicalTrials.gov/show/NCT02520895"
1541,"NCT01685606","Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma","273","Terminated","Has Results","Biological: cellular immunotherapy","Phase 2","June 26, 2015","https://ClinicalTrials.gov/show/NCT01685606"
1542,"NCT00003956","Combination Chemotherapy in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: fluorouracil|Drug: leucovorin calcium|Drug: lonafarnib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003956"
1543,"NCT00025129","VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: laromustine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00025129"
1544,"NCT00003993","Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma",,"Completed","No Results Available","Biological: aldesleukin|Drug: bryostatin 1","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003993"
1545,"NCT00049712","Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Biological: etaracizumab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00049712"
1546,"NCT00002862","Perillyl Alcohol in Treating Patients With Refractory Cancer",,"Completed","No Results Available","Drug: perillyl alcohol","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002862"
1547,"NCT00002663","Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",,"Recruiting","No Results Available","Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00002663"
1548,"NCT00005626","Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)",,"Completed","No Results Available","Drug: Irinotecan","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005626"
1549,"NCT00002956","Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants",,"Withdrawn","No Results Available","Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002956"
1550,"NCT00002553","Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: low-LET cobalt-60 gamma ray therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002553"
1551,"NCT01408160","Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",,"Unknown status","No Results Available","Drug: Cytarabine|Biological: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01408160"
1552,"NCT00019019","Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas",,"Completed","No Results Available","Drug: carboxyamidotriazole|Drug: paclitaxel","Phase 1","null","https://ClinicalTrials.gov/show/NCT00019019"
1553,"NCT00003567","Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: O6-benzylguanine|Drug: carmustine|Drug: temozolomide|Procedure: in vitro-treated peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003567"
1554,"NCT00005590","Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: levofloxacin","Phase 3","null","https://ClinicalTrials.gov/show/NCT00005590"
1555,"NCT00052572","Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders",,"Completed","No Results Available","Drug: ixabepilone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00052572"
1556,"NCT00996359","Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation",,"Terminated","No Results Available","Biological: Irradiated haploidentical allogeneic lymphocytes|Radiation: total-body irradiation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00996359"
1557,"NCT00547196","Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer",,"Active, not recruiting","No Results Available","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00547196"
1558,"NCT00002759","Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: cyclosporine|Drug: irinotecan hydrochloride|Drug: phenobarbital","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002759"
1559,"NCT00003885","Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma",,"Unknown status","No Results Available","Drug: arsenic trioxide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003885"
1560,"NCT00002657","SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant",,"Completed","No Results Available","Biological: bleomycin sulfate|Biological: recombinant interferon alfa|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002657"
1561,"NCT00004875","Heparin or Enoxaparin in Patients With Cancer",,"Completed","No Results Available","Drug: enoxaparin|Drug: heparin","","null","https://ClinicalTrials.gov/show/NCT00004875"
1562,"NCT00003294","Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer",,"Completed","No Results Available","Biological: filgrastim|Drug: amifostine trihydrate|Drug: carboplatin|Drug: paclitaxel","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003294"
1563,"NCT00513474","Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant",,"Completed","Has Results","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporin-A|Drug: etoposide|Drug: methotrexate|Drug: rasburicase|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine|Drug: allopurinol","Phase 1","April 11, 2017","https://ClinicalTrials.gov/show/NCT00513474"
1564,"NCT00004061","Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer",,"Completed","No Results Available","Biological: filgrastim|Biological: palifermin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Procedure: peripheral blood stem cell transplantation|Procedure: quality-of-life assessment|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004061"
1565,"NCT00003289","UCN-01 in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: 7-hydroxystaurosporine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003289"
1566,"NCT00317785","Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases",,"Completed","No Results Available","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00317785"
1567,"NCT02378038","PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)",,"Terminated","No Results Available","Drug: PNT2258","Phase 2","null","https://ClinicalTrials.gov/show/NCT02378038"
1568,"NCT00816413","Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer",,"Withdrawn","No Results Available","Drug: cyclosporine|Drug: mycophenolate mofetil|Drug: pentostatin|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Genetic: protein analysis|Other: flow cytometry|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: reduced-intensity transplant conditioning procedure|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation (PBSC)|Radiation: total-body irradiation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00816413"
1569,"NCT01077440","Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant",,"Terminated","No Results Available","Genetic: DNA analysis|Genetic: polymerase chain reaction|Other: flow cytometry|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT01077440"
1570,"NCT00787761","Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",,"Completed","Has Results","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic HSCT","Phase 2","October 1, 2012","https://ClinicalTrials.gov/show/NCT00787761"
1571,"NCT00740467","Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders",,"Unknown status","No Results Available","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00740467"
1572,"NCT00725062","Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant",,"Terminated","No Results Available","Biological: CD4+CD25+ regulatory T cells|Procedure: allogeneic hematopoietic stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00725062"
1573,"NCT00964821","Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant",,"Completed","No Results Available","Biological: trivalent influenza vaccine|Other: Immunoenzyme technique|Other: Laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT00964821"
1574,"NCT00445497","Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia",,"Unknown status","No Results Available","Drug: amoxicillin-clavulanate potassium|Drug: ciprofloxacin|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Phase 3","null","https://ClinicalTrials.gov/show/NCT00445497"
1575,"NCT00951626","A Standardized Nursing Intervention Protocol for HCT Patients",,"Completed","No Results Available","Behavioral: exercise intervention|Behavioral: telephone-based intervention|Dietary Supplement: dietary intervention|Other: educational intervention|Other: questionnaire administration|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: assessment of therapy complications|Procedure: peripheral blood stem cell transplantation|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment|Procedure: standard follow-up care","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00951626"
1576,"NCT00946283","Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome",,"Terminated","No Results Available","Dietary Supplement: Lactobacillus rhamnosus GG","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00946283"
1577,"NCT00006221","BMS-247550 in Treating Patients With Advanced Cancers",,"Completed","No Results Available","Drug: ixabepilone","Phase 1","null","https://ClinicalTrials.gov/show/NCT00006221"
1578,"NCT00005639","Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment",,"Completed","No Results Available","Drug: azacitidine|Drug: sodium phenylbutyrate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005639"
1579,"NCT00031941","CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy",,"Completed","No Results Available","Drug: lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00031941"
1580,"NCT00004189","Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Biological: filgrastim|Drug: becatecarin|Drug: cisplatin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004189"
1581,"NCT00004105","Combination Chemotherapy in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: estramustine phosphate sodium|Drug: paclitaxel|Drug: vinorelbine ditartrate","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00004105"
1582,"NCT00004157","Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors",,"Completed","No Results Available","Biological: filgrastim|Biological: recombinant interleukin-11","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004157"
1583,"NCT00900068","Blood Samples From Patients on a Clinical Trial to CINV During HSCT",,"Terminated","No Results Available","Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: medical chart review","","null","https://ClinicalTrials.gov/show/NCT00900068"
1584,"NCT00806767","Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",,"Completed","No Results Available","Biological: therapeutic immune globulin|Drug: busulfan|Drug: fludarabine phosphate|Procedure: allogeneic hematopoietic stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00806767"
1585,"NCT00006019","Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer",,"Completed","No Results Available","Drug: azacitidine|Drug: sodium phenylbutyrate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006019"
1586,"NCT00608517","Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil",,"Terminated","Has Results","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Radiation: total-body irradiation","Not Applicable","November 10, 2010","https://ClinicalTrials.gov/show/NCT00608517"
1587,"NCT00003962","Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: aldesleukin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003962"
1588,"NCT00813501","Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases",,"Terminated","No Results Available","Biological: immunosuppressive therapy|Other: immunological diagnostic method|Procedure: allogeneic hematopoietic stem cell transplantation","","null","https://ClinicalTrials.gov/show/NCT00813501"
1589,"NCT00691015","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",,"Completed","Has Results","Biological: rituximab|Drug: busulfan|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Radiation: total body irradiation (TBI)|Drug: anti-thymocyte globulin IV","Phase 2","June 28, 2017","https://ClinicalTrials.gov/show/NCT00691015"
1590,"NCT00482716","Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer",,"Unknown status","No Results Available","Biological: epoetin alfa|Biological: epoetin beta|Dietary Supplement: iron dextran complex|Dietary Supplement: iron sucrose injection","Phase 3","null","https://ClinicalTrials.gov/show/NCT00482716"
1591,"NCT00755040","Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder",,"Completed","Has Results","Drug: cyclosporine ophthalmic emulsion|Other: placebo","Phase 3","December 8, 2016","https://ClinicalTrials.gov/show/NCT00755040"
1592,"NCT01775475","Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: lomustine|Drug: etoposide|Drug: procarbazine hydrochloride|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT01775475"
1593,"NCT00049699","VNP40101M in Treating Patients With Advanced or Metastatic Cancer",,"Completed","No Results Available","Drug: laromustine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00049699"
1594,"NCT00003395","Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer",,"Completed","No Results Available","Drug: arsenic trioxide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003395"
1595,"NCT00716911","Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant",,"Completed","No Results Available","Drug: ganciclovir|Genetic: polymerase chain reaction|Other: flow cytometry|Other: immunologic technique|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: assessment of therapy complications|Procedure: peripheral blood stem cell transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00716911"
1596,"NCT00301951","Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: sargramostim|Drug: busulfan|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: umbilical cord blood transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00301951"
1597,"NCT00019344","Flavopiridol in Treating Patients With Refractory Cancer",,"Completed","No Results Available","Drug: alvocidib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00019344"
1598,"NCT00004114","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer",,"Withdrawn","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004114"
1599,"NCT00019513","Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium","Phase 1","null","https://ClinicalTrials.gov/show/NCT00019513"
1600,"NCT00453206","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases",,"Completed","Has Results","Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Not Applicable","July 2, 2014","https://ClinicalTrials.gov/show/NCT00453206"
1601,"NCT00448201","Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease",,"Completed","Has Results","Biological: anti-thymocyte globulin|Biological: sargramostim|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","May 30, 2017","https://ClinicalTrials.gov/show/NCT00448201"
1602,"NCT00448357","Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen","LCCC0510","Completed","Has Results","Biological: rabbit anti-thymocyte globulin (ATG)|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: methotrexate","Phase 1|Phase 2","July 17, 2017","https://ClinicalTrials.gov/show/NCT00448357"
1603,"NCT00661999","Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer",,"Completed","Has Results","Biological: darbepoetin alfa|Dietary Supplement: ferrous sulfate|Drug: sodium ferric gluconate complex in sucrose|Other: placebo","Phase 3","April 18, 2011","https://ClinicalTrials.gov/show/NCT00661999"
1604,"NCT00651716","T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant",,"Suspended","No Results Available","Other: flow cytometry|Other: laboratory biomarker analysis|Other: Data Collection","","null","https://ClinicalTrials.gov/show/NCT00651716"
1605,"NCT00611351","Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",,"Completed","Has Results","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: tacrolimus|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","April 3, 2018","https://ClinicalTrials.gov/show/NCT00611351"
1606,"NCT00544115","Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders",,"Active, not recruiting","No Results Available","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00544115"
1607,"NCT00104923","Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer",,"Completed","No Results Available","Drug: fenretinide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00104923"
1608,"NCT00438958","Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases",,"Completed","No Results Available","Biological: filgrastim|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Phase 3","null","https://ClinicalTrials.gov/show/NCT00438958"
1609,"NCT00423826","Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease",,"No longer available","No Results Available","Drug: Busulfan|Drug: Cytarabine|Drug: Fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","","null","https://ClinicalTrials.gov/show/NCT00423826"
1610,"NCT00016094","S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: bevacizumab|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00016094"
1611,"NCT00296023","Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00296023"
1612,"NCT00005606","Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation",,"Completed","No Results Available","Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|Biological: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005606"
1613,"NCT00424242","Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases",,"Active, not recruiting","No Results Available","Drug: Pemetrexed","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT00424242"
1614,"NCT00365287","Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer",,"Completed","No Results Available","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00365287"
1615,"NCT00416624","Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy",,"Completed","Has Results","Drug: darbepoetin alfa|Drug: epoetin alfa|Procedure: fatigue assessment and management|Procedure: quality-of-life assessment","Phase 2","February 10, 2017","https://ClinicalTrials.gov/show/NCT00416624"
1616,"NCT00410657","Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant",,"Completed","No Results Available","Biological: alemtuzumab|Drug: methylprednisolone|Drug: prednisone|Other: flow cytometry|Other: immunologic technique|Other: pharmacological study","Phase 2","null","https://ClinicalTrials.gov/show/NCT00410657"
1617,"NCT00002502","Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome",,"Completed","No Results Available","Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Procedure: allogeneic bone marrow transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002502"
1618,"NCT00005854","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005854"
1619,"NCT00134017","Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer",,"Completed","Has Results","Drug: Busulfan|Drug: Cyclophosphamide","Phase 2","August 31, 2018","https://ClinicalTrials.gov/show/NCT00134017"
1620,"NCT00134004","Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer",,"Completed","Has Results","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Phase 2","August 24, 2015","https://ClinicalTrials.gov/show/NCT00134004"
1621,"NCT00003396","Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003396"
1622,"NCT00003269","Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors",,"Completed","No Results Available","Biological: sargramostim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003269"
1623,"NCT00376922","Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases",,"Completed","No Results Available","Procedure: music therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00376922"
1624,"NCT00949052","Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer",,"Terminated","No Results Available","Genetic: DNA analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: medical chart review|Other: questionnaire administration|Procedure: assessment of therapy complications|Procedure: evaluation of cancer risk factors","","null","https://ClinicalTrials.gov/show/NCT00949052"
1625,"NCT00002818","High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies",,"Completed","No Results Available","Drug: cytarabine|Drug: deoxycytidine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002818"
1626,"NCT00006098","PS-341 in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Drug: bortezomib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00006098"
1627,"NCT00006350","Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: daclizumab|Biological: therapeutic allogeneic lymphocytes|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006350"
1628,"NCT00053053","Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer",,"Completed","No Results Available","Dietary Supplement: Juven|Dietary Supplement: Non-Juven Supplement","Phase 3","null","https://ClinicalTrials.gov/show/NCT00053053"
1629,"NCT00005946","Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation",,"Completed","No Results Available","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: etoposide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005946"
1630,"NCT00003572","Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers",,"Completed","No Results Available","Biological: peripheral blood lymphocyte therapy|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003572"
1631,"NCT00004145","Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004145"
1632,"NCT00904514","Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial",,"Terminated","No Results Available","Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: mutation analysis|Genetic: polymerase chain reaction|Other: flow cytometry|Other: immunoenzyme technique|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT00904514"
1633,"NCT00265837","Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer",,"Completed","No Results Available","Biological: graft versus host disease prophylaxis/therapy|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation","Phase 3","null","https://ClinicalTrials.gov/show/NCT00265837"
1634,"NCT00324324","Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",,"Terminated","No Results Available","Drug: moxifloxacin hydrochloride|Drug: Placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT00324324"
1635,"NCT01925131","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",,"Recruiting","No Results Available","Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: prednisone|Biological: inotuzumab ozogamicin|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01925131"
1636,"NCT00002989","Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome",,"Unknown status","No Results Available","Drug: busulfan|Drug: cyclophosphamide|Drug: idarubicin|Drug: melphalan|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00002989"
1637,"NCT00301912","Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer",,"Withdrawn","No Results Available","Biological: filgrastim|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00301912"
1638,"NCT00293384","Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant",,"Completed","Has Results","Drug: Aprepitant|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Granisetron hydrochloride","Not Applicable","October 3, 2014","https://ClinicalTrials.gov/show/NCT00293384"
1639,"NCT00161187","Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor",,"Completed","No Results Available","Biological: therapeutic allogeneic lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT00161187"
1640,"NCT00290628","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",,"Terminated","No Results Available","Drug: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: filgrastim|Drug: melphalan|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00290628"
1641,"NCT00281879","Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer",,"Terminated","Has Results","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: carmustine|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Phase 2","June 19, 2012","https://ClinicalTrials.gov/show/NCT00281879"
1642,"NCT00281814","Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant",,"Completed","No Results Available","Procedure: psychosocial assessment and care","","null","https://ClinicalTrials.gov/show/NCT00281814"
1643,"NCT00281801","Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation",,"Completed","No Results Available","Procedure: psychosocial assessment and care|Procedure: Quality of Life Assessments","","null","https://ClinicalTrials.gov/show/NCT00281801"
1644,"NCT00006340","Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus",,"Completed","No Results Available","Drug: arginine butyrate|Drug: ganciclovir","Phase 1","null","https://ClinicalTrials.gov/show/NCT00006340"
1645,"NCT00255749","Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer",,"Completed","No Results Available","Biological: epoetin alfa","Phase 2","null","https://ClinicalTrials.gov/show/NCT00255749"
1646,"NCT00255684","Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer",,"Terminated","Has Results","Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Not Applicable","June 27, 2016","https://ClinicalTrials.gov/show/NCT00255684"
1647,"NCT00253552","G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders",,"Terminated","No Results Available","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00253552"
1648,"NCT00245037","Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","Bu Flu TBI","Completed","Has Results","Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: Total Body Irradiation (TBI)|Drug: Granulocyte colony-stimulating factor (G-CSF)|Drug: Phenytoin|Drug: Methotrexate","Phase 1|Phase 2","July 2, 2017","https://ClinicalTrials.gov/show/NCT00245037"
1649,"NCT00769613","Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections",,"Unknown status","No Results Available","Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes|Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes|Biological: therapeutic allogeneic lymphocytes|Genetic: polymerase chain reaction|Other: flow cytometry|Other: immunological diagnostic method|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00769613"
1650,"NCT00062140","Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT00062140"
1651,"NCT00003661","Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003661"
1652,"NCT00002750","Melphalan in Patients With Neoplastic Meningitis",,"Completed","No Results Available","Drug: melphalan","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002750"
1653,"NCT00003270","Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methylprednisolone|Procedure: bone marrow ablation with stem cell support|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003270"
1654,"NCT00093678","Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer",,"Withdrawn","No Results Available","Drug: celecoxib|Procedure: anticachectic therapy|Procedure: nutritional support|Procedure: pain therapy|Procedure: supportive care/therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00093678"
1655,"NCT00008307","Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders",,"Unknown status","No Results Available","Biological: anti-thymocyte globulin|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00008307"
1656,"NCT00994500","Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma",,"Completed","No Results Available","Drug: vorinostat|Drug: bortezomib|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00994500"
1657,"NCT00109993","Campath-1H + FK506 and Methylprednisolone for GVHD",,"Completed","No Results Available","Biological: alemtuzumab|Drug: methylprednisolone|Drug: tacrolimus","Phase 2","null","https://ClinicalTrials.gov/show/NCT00109993"
1658,"NCT00004239","506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment",,"Terminated","No Results Available","Drug: Compound 506U78","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004239"
1659,"NCT00020865","Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia",,"Unknown status","No Results Available","Drug: cefepime hydrochloride|Drug: levofloxacin","Phase 3","null","https://ClinicalTrials.gov/show/NCT00020865"
1660,"NCT00942409","Study of Repeat Intranodal Injections of Ad-ISF35",,"Terminated","Has Results","Biological: ISF35","Phase 2","November 20, 2015","https://ClinicalTrials.gov/show/NCT00942409"
1661,"NCT00004132","Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: filgrastim|Biological: palifermin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Procedure: quality-of-life assessment|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00004132"
1662,"NCT00569283","Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant",,"Completed","No Results Available","Biological: therapeutic allogeneic lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT00569283"
1663,"NCT00005852","Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant",,"Terminated","No Results Available","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: muromonab-CD3|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005852"
1664,"NCT00096096","Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",,"Completed","No Results Available","Drug: mycophenolate mofetil|Drug: tacrolimus","Phase 2","null","https://ClinicalTrials.gov/show/NCT00096096"
1665,"NCT03690895","Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy","LCPVIH","Completed","No Results Available","Other: Retrospective survival analysis","","null","https://ClinicalTrials.gov/show/NCT03690895"
1666,"NCT00538850","Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",,"Completed","Has Results","Drug: Fentanyl sublingual spray|Drug: Placebo","Phase 3","March 5, 2014","https://ClinicalTrials.gov/show/NCT00538850"
1667,"NCT00003425","Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect",,"Completed","No Results Available","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00003425"
1668,"NCT00003451","Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Biological: recombinant interferon alfa|Biological: recombinant interleukin-12","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003451"
1669,"NCT00003331","Combination Chemotherapy in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: fluorouracil|Drug: leucovorin calcium|Drug: topotecan hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003331"
1670,"NCT00003398","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Radiation: radiation therapy","Phase 4","null","https://ClinicalTrials.gov/show/NCT00003398"
1671,"NCT00004036","Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer",,"Unknown status","No Results Available","Biological: sargramostim|Drug: amifostine trihydrate|Drug: carboplatin|Drug: cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004036"
1672,"NCT00002980","Decitabine in Treating Patients With Melanoma or Other Advanced Cancer",,"Completed","No Results Available","Drug: decitabine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00002980"
1673,"NCT00068523","Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methylprednisolone|Procedure: UV light therapy|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00068523"
1674,"NCT00003406","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer",,"Completed","No Results Available","Drug: carboplatin|Drug: docetaxel|Drug: ifosfamide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00003406"
1675,"NCT00080925","T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",,"Completed","No Results Available","Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: fludarabine phosphate|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00080925"
1676,"NCT00509691","Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy",,"Completed","No Results Available","Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes|Genetic: polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: flow cytometry|Other: immunologic technique","Phase 1","null","https://ClinicalTrials.gov/show/NCT00509691"
1677,"NCT00004258","EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer",,"Completed","No Results Available","Drug: cilengitide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004258"
1678,"NCT00002504","Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer",,"Completed","No Results Available","Biological: aldesleukin|Biological: recombinant interferon alfa","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002504"
1679,"NCT00089037","Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",,"Completed","No Results Available","Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00089037"
1680,"NCT00005805","St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer",,"Completed","No Results Available","Dietary Supplement: St. John's wort","Phase 3","null","https://ClinicalTrials.gov/show/NCT00005805"
1681,"NCT00003082","Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Biological: monoclonal antibody A27.15|Biological: monoclonal antibody E2.3","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003082"
1682,"NCT00003805","Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count",,"Completed","No Results Available","Drug: piperacillin sodium|Drug: piperacillin-tazobactam|Drug: tazobactam sodium|Drug: vancomycin","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003805"
1683,"NCT00006225","Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer",,"Completed","No Results Available","Biological: filgrastim|Biological: recombinant flt3 ligand|Biological: recombinant human thrombopoietin|Biological: recombinant interleukin-3|Procedure: in vitro-treated peripheral blood stem cell transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00006225"
1684,"NCT00006083","Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter",,"Completed","No Results Available","Drug: Fragmin|Other: placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT00006083"
1685,"NCT00005634","Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy",,"Completed","No Results Available","Drug: vorinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005634"
1686,"NCT00082654","Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients",,"Completed","No Results Available","Procedure: psychosocial assessment and care","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00082654"
1687,"NCT00006042","Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT00006042"
1688,"NCT00003887","Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation",,"Completed","No Results Available","Biological: peripheral blood lymphocyte therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003887"
1689,"NCT00003116","High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003116"
1690,"NCT00027560","Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",,"Completed","Has Results","Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Phase 2","January 7, 2013","https://ClinicalTrials.gov/show/NCT00027560"
1691,"NCT00006348","Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment",,"Completed","No Results Available","Drug: ondansetron|Other: placebo","Phase 3","null","https://ClinicalTrials.gov/show/NCT00006348"
1692,"NCT00010283","Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon",,"Completed","No Results Available","Drug: beclomethasone dipropionate","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00010283"
1693,"NCT00019656","Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer",,"Completed","No Results Available","Drug: perifosine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00019656"
1694,"NCT00005967","Tipifarnib in Treating Patients With Advanced Hematologic Cancer",,"Completed","No Results Available","Drug: tipifarnib","Phase 1","null","https://ClinicalTrials.gov/show/NCT00005967"
1695,"NCT00003335","Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003335"
1696,"NCT00006368","Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer",,"Completed","No Results Available","Radiation: yttrium Y 90-edotreotide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00006368"
1697,"NCT00003107","Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors",,"Completed","No Results Available","Biological: recombinant interleukin-12","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003107"
1698,"NCT00445731","A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant",,"Completed","No Results Available","Behavioral: exercise intervention|Procedure: management of therapy complications|Procedure: observation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00445731"
1699,"NCT00445952","Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant",,"Completed","No Results Available","Other: clinical observation|Procedure: management of therapy complications","","null","https://ClinicalTrials.gov/show/NCT00445952"
1700,"NCT00004904","Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cladribine|Drug: cyclophosphamide|Drug: etoposide|Drug: methylprednisolone|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004904"
1701,"NCT00378781","Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection",,"Withdrawn","No Results Available","Drug: Heparin|Drug: Minocycline-EDTA","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00378781"
1702,"NCT00005804","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005804"
1703,"NCT00002520","Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer",,"Completed","No Results Available","Drug: nicotine|Behavioral: Usual Care","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00002520"
1704,"NCT00361049","Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant",,"Completed","No Results Available","Biological: graft versus host disease prophylaxis/therapy|Genetic: fluorescence in situ hybridization|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: in vitro-treated bone marrow transplantation|Procedure: management of therapy complications","Phase 1","null","https://ClinicalTrials.gov/show/NCT00361049"
1705,"NCT00357084","Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant",,"Completed","No Results Available","Drug: methotrexate|Drug: methylprednisolone|Drug: prednisone","Phase 2","null","https://ClinicalTrials.gov/show/NCT00357084"
1706,"NCT00042900","Pyroxamide in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: pyroxamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00042900"
1707,"NCT00054236","Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: umbilical cord blood transplantation|Drug: methylprednisolone","Phase 1","null","https://ClinicalTrials.gov/show/NCT00054236"
1708,"NCT00053196","Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: G-CSF|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic cell transplantation|Drug: allopurinol","Phase 2","null","https://ClinicalTrials.gov/show/NCT00053196"
1709,"NCT00053989","Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Biological: sargramostim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00053989"
1710,"NCT00064311","Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",,"Completed","No Results Available","Drug: ravuconazole","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00064311"
1711,"NCT00008164","Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia",,"Unknown status","No Results Available","Procedure: umbilical cord blood transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00008164"
1712,"NCT00053157","Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia",,"Completed","No Results Available","Biological: sargramostim","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00053157"
1713,"NCT00062231","Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer",,"Terminated","No Results Available","Drug: amoxicillin-clavulanate potassium|Drug: ciprofloxacin|Drug: moxifloxacin hydrochloride|Procedure: management of therapy complications","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00062231"
1714,"NCT00004232","Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclosporine|Drug: methylprednisolone|Drug: prednisone|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Phase 1","null","https://ClinicalTrials.gov/show/NCT00004232"
1715,"NCT00003408","Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer",,"Completed","No Results Available","Biological: aldesleukin|Biological: recombinant interferon alfa|Biological: sargramostim","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003408"
1716,"NCT00060255","High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors",,"Completed","No Results Available","Drug: busulfan|Drug: carboplatin|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00060255"
1717,"NCT01943682","Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma",,"Active, not recruiting","No Results Available","Drug: CPX-351","Phase 1","null","https://ClinicalTrials.gov/show/NCT01943682"
1718,"NCT00305851","Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant",,"Completed","No Results Available","Procedure: music therapy (books on tape)|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment|Behavioral: Music Video","Phase 3","null","https://ClinicalTrials.gov/show/NCT00305851"
1719,"NCT00003816","Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer",,"Active, not recruiting","No Results Available","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: thiotepa|Radiation: total-body irradiation","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT00003816"
1720,"NCT00003687","Treatment for Chronic Pain in Patients With Advanced Cancer",,"Completed","No Results Available","Drug: dextromethorphan hydrobromide|Drug: morphine sulfate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003687"
1721,"NCT00006379","Non-Ablative Allo HSCT For Hematologic Malignancies or SAA",,"Completed","No Results Available","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00006379"
1722,"NCT00008216","Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer",,"Terminated","No Results Available","Procedure: Peripheral Blood Stem Cell Transplantation","","null","https://ClinicalTrials.gov/show/NCT00008216"
1723,"NCT00014482","Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation",,"Completed","No Results Available","Procedure: pain therapy|Procedure: psychosocial assessment and care","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00014482"
1724,"NCT00036790","Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: doxorubicin hydrochloride|Drug: motexafin gadolinium","Phase 1","null","https://ClinicalTrials.gov/show/NCT00036790"
1725,"NCT00248547","Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant",,"Completed","Has Results","Drug: aprepitant|Drug: dexamethasone|Drug: ondansetron|Drug: placebo","Not Applicable","December 21, 2011","https://ClinicalTrials.gov/show/NCT00248547"
1726,"NCT00110045","Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant",,"Completed","No Results Available","Drug: caspofungin acetate","Phase 2","null","https://ClinicalTrials.gov/show/NCT00110045"
1727,"NCT02823327","Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma",,"Recruiting","No Results Available","Genetic: Laboratory Biomarker Analysis|Other: Medical Chart Review","","null","https://ClinicalTrials.gov/show/NCT02823327"
1728,"NCT01961063","Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Drug: busulfan|Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT01961063"
1729,"NCT02585947","To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: Tenofovir","Phase 4","null","https://ClinicalTrials.gov/show/NCT02585947"
1730,"NCT00131937","Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: sorafenib tosylate","Phase 2","September 3, 2015","https://ClinicalTrials.gov/show/NCT00131937"
1731,"NCT00089141","Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)",,"Terminated","Has Results","Drug: mycophenolate mofetil|Drug: placebo","Phase 3","August 26, 2009","https://ClinicalTrials.gov/show/NCT00089141"
1732,"NCT00217412","Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia",,"Completed","No Results Available","Drug: vorinostat|Drug: isotretinoin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00217412"
1733,"NCT00002673","Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation",,"Completed","No Results Available","Procedure: infection prophylaxis and management","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002673"
1734,"NCT00004230","Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation",,"Completed","No Results Available","Drug: captopril|Drug: cyclophosphamide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00004230"
1735,"NCT00014391","Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation",,"Completed","No Results Available","Biological: palivizumab|Drug: ribavirin","Phase 3","null","https://ClinicalTrials.gov/show/NCT00014391"
1736,"NCT00003883","Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation",,"Completed","No Results Available","Drug: fluconazole|Drug: itraconazole","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003883"
1737,"NCT00079222","Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",,"Completed","No Results Available","Drug: itraconazole|Drug: voriconazole","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00079222"
1738,"NCT00101270","Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas",,"Completed","No Results Available","Drug: irinotecan hydrochloride|Drug: oxaliplatin","Phase 1","null","https://ClinicalTrials.gov/show/NCT00101270"
1739,"NCT00073944","BCX-1777 in Treating Patients With Refractory Cancer",,"Completed","No Results Available","Drug: forodesine hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT00073944"
1740,"NCT00008359","Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment",,"Completed","No Results Available","Drug: caspofungin acetate|Drug: liposomal amphotericin B","Phase 3","null","https://ClinicalTrials.gov/show/NCT00008359"
1741,"NCT00060021","Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation",,"Completed","No Results Available","Procedure: acupuncture therapy|Procedure: management of therapy complications|Procedure: pain therapy","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00060021"
1742,"NCT00058019","Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",,"Completed","Has Results","Drug: ixabepilone","Phase 2","February 27, 2014","https://ClinicalTrials.gov/show/NCT00058019"
1743,"NCT00003938","Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients",,"Completed","No Results Available","Drug: liposomal amphotericin B","Phase 3","null","https://ClinicalTrials.gov/show/NCT00003938"
1744,"NCT00003538","Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation",,"Completed","No Results Available","Biological: graft versus host disease prophylaxis/therapy|Procedure: allogeneic bone marrow transplantation","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00003538"
1745,"NCT00049296","Thalidomide and Docetaxel in Treating Patients With Advanced Cancer",,"Completed","No Results Available","Drug: docetaxel|Drug: thalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT00049296"
1746,"NCT00049465","Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer",,"Completed","No Results Available","Procedure: fatigue assessment and management|Procedure: management of therapy complications|Procedure: psychosocial assessment and care","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00049465"
1747,"NCT00045292","Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation",,"Completed","No Results Available","Drug: acyclovir|Drug: acyclovir sodium|Drug: valacyclovir","Phase 3","null","https://ClinicalTrials.gov/show/NCT00045292"
1748,"NCT00086840","CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",,"Terminated","No Results Available","Drug: temsirolimus|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00086840"
1749,"NCT03638206","Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies",,"Recruiting","No Results Available","Biological: CAR-T cell immunotherapy","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03638206"
1750,"NCT02228512","Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas",,"Withdrawn","No Results Available","Drug: Pomalidomide|Drug: Rituximab|Drug: Prednisone|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02228512"
1751,"NCT02730312","PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies",,"Recruiting","No Results Available","Biological: XmAb14045","Phase 1","null","https://ClinicalTrials.gov/show/NCT02730312"
1752,"NCT03136146","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",,"Recruiting","No Results Available","Drug: Clofarabine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Liposomal Vincristine|Drug: Bortezomib|Drug: Ofatumumab|Drug: Rituximab|Drug: Pegfilgrastim|Drug: Dexamethasone","Phase 2","null","https://ClinicalTrials.gov/show/NCT03136146"
1753,"NCT00002649","Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: aldesleukin|Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy|Procedure: peripheral blood stem cell transplantation|Procedure: bone marrow ablation with stem cell support","Phase 3","null","https://ClinicalTrials.gov/show/NCT00002649"
1754,"NCT01623856","Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients",,"Completed","No Results Available","Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT01623856"
1755,"NCT03677128","Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment",,"Not yet recruiting","No Results Available","Other: mHealth Case Management System","Not Applicable","null","https://ClinicalTrials.gov/show/NCT03677128"
1756,"NCT01516593","Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","CARMEN","Unknown status","No Results Available","Drug: Induction Phase|Drug: Consolidation Phase (on day +50)|Drug: Intensification phase|Drug: BEAM conditioning|Radiation: Consolidation radiotherapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT01516593"
1757,"NCT02797470","Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant",,"Recruiting","No Results Available","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02797470"
1758,"NCT02378922","Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma",,"Suspended","No Results Available","Biological: Gene-Modified HIV-Protected Hematopoietic Stem Cells|Other: Laboratory Biomarker Analysis|Other: Transplant Conditioning","Phase 1","null","https://ClinicalTrials.gov/show/NCT02378922"
1759,"NCT01290120","Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma",,"Completed","No Results Available","Drug: Chemotherapy-Rituximab combination","Phase 2","null","https://ClinicalTrials.gov/show/NCT01290120"
1760,"NCT02240719","Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer",,"Active, not recruiting","No Results Available","Drug: everolimus|Drug: bendamustine hydrochloride","Phase 1","null","https://ClinicalTrials.gov/show/NCT02240719"
1761,"NCT01045889","High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk","HDT-HIV","Completed","No Results Available","Other: Rituximab and CHOP regimen + PBSCT","Phase 2","null","https://ClinicalTrials.gov/show/NCT01045889"
1762,"NCT01196520","Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01196520"
1763,"NCT00669877","Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma",,"Completed","Has Results","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: G-CSF|Drug: Cytarabine|Drug: Methotrexate","Phase 2","May 16, 2018","https://ClinicalTrials.gov/show/NCT00669877"
1764,"NCT00392834","Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma",,"Completed","Has Results","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: liposomal cytarabine|Drug: methotrexate|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Phase 2","February 28, 2013","https://ClinicalTrials.gov/show/NCT00392834"
1765,"NCT00392990","Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma",,"Active, not recruiting","No Results Available","Drug: Regimen A|Drug: Regimen B","Phase 2","null","https://ClinicalTrials.gov/show/NCT00392990"
1766,"NCT00217503","Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma",,"Completed","No Results Available","Biological: bevacizumab|Biological: filgrastim|Biological: pegfilgrastim|Drug: bortezomib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ganciclovir|Drug: valganciclovir|Drug: zidovudine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00217503"
1767,"NCT00002003","Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas",,"Completed","No Results Available","Drug: Mitoxantrone hydrochloride|Drug: Etoposide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002003"
1768,"NCT00002524","Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma",,"Completed","No Results Available","Biological: Bleomycin Sulfate|Biological: Filgrastim|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin Hydrochloride (DOX)|Drug: Etoposide|Drug: Fluorouracil|Drug: Ifosfamide|Drug: Leucovorin calcium|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Pentamidine|Drug: Prednisone|Drug: Trimethoprim-Sulfamethoxazole|Drug: Vincristine Sulfate|Drug: Zidovudine (AZT)|Radiation: Radiation Therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002524"
1769,"NCT00388193","Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma",,"Completed","No Results Available","Drug: RITUXIMAB","Phase 2","null","https://ClinicalTrials.gov/show/NCT00388193"
1770,"NCT00126243","Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma",,"Terminated","No Results Available","Drug: rituximab|Drug: CHOP","Phase 2","null","https://ClinicalTrials.gov/show/NCT00126243"
1771,"NCT00126191","Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma",,"Terminated","Has Results","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Methotrexate|Drug: Leucovorin|Drug: Ifosfamide|Drug: Etoposide|Drug: Cytarabine|Drug: Mesna","Phase 2","May 23, 2013","https://ClinicalTrials.gov/show/NCT00126191"
1772,"NCT00024128","Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma",,"Withdrawn","No Results Available","Biological: anti-thymocyte globulin|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00024128"
1773,"NCT00002571","SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma",,"Completed","No Results Available","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: trimethoprim-sulfamethoxazole|Drug: vincristine sulfate|Radiation: radiation therapy|Drug: Intrathecal cytarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00002571"
1774,"NCT00621036","Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma",,"Unknown status","No Results Available","Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: sargramostim|Drug: methotrexate|Drug: thiotepa|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00621036"
1775,"NCT01164436","Cohort of HIV Associated Lymphomas","ANRS CO16","Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01164436"
1776,"NCT00310128","Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma",,"Withdrawn","No Results Available","Drug: cisplatin|Drug: cytarabine|Drug: etoposide|Drug: methylprednisolone|Drug: rituximab|Drug: yttrium Y 90 ibritumomab tiuxetan|Procedure: antibody therapy|Procedure: biological therapy|Procedure: chemotherapy|Procedure: monoclonal antibody therapy|Procedure: radiation therapy|Procedure: radioimmunotherapy|Procedure: radioisotope therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00310128"
1777,"NCT00267865","Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma",,"Recruiting","No Results Available","Drug: Methotrexate|Drug: Rituximab|Drug: Leucovorin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00267865"
1778,"NCT00133991","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia",,"Completed","Has Results","Biological: Filgrastim|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Methotrexate|Drug: Prednisone|Drug: Hydrocortisone|Drug: Vincristine|Drug: Leucovorin","Phase 2","September 17, 2018","https://ClinicalTrials.gov/show/NCT00133991"
1779,"NCT02443831","CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies",,"Recruiting","No Results Available","Procedure: Leukapheresis|Drug: Lymphodepletion with fludarabine|Drug: Lymphodepletion with cyclophosphamide|Biological: CD19 CAR T-cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02443831"
1780,"NCT01088763","Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia",,"Terminated","No Results Available","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study|Drug: dexamethasone","Phase 1","null","https://ClinicalTrials.gov/show/NCT01088763"
1781,"NCT00005824","Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005824"
1782,"NCT00180882","LMBA02 Protocol for Patients With a Burkitt Lymphoma",,"Unknown status","No Results Available","Drug: rituximab","Phase 3","null","https://ClinicalTrials.gov/show/NCT00180882"
1783,"NCT00871546","SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)",,"Terminated","No Results Available","Drug: SCH 727965|Drug: Bortezomib|Biological: Alemtuzumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00871546"
1784,"NCT03674411","Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy",,"Not yet recruiting","No Results Available","Drug: Fludarabine (FLU)|Drug: Cyclophosphamide (CY)|Drug: Total Body Irradiation (TBI)|Drug: Tacrolimus (Tac)|Drug: Mycophenolate Mofetil (MMF)|Drug: Granulocyte Colony-Stimulating Factor (G-CSF)|Drug: Busulfan (BU)|Drug: Melphalan|Drug: MGTA 456 Infusion","Phase 2","null","https://ClinicalTrials.gov/show/NCT03674411"
1785,"NCT00040690","Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00040690"
1786,"NCT00039130","Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia",,"Completed","Has Results","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Drug: Allopurinol","Phase 2","October 22, 2014","https://ClinicalTrials.gov/show/NCT00039130"
1787,"NCT02931110","Study of IV CBL0137 in Previously Treated Hematological Subjects",,"Recruiting","No Results Available","Drug: CBL0137","Phase 1","null","https://ClinicalTrials.gov/show/NCT02931110"
1788,"NCT00598624","Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)","AlloTreo","Unknown status","No Results Available","Drug: Treosulfan IV","Phase 2","null","https://ClinicalTrials.gov/show/NCT00598624"
1789,"NCT00226304","Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00226304"
1790,"NCT00001563","EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma",,"Completed","No Results Available","Biological: Filgrastim|Biological: Rituximab|Drug: EPOCH","Phase 2","null","https://ClinicalTrials.gov/show/NCT00001563"
1791,"NCT00514722","Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies",,"Terminated","No Results Available","Other: umbilical cord stem cells","Not Applicable","null","https://ClinicalTrials.gov/show/NCT00514722"
1792,"NCT02822495","Expanded Access Protocol for Tabelecleucel for Patients With EBV-Associated Viremia or Malignancies (ATA129-EAP-901)",,"Available","No Results Available","Biological: tabelecleucel","","null","https://ClinicalTrials.gov/show/NCT02822495"
1793,"NCT00858793","High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT",,"Completed","No Results Available","Procedure: PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00858793"
1794,"NCT00001571","A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00001571"
1795,"NCT02199184","Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)",,"Recruiting","No Results Available","Drug: Ofatumumab|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Rituximab|Drug: Pegfilgrastim|Drug: G-CSF|Behavioral: Phone Calls","Phase 2","null","https://ClinicalTrials.gov/show/NCT02199184"
1796,"NCT01513603","Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia",,"Unknown status","No Results Available","Drug: CLAG-M","Phase 2","null","https://ClinicalTrials.gov/show/NCT01513603"
1797,"NCT01676805","Tissue Collection for Studies of Lymph Cancer",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01676805"
1798,"NCT02898870","Occupational Exposure to Pesticides in the Prognosis of Lymphomas","ProLyPhy","Terminated","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02898870"
1799,"NCT00060372","Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer",,"Completed","No Results Available","Drug: ipilimumab|Drug: therapeutic allogeneic lymphocytes","Phase 1","null","https://ClinicalTrials.gov/show/NCT00060372"
1800,"NCT01597778","Double Cord Versus Haploidentical (BMT CTN 1101)",,"Active, not recruiting","No Results Available","Biological: Haploidentical Bone Marrow Transplant|Biological: Double Umbilical Cord Blood Transplant","Phase 3","null","https://ClinicalTrials.gov/show/NCT01597778"
1801,"NCT01219816","Multi-centric Study","CHEPRALL","Completed","No Results Available","Drug: Epratuzumab","Phase 2","null","https://ClinicalTrials.gov/show/NCT01219816"
1802,"NCT00412243","Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients",,"Completed","Has Results","Drug: Clofarabine|Drug: Cyclophosphamide","Phase 1|Phase 2","March 4, 2013","https://ClinicalTrials.gov/show/NCT00412243"
1803,"NCT00363272","Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: ispinesib|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT00363272"
1804,"NCT00064246","Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder",,"Completed","No Results Available","Biological: rituximab|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00064246"
1805,"NCT01564277","Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies",,"Terminated","Has Results","Drug: rasburicase|Drug: allopurinol","Phase 2","December 8, 2017","https://ClinicalTrials.gov/show/NCT01564277"
1806,"NCT01184885","A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",,"Completed","Has Results","Drug: Hyper-CVAD|Drug: Sirolimus","Early Phase 1","January 3, 2014","https://ClinicalTrials.gov/show/NCT01184885"
1807,"NCT00898755","Collecting and Storing Tissue From Young Patients With Cancer",,"Completed","No Results Available","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","","null","https://ClinicalTrials.gov/show/NCT00898755"
1808,"NCT00776373","Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies","UPCC 25406","Terminated","No Results Available","Drug: Rapamycin + high dose etoposide and cytarabine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00776373"
1809,"NCT00005811","Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment",,"Completed","No Results Available","Drug: topotecan hydrochloride|Other: laboratory biomarker analysis","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005811"
1810,"NCT00001120","A Study of Patients With AIDS Syndrome",,"Completed","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00001120"
1811,"NCT00001379","Treatment and Natural History Study of Lymphomatoid Granulomatosis",,"Recruiting","No Results Available","Biological: Interferon|Drug: Rituxan and EPOCH","Phase 2","null","https://ClinicalTrials.gov/show/NCT00001379"
1812,"NCT00006518","Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00006518"
1813,"NCT00702052","Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.","PILLAR-1","Completed","No Results Available","Drug: RAD001","Phase 2","null","https://ClinicalTrials.gov/show/NCT00702052"
1814,"NCT00413075","Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: oral belinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT00413075"
1815,"NCT00596804","Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: veltuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00596804"
1816,"NCT01317901","A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma",,"Completed","Has Results","Drug: TRU-016|Drug: Bendamustine|Drug: Rituximab","Phase 1","October 6, 2016","https://ClinicalTrials.gov/show/NCT01317901"
1817,"NCT00889798","Tumor Registry of Lymphatic Neoplasia","TLN-Registry","Active, not recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT00889798"
1818,"NCT02144623","Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia","PREVAIL","Completed","No Results Available","Drug: Valproate","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT02144623"
1819,"NCT00383994","Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation",,"Active, not recruiting","No Results Available","Drug: GM-CSF|Drug: Rituximab|Biological: NK Cell Infusion","Phase 1","null","https://ClinicalTrials.gov/show/NCT00383994"
1820,"NCT02392039","Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma",,"Terminated","No Results Available","Drug: Pegfilgrastim|Drug: Loratadine|Other: Placebo|Behavioral: Questionnaires","Early Phase 1","null","https://ClinicalTrials.gov/show/NCT02392039"
1821,"NCT02718755","Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies",,"Withdrawn","No Results Available","Drug: Fludarabine|Drug: Cytarabine|Drug: Erwinase","Phase 2","null","https://ClinicalTrials.gov/show/NCT02718755"
1822,"NCT02961816","Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma",,"Withdrawn","No Results Available","Drug: Palifermin|Drug: Panobinostat|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Rituximab|Drug: Dexamethasone|Drug: Caphosol|Drug: Glutamine|Other: Oral Cryotherapy (ice chips)|Drug: Pyridoxine|Biological: Stem Cell Infusion|Drug: G-CSF","Phase 2","null","https://ClinicalTrials.gov/show/NCT02961816"
1823,"NCT02186821","Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)","SIGNATURE","Completed","No Results Available","Drug: Ceritinib (LDK378)","Phase 2","null","https://ClinicalTrials.gov/show/NCT02186821"
1824,"NCT00602693","T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer",,"Completed","No Results Available","Biological: umbilical cord blood transplantation|Drug: Allopurinol|Drug: fludarabine phosphate|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Treg infusion|Drug: Sirolimus","Phase 1","null","https://ClinicalTrials.gov/show/NCT00602693"
1825,"NCT03259503","Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas",,"Not yet recruiting","No Results Available","Drug: Palifermin|Drug: Olaparib|Drug: Vorinostat|Drug: Dexamethasone|Drug: Rituximab|Drug: Caphosol|Drug: Glutamine|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Drug: Pyridoxine|Procedure: Autologous Stem-Cell Transplant|Drug: G-CSF","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03259503"
1826,"NCT02978235","A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma",,"Terminated","No Results Available","Drug: TAS4464","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02978235"
1827,"NCT02446457","Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma",,"Active, not recruiting","No Results Available","Drug: Rituximab|Drug: Pembrolizumab|Drug: Lenalidomide","Phase 2","null","https://ClinicalTrials.gov/show/NCT02446457"
1828,"NCT02420795","Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Drug: ONC201|Behavioral: Phone Call","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02420795"
1829,"NCT00785330","Allo-hNHL (FluBuCy)",,"Unknown status","No Results Available","Drug: standard GVHD prophylaxis|Drug: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00785330"
1830,"NCT00244946","Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation (PBSCT)","Phase 1","null","https://ClinicalTrials.gov/show/NCT00244946"
1831,"NCT02274506","Infusion of Allogeneic, 3rd Party CD19-specific T Cells",,"Withdrawn","No Results Available","Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: T-Cell Infusion","Phase 1","null","https://ClinicalTrials.gov/show/NCT02274506"
1832,"NCT01998035","Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies",,"Recruiting","No Results Available","Drug: Romidepsin|Drug: Oral 5-Azacitidine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01998035"
1833,"NCT01497184","Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",,"Active, not recruiting","No Results Available","Procedure: HSCT|Genetic: DLI","Phase 1","null","https://ClinicalTrials.gov/show/NCT01497184"
1834,"NCT01947140","Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies","PDX+Romi","Recruiting","No Results Available","Drug: Pralatrexate|Drug: Romidepsin","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01947140"
1835,"NCT00712556","PET Study in Patients With Non-Hodgkin Lymphoma",,"Completed","No Results Available","Radiation: fluorine 18-fludeoxyglucose positron emission tomography","","null","https://ClinicalTrials.gov/show/NCT00712556"
1836,"NCT02298816","B-Cell Hematologic Malignancy Vaccination Registry","HMvax-Regist","Enrolling by invitation","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT02298816"
1837,"NCT00980395","Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma","VCR","Active, not recruiting","No Results Available","Drug: rituximab|Drug: bortezomib|Drug: cladribine","Phase 2","null","https://ClinicalTrials.gov/show/NCT00980395"
1838,"NCT02238522","Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML",,"Withdrawn","No Results Available","Drug: ZEN003365","Phase 1","null","https://ClinicalTrials.gov/show/NCT02238522"
1839,"NCT02118311","Treg Cells for AGVHD in Non-myeloablative UCB Transplant",,"Withdrawn","No Results Available","Biological: T Regulatory cells|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation","Phase 2","null","https://ClinicalTrials.gov/show/NCT02118311"
1840,"NCT01353625","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",,"Active, not recruiting","No Results Available","Drug: CC-115","Phase 1","null","https://ClinicalTrials.gov/show/NCT01353625"
1841,"NCT01827579","Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)","ICAT","Recruiting","No Results Available","Biological: CD25/71 allodepleted donor T-cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT01827579"
1842,"NCT00014326","Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Radiation: radiation therapy","Phase 3","null","https://ClinicalTrials.gov/show/NCT00014326"
1843,"NCT02431260","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",,"Completed","No Results Available","Drug: INCB054329 Monotherapy","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02431260"
1844,"NCT00719849","Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease",,"Terminated","Has Results","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total body irradiation","Phase 2","June 14, 2017","https://ClinicalTrials.gov/show/NCT00719849"
1845,"NCT03082209","A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies",,"Recruiting","No Results Available","Drug: ABBV-621|Drug: Venetoclax","Phase 1","null","https://ClinicalTrials.gov/show/NCT03082209"
1846,"NCT02711137","Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",,"Active, not recruiting","No Results Available","Drug: INCB057643|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Rucaparib|Drug: Abiraterone|Drug: Ruxolitinib|Drug: Azacitidine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02711137"
1847,"NCT00719472","A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)","RATE","Completed","Has Results","Drug: Rituximab|Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Drug: CVP (cyclophosphamide, vincristine, prednisone)|Drug: Analgesic/antipyretic and antihistamine drugs","Phase 3","June 26, 2012","https://ClinicalTrials.gov/show/NCT00719472"
1848,"NCT00957736","Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant",,"Terminated","No Results Available","Genetic: polymorphism analysis|Other: laboratory biomarker analysis","","null","https://ClinicalTrials.gov/show/NCT00957736"
1849,"NCT02933775","CD19-redirected Autologous Cells (CAR-CD19 T Cells)",,"Not yet recruiting","No Results Available","Genetic: CAR-CD19 T cells|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT02933775"
1850,"NCT01705847","A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies",,"Completed","No Results Available","Drug: GS-9820","Phase 1","null","https://ClinicalTrials.gov/show/NCT01705847"
1851,"NCT03597685","Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes","ProLyPhy-GEP","Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03597685"
1852,"NCT00742495","Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.","BCX1777-108","Terminated","No Results Available","Drug: Forodesine","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00742495"
1853,"NCT01117142","A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers",,"Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT01117142"
1854,"NCT00251394","Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma",,"Completed","No Results Available","Drug: Rituxan|Drug: 1018 ISS","Phase 2","null","https://ClinicalTrials.gov/show/NCT00251394"
1855,"NCT02875002","Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas",,"Withdrawn","No Results Available","Drug: volasertib|Drug: belinostat","Phase 1","null","https://ClinicalTrials.gov/show/NCT02875002"
1856,"NCT01144754","Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT",,"Terminated","No Results Available","Drug: Rituximab","","null","https://ClinicalTrials.gov/show/NCT01144754"
1857,"NCT01005979","A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)",,"Terminated","No Results Available","Drug: Lenalidomide, Rituximab, and Cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01005979"
1858,"NCT02988466","Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic",,"Recruiting","No Results Available","Biological: Haplo HCT <55 years old|Biological: Haplo HCT ≥55 years old|Drug: GVHD Prophylaxis","Phase 2","null","https://ClinicalTrials.gov/show/NCT02988466"
1859,"NCT01990534","A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma",,"Active, not recruiting","Has Results","Drug: Brentuximab vedotin","Phase 4","May 5, 2017","https://ClinicalTrials.gov/show/NCT01990534"
1860,"NCT01126502","Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia",,"Terminated","No Results Available","Drug: alvespimycin hydrochloride|Other: diagnostic laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01126502"
1861,"NCT02349698","A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma",,"Recruiting","No Results Available","Biological: Chimeric Antigen Receptor Modified T cells Targeting CD19","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02349698"
1862,"NCT02556346","Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Withdrawn","No Results Available","Drug: MT-3724","Phase 1","null","https://ClinicalTrials.gov/show/NCT02556346"
1863,"NCT01153971","A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas",,"Completed","Has Results","Drug: rituximab","Phase 2","August 21, 2014","https://ClinicalTrials.gov/show/NCT01153971"
1864,"NCT00365274","SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma",,"Terminated","Has Results","Drug: Cyclophosphamide|Drug: Doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: SGN-30","Phase 2","November 18, 2013","https://ClinicalTrials.gov/show/NCT00365274"
1865,"NCT00103779","A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: SGN-40 (anti-huCD40 mAb)","Phase 1","null","https://ClinicalTrials.gov/show/NCT00103779"
1866,"NCT00825149","A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma","GAUDI","Completed","No Results Available","Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Fludarabine|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine","Phase 1","null","https://ClinicalTrials.gov/show/NCT00825149"
1867,"NCT01685008","Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)",,"Active, not recruiting","No Results Available","Drug: MOR00208 (formerly Xmab 5574)","Phase 2","null","https://ClinicalTrials.gov/show/NCT01685008"
1868,"NCT01289223","A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.","ROBIN","Terminated","No Results Available","Drug: Bendamustine IV|Other: Treatment of Physicians Choice","Phase 3","null","https://ClinicalTrials.gov/show/NCT01289223"
1869,"NCT02315118","Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies",,"Recruiting","No Results Available","Drug: T-cell therapy + Rituximab + IL-2","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02315118"
1870,"NCT00724984","Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma","PCYC-0403","Completed","Has Results","Drug: PCI-24781","Phase 1|Phase 2","April 7, 2014","https://ClinicalTrials.gov/show/NCT00724984"
1871,"NCT00521261","Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Withdrawn","No Results Available","Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT00521261"
1872,"NCT00377104","Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Terminated","No Results Available","Drug: alvocidib|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00377104"
1873,"NCT01273090","Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma",,"Completed","No Results Available","Drug: imetelstat sodium|Other: laboratory biomarker analysis|Other: pharmacological study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01273090"
1874,"NCT03088878","A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",,"Recruiting","No Results Available","Drug: Cirmtuzumab|Drug: Ibrutinib|Drug: Cirmtuzumab plus ibrutinib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03088878"
1875,"NCT03384654","A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",,"Recruiting","No Results Available","Drug: Daratumumab|Drug: Vincristine|Drug: Prednisone|Drug: Doxorubicin|Biological: Peg-asparaginase|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: 6-mercaptopurine|Drug: Methotrexate","Phase 2","null","https://ClinicalTrials.gov/show/NCT03384654"
1876,"NCT03331198","Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",,"Recruiting","No Results Available","Biological: JCAR017 (lisocabtagene maraleucel)|Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib|Drug: Standard of care","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03331198"
1877,"NCT01589302","PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia",,"Active, not recruiting","No Results Available","Drug: ibrutinib|Other: Correlative laboratory samples|Other: quality of life assessment","Phase 2","null","https://ClinicalTrials.gov/show/NCT01589302"
1878,"NCT03425591","A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice","FIRE","Recruiting","No Results Available","Drug: Ibrutinib","","null","https://ClinicalTrials.gov/show/NCT03425591"
1879,"NCT01744626","Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",,"Completed","No Results Available","Drug: CC-292|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01744626"
1880,"NCT03420183","A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",,"Recruiting","No Results Available","Drug: Cirmtuzumab followed by Cirmtuzumab plus ibrutinib|Drug: Cirmtuzumab plus ibrutinib|Drug: Ibrutinib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03420183"
1881,"NCT02488512","Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas","itTRIOlym","Terminated","No Results Available","Drug: 90Y-DOTATOC","Phase 2","null","https://ClinicalTrials.gov/show/NCT02488512"
1882,"NCT03289182","An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)",,"Recruiting","No Results Available","Drug: MabThera","","null","https://ClinicalTrials.gov/show/NCT03289182"
1883,"NCT03190330","A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion",,"Not yet recruiting","No Results Available","Drug: Ibrutinib 420 mg|Drug: Ibrutinib 560 mg","Phase 4","null","https://ClinicalTrials.gov/show/NCT03190330"
1884,"NCT00602836","Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","Has Results","Biological: Rituximab|Drug: Cyclophosphamide|Drug: Lenalidomide|Drug: Pentostatin","Phase 2","April 11, 2012","https://ClinicalTrials.gov/show/NCT00602836"
1885,"NCT02309515","Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis",,"Active, not recruiting","No Results Available","Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Pneumococcal 13-valent Conjugate Vaccine","Phase 2","null","https://ClinicalTrials.gov/show/NCT02309515"
1886,"NCT02406742","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","ENHANCE","Active, not recruiting","No Results Available","Drug: CC-122|Drug: Ibrutinib|Drug: Obinutuzumab","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02406742"
1887,"NCT00058240","Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma",,"Completed","Has Results","Drug: alvocidib","Phase 1|Phase 2","June 2, 2017","https://ClinicalTrials.gov/show/NCT00058240"
1888,"NCT00646750","Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom","Z-BEAM LDGGB","Completed","No Results Available","Drug: Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)","Phase 2","null","https://ClinicalTrials.gov/show/NCT00646750"
1889,"NCT00385125","Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL",,"Unknown status","No Results Available","Drug: Bendamustine|Drug: Rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00385125"
1890,"NCT03110640","Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma",,"Not yet recruiting","No Results Available","Biological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide","Phase 1","null","https://ClinicalTrials.gov/show/NCT03110640"
1891,"NCT03476655","Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India",,"Recruiting","No Results Available","Drug: Ibrutinib","","null","https://ClinicalTrials.gov/show/NCT03476655"
1892,"NCT00049413","Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00049413"
1893,"NCT02013128","Ublituximab + Ibrutinib in Select B-cell Malignancies",,"Active, not recruiting","No Results Available","Drug: Ublituximab|Drug: Ibrutinib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02013128"
1894,"NCT03671590","Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies",,"Recruiting","No Results Available","Drug: TG-1701|Drug: Umbralisib|Biological: Ublituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT03671590"
1895,"NCT01732861","Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma",,"Active, not recruiting","No Results Available","Drug: CC-292|Drug: Lenalidomide","Phase 1","null","https://ClinicalTrials.gov/show/NCT01732861"
1896,"NCT02290951","A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies",,"Recruiting","No Results Available","Drug: REGN1979 multiple dose levels","Phase 1","null","https://ClinicalTrials.gov/show/NCT02290951"
1897,"NCT00504972","Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies",,"Completed","No Results Available","Drug: hLL1","Phase 1","null","https://ClinicalTrials.gov/show/NCT00504972"
1898,"NCT02006485","Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies",,"Active, not recruiting","No Results Available","Drug: Ublituximab + TGR-1202|Drug: Ublituximab + TGR-1202 + ibrutinib|Drug: Ublituximab + TGR-1202 + bendamustine","Phase 1","null","https://ClinicalTrials.gov/show/NCT02006485"
1899,"NCT00151320","Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL",,"Completed","Has Results","Drug: Bortezomib, CHOP, Rituximab","Phase 1|Phase 2","April 7, 2017","https://ClinicalTrials.gov/show/NCT00151320"
1900,"NCT00398112","Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","Has Results","Drug: sunitinib malate|Other: pharmacological study|Other: laboratory biomarker analysis","Phase 2","February 10, 2014","https://ClinicalTrials.gov/show/NCT00398112"
1901,"NCT03462719","A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",,"Recruiting","No Results Available","Drug: Ibrutinib|Drug: Venetoclax|Drug: Chlorambucil|Drug: Obinutuzumab","Phase 3","null","https://ClinicalTrials.gov/show/NCT03462719"
1902,"NCT02916316","Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell",,"Recruiting","No Results Available","Drug: R-CHOP with doxorubicin","","null","https://ClinicalTrials.gov/show/NCT02916316"
1903,"NCT00816595","Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","Has Results","Biological: bevacizumab|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Phase 2","May 9, 2014","https://ClinicalTrials.gov/show/NCT00816595"
1904,"NCT00421395","Safety Study of NHL With 90Y-hLL2 IgG",,"Completed","No Results Available","Biological: 90Y-hLL2","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00421395"
1905,"NCT02315612","Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies",,"Recruiting","No Results Available","Biological: CD22-CAR","Phase 1","null","https://ClinicalTrials.gov/show/NCT02315612"
1906,"NCT01116193","Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia","RV-405 LAL","Completed","No Results Available","Drug: Lenalidomide plus dexamethasone","Phase 2","null","https://ClinicalTrials.gov/show/NCT01116193"
1907,"NCT03344809","Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing","ENABLE-NGS","Recruiting","No Results Available","","","null","https://ClinicalTrials.gov/show/NCT03344809"
1908,"NCT01076556","Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Terminated","No Results Available","Drug: Alvocidib Hydrochloride|Drug: Cyclophosphamide|Other: Diagnostic Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT01076556"
1909,"NCT01430390","In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies",,"Recruiting","No Results Available","Biological: Biological/Genetically Modified T cells|Drug: Cyclophosphamide-based chemotherapy","Phase 1","null","https://ClinicalTrials.gov/show/NCT01430390"
1910,"NCT00005977","Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate","Phase 3","null","https://ClinicalTrials.gov/show/NCT00005977"
1911,"NCT02268851","A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",,"Active, not recruiting","No Results Available","Drug: TGR-1202|Drug: Ibrutinib","Phase 1","null","https://ClinicalTrials.gov/show/NCT02268851"
1912,"NCT01570049","Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma",,"Unknown status","No Results Available","Drug: Bendamustine","Phase 3","null","https://ClinicalTrials.gov/show/NCT01570049"
1913,"NCT00864942","Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)","Phase I BLR","Completed","No Results Available","Drug: bendamustine and lenalidomide|Drug: BL-NHL|Drug: BLR-CLL|Drug: BLR-NHL","Phase 1","null","https://ClinicalTrials.gov/show/NCT00864942"
1914,"NCT00003217","Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vincristine sulfate","Phase 1","null","https://ClinicalTrials.gov/show/NCT00003217"
1915,"NCT00334438","Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Biological: rituximab|Drug: bortezomib|Radiation: yttrium Y 90 ibritumomab tiuxetan|Radiation: Indium 111 ibritumomab tiuxetan","Phase 1","null","https://ClinicalTrials.gov/show/NCT00334438"
1916,"NCT00003849","Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease",,"Completed","No Results Available","Biological: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003849"
1917,"NCT01403948","BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)",,"Completed","No Results Available","Drug: BI 836826","Phase 1","null","https://ClinicalTrials.gov/show/NCT01403948"
1918,"NCT00918723","Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Active, not recruiting","Has Results","Drug: Fludarabine Phosphate|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Vorinostat","Phase 1|Phase 2","February 8, 2018","https://ClinicalTrials.gov/show/NCT00918723"
1919,"NCT00476047","Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission",,"Completed","Has Results","Combination Product: Tositumomab and Iodine I 131 Tositumomab","Phase 2","October 12, 2017","https://ClinicalTrials.gov/show/NCT00476047"
1920,"NCT02710149","A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies",,"Recruiting","No Results Available","Biological: Anti-CD20-CAR-transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02710149"
1921,"NCT00735930","Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","No Results Available","Drug: Alvocidib Hydrochloride|Drug: Lenalidomide|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis","Phase 1","null","https://ClinicalTrials.gov/show/NCT00735930"
1922,"NCT02935153","A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies",,"Recruiting","No Results Available","Biological: Anti-CD22-CAR-transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02935153"
1923,"NCT00039351","Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Phase 2","null","https://ClinicalTrials.gov/show/NCT00039351"
1924,"NCT03262298","Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies",,"Recruiting","No Results Available","Biological: Anti-CD22-CAR-transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03262298"
1925,"NCT00005631","Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide","Phase 2","null","https://ClinicalTrials.gov/show/NCT00005631"
1926,"NCT00060385","Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma",,"Terminated","No Results Available","Drug: CHOP regimen|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Phase 2|Phase 3","null","https://ClinicalTrials.gov/show/NCT00060385"
1927,"NCT03191773","A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies",,"Recruiting","No Results Available","Combination Product: Drugs and anti-CD19 CAR transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03191773"
1928,"NCT03076437","Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies",,"Recruiting","No Results Available","Combination Product: Drugs and Anti-CD19-CAR transduced T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT03076437"
1929,"NCT02651662","Study of REGN2810 and REGN1979 in Patients With Lymphoma",,"Recruiting","No Results Available","Drug: REGN2810|Drug: REGN1979","Phase 1","null","https://ClinicalTrials.gov/show/NCT02651662"
1930,"NCT02456350","Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies",,"Recruiting","No Results Available","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR transduced T cells","Phase 1","null","https://ClinicalTrials.gov/show/NCT02456350"
1931,"NCT00107380","S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma",,"Completed","Has Results","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: tositumomab and iodine I 131 tositumomab","Phase 2","February 11, 2014","https://ClinicalTrials.gov/show/NCT00107380"
1932,"NCT02050347","Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)","CARPASCIO","Recruiting","No Results Available","Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2|Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1","Phase 1","null","https://ClinicalTrials.gov/show/NCT02050347"
1933,"NCT03677596","A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",,"Not yet recruiting","No Results Available","Drug: inotuzumab ozogamicin-dose level 2|Drug: Inotuzumab ozogamicin-dose level 1","Phase 4","null","https://ClinicalTrials.gov/show/NCT03677596"
1934,"NCT02328014","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",,"Unknown status","No Results Available","Drug: ACP-196 and ACP-319","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02328014"
1935,"NCT00003658","Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers",,"Completed","No Results Available","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003658"
1936,"NCT03151057","Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies",,"Recruiting","No Results Available","Drug: Idelalisib 100 MG|Drug: Placebo Oral Tablet","Phase 1","null","https://ClinicalTrials.gov/show/NCT03151057"
1937,"NCT00873457","Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",,"Completed","Has Results","Drug: perifosine","Phase 2","January 24, 2013","https://ClinicalTrials.gov/show/NCT00873457"
1938,"NCT02795182","BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies",,"Recruiting","No Results Available","Drug: BGB-3111|Drug: BGB-A317","Phase 1","null","https://ClinicalTrials.gov/show/NCT02795182"
1939,"NCT02537977","CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy",,"Recruiting","No Results Available","Biological: CD19-directed CAR-T cells","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT02537977"
1940,"NCT01120457","First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers",,"Completed","No Results Available","Drug: BMS-936564 (Anti-CXCR4)","Phase 1","null","https://ClinicalTrials.gov/show/NCT01120457"
1941,"NCT00669318","Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Completed","Has Results","Biological: alemtuzumab|Biological: rituximab|Drug: pentostatin|Drug: sargramostim","Phase 2","June 20, 2014","https://ClinicalTrials.gov/show/NCT00669318"
1942,"NCT01515176","Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia",,"Completed","Has Results","Drug: Dinaciclib|Other: Laboratory Biomarker Analysis|Biological: Ofatumumab|Other: Pharmacological Study","Phase 1|Phase 2","March 15, 2018","https://ClinicalTrials.gov/show/NCT01515176"
1943,"NCT02662296","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",,"Withdrawn","No Results Available","Drug: Ibrutinib|Drug: Idelalisib","Phase 2","null","https://ClinicalTrials.gov/show/NCT02662296"
1944,"NCT00905398","Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","ALLPhi","Terminated","No Results Available","Drug: Nilotinib","Phase 1|Phase 2","null","https://ClinicalTrials.gov/show/NCT00905398"
1945,"NCT02518750","Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma",,"Terminated","No Results Available","Drug: Dexamethasone|Drug: Panobinostat|Drug: Liposomal vincristine|Drug: Mitoxantrone|Drug: Peg-asparaginase|Drug: Bortezomib|Drug: Intrathecal Triples|Drug: High-dose methotrexate|Drug: 6-Mercaptopurine|Drug: High-dose cytarabine|Drug: Nelarabine|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Clofarabine","Phase 2","null","https://ClinicalTrials.gov/show/NCT02518750"
1946,"NCT01212380","Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)",,"Completed","No Results Available","Drug: carfilzomib|Other: Cytokine Assessment|Other: Pharmacodynamic Studies|Other: Proteosome Inhibition Assessment|Other: Pharmacogenomic Studies","Phase 1","null","https://ClinicalTrials.gov/show/NCT01212380"
1947,"NCT01886859","Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",,"Active, not recruiting","No Results Available","Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Pharmacogenomic Study|Other: Pharmacological Study","Phase 1","null","https://ClinicalTrials.gov/show/NCT01886859"
1948,"NCT02369653","A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase",,"Recruiting","No Results Available","Drug: Apixaban|Other: No systemic anticoagulant prophylaxis","Phase 3","null","https://ClinicalTrials.gov/show/NCT02369653"
1949,"NCT01217749","Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL","PCYC-1109-CA","Completed","Has Results","Drug: PCI-32765|Drug: ofatumumab","Phase 1|Phase 2","April 16, 2015","https://ClinicalTrials.gov/show/NCT01217749"
1950,"NCT00003716","Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy",,"Unknown status","No Results Available","Biological: rituximab","Phase 2","null","https://ClinicalTrials.gov/show/NCT00003716"
1951,"NCT02258529","Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma",,"Terminated","Has Results","Drug: Idelalisib|Biological: Rituximab","Phase 2","May 18, 2017","https://ClinicalTrials.gov/show/NCT02258529"
1952,"NCT00500058","A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18",,"Completed","No Results Available","Drug: SB-485232|Drug: Rituximab","Phase 1","null","https://ClinicalTrials.gov/show/NCT00500058"
